tazobactam has been researched along with penicillanic acid in 842 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (penicillanic acid) | Trials (penicillanic acid) | Recent Studies (post-2010) (penicillanic acid) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 2,764 | 327 | 880 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (3.44) | 18.7374 |
| 1990's | 258 (30.64) | 18.2507 |
| 2000's | 229 (27.20) | 29.6817 |
| 2010's | 300 (35.63) | 24.3611 |
| 2020's | 26 (3.09) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, A; Faulkner, R; Greene, DS; Halstenson, CE; Haynes, J; Johnson, CA; Kelloway, JS; Shapiro, BE; Tonelli, A; Zimmerman, SW | 1 |
| Bonomo, RA; Currie-McCumber, C; Shlaes, DM | 1 |
| Spencer, RC; Wilcox, MH; Winstanley, TG | 1 |
| Brismar, B; Kasholm-Tengve, B; Nord, CE; Tunevall, G | 2 |
| Bure, A; Carbon, C; Jehl, F; Mentec, H; Saleh-Mghir, A; Vallois, JM | 1 |
| Brismar, B; Kinzig, M; Nord, CE; Sörgel, F | 1 |
| Aldridge, KE; Barry, AL; Gelfand, MS; Jones, RN | 1 |
| Barry, AL; Fuchs, PC; Gerlach, EH; Hardy, DJ; McLaughlin, JC; Pfaller, MA | 1 |
| Hedberg, M; Lindqvist, L; Nord, CE; Tunér, K | 2 |
| Kelsey, SM; Newland, AC; Pocock, CE; Shaw, E; Weinhardt, B | 1 |
| Bäckstrand, B; Bergman, L; Brismar, B; Kihlström, E; Malmborg, AS; Mentzing, LO; Nyström, PO; Skau, T; Tunevall, G; Wretlind, B | 1 |
| Lambert, PA; Lee, VJ; Lowe, PR; Ringan, NS; Schwalbe, CH; Toomer, CA | 1 |
| Meyran, M; Thabaut, A | 1 |
| Carret, G; Chanal, C; Derlot, E; Kitzis, MD; Soussy, CJ | 1 |
| Cordin, X; Duex, JM; Kazmierczak, A; Péchinot, A; Siebor, E | 1 |
| Dubreuil, L; Sedallian, A | 1 |
| Baquero, F; Martínez, JL; Pérez-Díaz, JC; Reguera, JA | 1 |
| Ansari, A; Douglas, JG; Gould, IM; Harvey, G; Reid, TM; Smith, CC | 1 |
| Aspinall, S; Corkill, JE; Hart, CA; McLennan, AG | 1 |
| Andrews, JM; Cooper, M; Logan, M; Wise, R | 1 |
| Luft, B; Rahal, JJ; Urban, C | 1 |
| Kunii, O; Miyashita, T; Ono, Y | 1 |
| Cullmann, W | 2 |
| Bauernfeind, A; Eberlein, E; Jungwirth, R; Schweighart, S | 1 |
| Livermore, DM; Seetulsingh, P | 1 |
| Chang, SC; Hsieh, WC; Hsu, LY; Luh, KT | 1 |
| Nishino, T; Obana, Y | 1 |
| Castiglia, P; Maida, A; Mezzatesta, ML; Muresu, E; Nicoletti, G; Stefani, S | 1 |
| Karp, WB | 1 |
| Akova, M; Livermore, DM; Yang, Y | 1 |
| Stobberingh, EE | 1 |
| Crokaert, F; Lismont, MJ; Van der Linden, MP; Yourassowsky, E | 1 |
| Corkill, JE; Hart, CA | 1 |
| Higashitani, F; Hyodo, A; Inoue, M; Ishida, N; Mitsuhashi, S | 1 |
| Gunderson, D; Kennedy, SL; Kern, W; Sachdeva, M; Sande, ER; Täuber, MG | 1 |
| Blakemore, PH; Drabu, YJ; Mehtar, S | 1 |
| Cullmann, W; Stieglitz, M | 1 |
| Giwercman, B; Høiby, N; Lambert, PA; Rosdahl, VT; Shand, GH | 1 |
| Cherubin, CE; Eng, RH; Smith, SM | 1 |
| Dornbusch, K; Göransson, E; Mörtsell, E | 1 |
| Kempers, J; MacLaren, DM | 1 |
| Echols, RM; Robbiano, EM; Venezia, RA; Yocum, DM | 1 |
| Ràfols, M; Reig, R; Roy, C; Teruel, D; Tirado, M | 1 |
| Descamps, P; Moittie, D; Philippon, A; Simonet, M; Veron, M | 1 |
| Diver, JM; Thornber, D; Wise, R | 1 |
| Appelbaum, PC; Aronoff, SC; Jacobs, MR; Yamabe, S | 1 |
| Kuck, NA; Petersen, PJ; Testa, RT; Weiss, WJ | 1 |
| Fass, RJ; Prior, RB | 1 |
| Acar, JF; Coutrot, A; Ferré, B; Gutmann, L; Kitzis, MD | 1 |
| Carver, AH; Hoyt, KD; Ocampo, AP; Puglisi, CV; Wadgaonkar, N | 1 |
| Jacobus, NV; Kuck, NA; Petersen, PJ; Testa, RT; Weiss, WJ | 1 |
| Adachi, K; Ueda, S; Watanabe, M; Yamabe, S | 1 |
| Acar, JF; Billot-Klein, D; Carlet, J; Goldstein, FW; Gutmann, L; Kitzis, MD; Tran Van Nhieu, G; Williamson, R | 1 |
| Moosdeen, F; Williams, JD; Yamabe, S | 1 |
| Maniwa, M; Marunaka, T; Matsushima, E; Minami, Y | 1 |
| Azuma, R; Marunaka, T; Matsushima, E; Minami, Y; Yoshida, K | 1 |
| Moosdeen, F; Williams, J; Yamabe, S | 1 |
| McCoy, EC; Rosenkranz, HS; Yamabe, S | 1 |
| Acar, JF; Gutmann, L; Kitzis, MD; Yamabe, S | 1 |
| Aronoff, SC; Jacobs, MR; Johenning, S; Shlaes, DM; Yamabe, S | 1 |
| Aronoff, SC; Jacobs, MR; Labrozzi, PH; Yamabe, S | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK; Yamabe, S | 1 |
| Hall, TW; Ishida, N; Maiti, SN; Micetich, RG; Nakai, A; Ogawa, K; Spevak, P; Tanaka, M; Yamabe, S; Yamazaki, T | 1 |
| Aronoff, SC; Jacobs, MR; Johenning, S; Yamabe, S | 1 |
| Hyatt, JM; Nix, DE; Schentag, JJ; Stratton, CW | 1 |
| Arakawa, Y; Horii, T; Ito, H; Ohsuka, S; Ohta, M | 1 |
| Brogden, RN; Bryson, HM | 1 |
| Betschel, S; Kreiswirth, B; Low, DE; Willey, BM | 1 |
| Grimm, H | 1 |
| Aldridge, KE | 2 |
| Kinzig, M; Sörgel, F | 3 |
| Lahnborg, G; Nord, CE | 1 |
| File, TM; Tan, JS | 2 |
| Grundel, E; Vestweber, KH | 1 |
| Neu, HC | 1 |
| Brewster, SF; Gingell, JC; MacGowan, AP | 1 |
| Chin, A; Chung, KC; Gill, MA; Moon, YS; Ulrich, RW | 1 |
| Blahová, J; Hupková, M; Krcméry, V | 1 |
| Duval, J; Leclercq, R | 1 |
| Cony Makhoul, P; Darmaillac, V; Fourche, J; Maugein, J; Perrier, F | 1 |
| Higashitani, F; Hyodo, A; Inoue, M; Nishida, K | 1 |
| Dudley, MN | 1 |
| Jones, RN | 1 |
| Jones, R; Satishchandran, V; Shapiro, T; Suh, B; Truant, AL | 1 |
| Chang, SC; Hsieh, WC; Luh, KT | 1 |
| Amyes, SG; London, N; Stobberingh, E; Thomson, CJ | 1 |
| Chin, A; Chung, KC; Gill, MA; Moon, YS | 1 |
| Danziger, LH; Occhipinti, DJ; Rodvold, KA; Schoonover, LL | 1 |
| Chamard-Neuwirth, C; Cordin, X; Duez, JM; Kazmierczak, A; Pechinot, A; Siebor, E | 2 |
| Bergogne-Berezin, E; de Larminat, V; Jehl, F; Monteil, H; Muller-Serieys, C | 1 |
| Blumer, JL; Goldfarb, J; Lemon, E; Reed, MD; Yamashita, TS | 1 |
| Appelbaum, PC; Jacobs, MR; Pankuch, GA | 1 |
| Bansal, S; Doepner, M; Halstenson, CE; Johnson, CA; Keane, WF; Onorato, JJ; Sia, L; Tantillo, K; Wong, MO; Zimmerman, SW | 1 |
| Fujii, R; Fujita, K; Fukushima, N; Inyaku, F; Ishikawa, A; Okuno, A; Saijo, M; Takimoto, M; Wagatsuma, S; Yoshikawa, M | 1 |
| Hirayama, T; Iwai, S; Mashita, K; Matsuno, S; Nakagawa, Y; Otsuka, K; Rikiyama, T; Shinagawa, N; Tanaka, T; Yura, J | 1 |
| Harris, EB; Hastings, RC; Prabhakaran, K; Randhawa, B | 1 |
| Blickle, JF; Brogard, JM; Caro-Sampara, F; Jehl, F; Westphal, JF | 1 |
| Kwon, HH; Saito, H; Tomioka, H | 1 |
| Kawaguchi, S; Kawahara, M; Koike, T; Mitutake, Y; Ohno, T; Oizumi, K; Saisho, M; Saito, A; Takebe, K; Tomizawa, M | 1 |
| Hiraga, Y; Inoue, H; Kawaguchi, S; Kawahara, M; Ohmichi, M; Oizumi, K; Saito, A; Sano, N; Sigematsu, H; Tanaka, F | 1 |
| Guillaume, Y; Guinchard, C; Peyrin, E | 2 |
| Burm, JP; Chin, A; Choi, JS; Gill, MA; Jhee, SS; Ulrich, RW | 1 |
| Cantrell, HF; Lankford, RB; Murray, PR | 1 |
| Hashimoto, M; Niidome, K; Nishida, K; Nishino, T; Otsuki, M | 1 |
| Bonfiglio, G; Livermore, DM | 2 |
| MacLaren, DM; Namavar, F; Severin, WP; Smeets, T; Stobberingh, E | 1 |
| Anai, M; Anai, S; Hayashi, T; Kawazu, K; Kaziwara, T; Umano, T; Yada, H; Yamasaki, K | 1 |
| Auletta, CS; Cockrell, BY; Daly, IW; Hayashi, T; Knezevich, AL; Yada, H | 1 |
| Blair, M; Blanchard, GL; Geil, RG; Hayashi, T; Laughlin, KA; Tucek, PC; Yada, H | 1 |
| Christian, MS; Hoberman, AM; Lochry, EA; Sato, T | 2 |
| Christian, MS; Hoberman, AM; Sato, T | 1 |
| Kouchi, Y; Matsuo, K; Oguro, M; Takemoto, M | 1 |
| Kashihara, A; Kouchi, Y; Maeda, Y; Ohuchida, A; Omae, S; Taniguti, A | 1 |
| Dudley, MN; Gilbert, DH; Medeiros, AA; Pivarnik, P; Strayer, AH; Zinner, SH | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 3 |
| Aldridge, KE; Morice, N; Schiro, DD | 1 |
| Kakuo, H; Komuro, M; Maeda, T; Matsushita, H; Shimada, J | 1 |
| Baughman, R; Boylen, CT; Chan, JC; Charan, NB; Cormier, YC; Erickson, A; Grossman, R; Kirmani, N; Shlaes, DM; Suh, B | 1 |
| Carias, LL; Rice, LB; Shlaes, DM | 1 |
| Cantrell, HF; Jones, RN; Lankford, RB; Sutton, LD | 1 |
| Bethea, C; Das Gupta, V; Mathew, M | 1 |
| Cony-Makhoul, P; Fière, D; Guy, H; Herbrecht, R; Marie, JP; Milpied, N; Pico, JL; Plantier, I; Vekhoff, A | 1 |
| Atchison, K; Daneshtalab, M; Im, C; Kunugita, C; Maiti, SN; Micetich, RG; Phillips, OA | 1 |
| Sanders, CV | 1 |
| Gorbach, SL | 1 |
| Nord, CE | 2 |
| Nowé, P | 1 |
| Charbonneau, P | 1 |
| Hardegger, U; Wüst, J | 1 |
| Cramp, R; Knowles, DJ; Payne, DJ; Winstanley, DJ | 1 |
| Choi, JH; Incavo, SJ; Kinzig, M; Ronchetti, PJ; Sörgel, F; Wu, H | 1 |
| Denny, BJ; Lambert, PA; Toomer, CA | 1 |
| Bradford, PA; Sanders, CC | 1 |
| Murray, BE; Okhuysen, PC; Singh, KV | 1 |
| Alós, JI; Gómez-Garcés, JL; Mateos, MV | 1 |
| Collins, LA; Eliopoulos, GM; Ferraro, MJ; Moellering, RC; Wennersten, CB | 1 |
| Baquero, F; Reig, M | 1 |
| Decazes, JM; Gutmann, L; Kitzis, MD; Leleu, G; Vallois, JM | 1 |
| Edelstein, MA; Edelstein, PH | 1 |
| Duncanson, FP; Norden, CW; Talan, DA; Tan, JS; Wishnow, RM | 1 |
| Bywater, MJ; Holt, HA; MacGowan, AP; Reeves, DS | 1 |
| Allen, M; Bonfiglio, G; Chen, HY; Edwardson, T; Livermore, DM; McVey, D; Piper, D | 1 |
| Eliopoulos, GM; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C | 1 |
| Duchateau, V; Husson, M; Kinzig, M; Lambert, C; Sörgel, F; Van der Auwera, P | 1 |
| Alos, I; Baquero, F; Baquero, MR; Blazquez, J; Canton, R | 1 |
| Inoue, E; Mitsuhashi, S; Muratani, T; Nakane, T; Yokota, E | 1 |
| Faro, S; O'Brien, WF; Roy, S; Sanfilippo, JS; Seidlin, M; Sweet, RL | 1 |
| Alhava, E; Haapiainen, R; Havia, T; Kivilaakso, E; Laitinen, S; Matikainen, M; Miettinen, P; Niinikoski, J; Pääkkönen, M | 1 |
| Jin, YF; Piddock, LJ; Turner, HL | 1 |
| Cullmann, W; Elhardt, D; Tassler, H | 1 |
| DeVries, VG; Kuye, O; Morrow, CA; Tally, FP; Teal, J | 1 |
| Acar, JF; Goldstein, FW; Kitzis, MD | 1 |
| Appelbaum, PC | 1 |
| Eklund, AE; Nord, CE | 1 |
| Ajana, F; Beuscart, C; Chidiac, C; Lecocq, P; Leroy, O; Mouton, Y; Senneville, E | 1 |
| Wise, R | 1 |
| Allen, SD; Barry, AL; Fuchs, PC; Hardy, DJ; Jorgensen, JH; McLaughlin, JC; Tenover, FC | 1 |
| Gentile, G; Girmenia, C; Martino, P; Meloni, G; Micozzi, A; Nucci, M; Venditti, M | 1 |
| Bush, K; Lee, VJ; Macalintal, C; Rasmussen, BA; Yang, Y | 1 |
| Barry, A; Fuchs, P; Gerlach, E; Hardy, D; McLaughlin, J; Pfaller, M | 1 |
| Gaudreau, C; Lachance, N; Lamothe, F; Turgeon, F | 1 |
| Gupte, JM; Immermann, FW; Jacobus, NV; Testa, RT | 1 |
| Amyes, SG; Thomson, CJ | 1 |
| Barie, PS; Cheadle, WG; Fink, MP; Garber, GE; Hebert, JC; Laverdiere, M; Polk, HC; Wilson, SE | 1 |
| Amicosante, G; Franceschini, N; Oratore, A; Perilli, M; Segatore, B; Setacci, D | 1 |
| Chung, KC; Gill, MA; Le-Bui, LP; Park, TW; Rho, JP | 1 |
| Dhoore, P; Verbist, L | 1 |
| Behbahani, R; Kostman, JR | 1 |
| Atchison, K; Czajkowski, DP; Fiakpui, C; Hyodo, A; Kunugita, C; Maiti, SN; Micetich, RG; Phillips, OA; Setti, EL | 1 |
| Arpi, M; Bruun, B; Gottschau, A; Mortensen, I; Victor, MA | 1 |
| Gerber, L; Wing, EJ | 1 |
| Vandenhoven, G; Verbist, L; Verhaegen, J; Wouters, C | 1 |
| Daley, D; Dimech, W; Mulgrave, L; Munro, R; Neville, S; Smith, H | 1 |
| Bourget, P; Carsin, H; Le Bever, H; Le Reveillé, R; Lesne-Hulin, A | 1 |
| Labia, R; Mariotte-Boyer, S; Nicolas-Chanoine, MH | 1 |
| Sanders, CC; Sanders, WE | 1 |
| Blaser, J; König, C | 1 |
| Albert, G; Audran, M; Augey, V; Bressolle, F; Grosse, PY | 1 |
| Alonso, JM; Fournier, JL; Jacolot, AC; Petitjean, OJ; Ramisse, F; Scavizzi, MR; Szatanik, M | 1 |
| Alós, JI; Balas, D; Cogollos, R; Gomez-Graces, JL; Tajada, P | 1 |
| Greenwood, D | 1 |
| Bowker, KE; Hedges, AJ; Holt, HA; MacGowan, AP; Reeves, DS; Wootton, M | 1 |
| Livermore, DM; Yuan, M | 1 |
| Atwood, E; DiTore, V; Landman, D; Patel, K; Quale, J; Saurina, G | 1 |
| Arredondo-Garcia, JL; Figueroa-Damian, R; San Martín-Herrasti, JM; Villagrana-Zesati, R | 1 |
| Atchison, K; Atwal, H; Czajkowski, DP; Hyodo, A; Kunugita, C; Maiti, SN; Micetich, RG; Phillips, OA; Reddy, NA; Setti, EL | 1 |
| Dalla Costa, T; Derendorf, H | 1 |
| Knapp, CC; Ludwig, MD; Pohlman, JK; Washington, JA | 1 |
| Aguirre, C; Barreiro, G; Ruiz-Irastorza, G | 1 |
| Klepser, ME; Marangos, MN; Nicolau, DP; Nightingale, CH; Quintiliani, R; Zhu, Z | 1 |
| Blumer, JL; Bonafede, ME | 1 |
| Gould, IM; Milne, K | 1 |
| Chimura, T; Hirayama, T | 1 |
| Bonomo, RA; Rudin, SA; Shlaes, DM | 1 |
| Lister, PD; Prevan, AM; Sanders, CC | 1 |
| Brunschwig, C; Jourdan, J; Ramuz, M; Sotto, A | 1 |
| Klimonova, NV; Lobakov, AI; Nasonov, VN; Savitskaia, KI; Savov, AM | 1 |
| Palmer, SM; Rybak, MJ | 1 |
| Kinzig-Schippers, M; Kolenda, H; Müller, C; Nau, R; Prange, HW; Rössing, R; Schinschke, S; Sörgel, F | 1 |
| Eliopoulos, GM; Moellering, RC; Thauvin-Eliopoulos, C; Tripodi, MF | 1 |
| Higashitani, F; Hyodo, A; Kunugita, C; Nishida, K; Unemi, N | 1 |
| Bayle, C; Bourhis, JH; Cartron, J; Gautier, E; Pico, JL; Tchernia, G | 1 |
| Hanaki, H; Nagayama, A; Nomura, S | 1 |
| Czajkowski, DP; Hanehara-Kunugita, C; Hyodo, A; Maiti, SN; Micetich, RG; Phillips, OA; Singh, MP; Spevak, P | 1 |
| Adloff, M; Blicklé, JF; Brogard, JM; Caro-Sampara, F; Jehl, F; Monteil, H; Westphal, JF | 1 |
| Mulder, PO; Stegeman, CA; Uges, DR; van der Werf, TS; Zijlstra, JG | 1 |
| Kadima, TA; Weiner, JH | 1 |
| Chen, HY; Livermore, DM | 1 |
| Douboyas, J; Tsakris, A; Tzouvelekis, LS | 1 |
| Dalla Costa, T; Derendorf, H; Nolting, A; Rand, K | 1 |
| Danziger, LH; Occhipinti, DJ; Pendland, SL; Rodvold, KA; Rypins, EB; Schoonover, LL | 1 |
| Constantoulaki, S; Paniara, O; Platsouka, E; Zissis, NP | 1 |
| Hitt, CM; Nicolau, DP; Nightingale, CH; Patel, KB; Zhu, Z | 1 |
| Adhikari, M; Pillay, DG; Pillay, T; Sturm, AW | 1 |
| Barthélémy, M; Chaibi, EB; Farzaneh, S; Labia, R; Péduzzi, J; Sirot, D | 1 |
| Babini, GS; Danel, F; Livermore, DM; Micklesen, PA; Munro, SD | 1 |
| Calcagno, ML; Danelon, G; Gutkind, G; Mascaretti, O; Mata, EG; Power, P; Radice, M | 1 |
| Diepersloot, RJ; Hoekstra, JB; Hoynck van Papendrecht, AA; van Kraaij, MG; Veldkamp, KE; Zeillemaker, AM | 1 |
| Ishiguro, M; Ishii, Y; Ma, L; Matsuzawa, H; Yamaguchi, K | 1 |
| Barthélémy, M; Caniça, MM; Caroff, N; Dupret, JM; Krishnamoorthy, R; Labia, R; Paul, G | 1 |
| Amicosante, G; Cornaglia, G; Franceschini, N; Mazzariol, A; Perilli, M; Segatore, B; Setacci, D | 1 |
| Bryce, E; Frighetto, L; Jewesson, P; MacDougall, C; Marra, F; Reynolds, R; Sleigh, K; Stiver, G | 1 |
| Makandiramba, B; Moyo, SR; Nziramasanga, P; Obi, CL; Robertson, V; Tswana, SA | 1 |
| Bianchi, C; Bonfiglio, G; Nicoletti, G; Stefani, S; Zollo, A | 1 |
| Böhme, A; Hoelzer, D; Shah, PM; Stille, W | 1 |
| Dudley, MN; Okereke, C | 1 |
| Andremont, A; Guy, H; Marie, JP; Pico, JL; Richet, H; Vekhoff, A | 1 |
| Böhme, C; Hess, U; Rey, K; Senn, HJ | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Anderson, V; Bonomo, RA; Knox, JR; Lin, S; Rudin, SD; Shlaes, DM; Thomas, M | 1 |
| Levesque, RC; Palzkill, T; Sabbagh, Y; Sanschagrin, F; Thériault, E; Voyer, N | 1 |
| Haruta, T; Kobayashi, Y; Nishio, T | 1 |
| Pastor, JM; Pérez-Vázquez, A; Riancho, JA | 1 |
| Alvarez-Bravo, J; Bouza, E; García Rodríguez, JA; Gobernado, M; Perea, E | 1 |
| Ambrosetti, P; Aymon, D; Bille, J; Chiolero, R; Cometta, A; Glauser, MP; Harbarth, S; Huber, O; Jaccard, C; Lew, D; Praz, G; Ricou, B; Romand, J; Schneider, R; Troillet, N; Zanetti, G | 1 |
| Jarlier, V | 1 |
| Forrest, A; Nix, DE; Schentag, JJ; Strenkoski-Nix, LC | 1 |
| Birawska, I; Fuchs, J; Szulakowska, E | 1 |
| Corrado, OJ; Fawley, WN; Hawkey, PM; Settle, CD; Wilcox, MH | 1 |
| Lessing, MP; Stewart, BA | 1 |
| de Seny, D; Frere, JM; Galleni, M; Laraki, N; Llabres, G; Prosperi-Meys, C; Soto, RP; Valladares, MH | 1 |
| Dalla Costa, T; Derendorf, H; Kovar, A; Nolting, A | 1 |
| de la Pena, A; Derendorf, H | 1 |
| Bryce, EA; Frighetto, LO; Jewesson, PJ; Marra, CA; Marra, FO; Reynolds, RP; Sleigh, KM; Stiver, HG | 1 |
| Baudard, M; Bouvet, A; Chast, F; Delmer, A; Legrand, O; Levy, V; Marie, JP; Marjanovic, Z; Rio, B; Vekhoff, A; Zittoun, R | 1 |
| Gardner, VM; Lister, PD; Sanders, CC | 1 |
| Caballero, D; Encinas, MP; García-Sanz, R; Gutiérrez, N; Hurlé, AD; Morín, LS; Vázquez, L; Vilches, P | 1 |
| Ell, C; Gossner, L; Hahn, EG; Keymling, J | 1 |
| Auclair, B; Ducharme, MP | 1 |
| Buxbaum, A; Georgopoulos, A; Graninger, W | 1 |
| Markham, A; Perry, CM | 1 |
| Giakkoupi, P; Legakis, NJ; Tzelepi, E; Tzouvelekis, LS | 1 |
| Betriu, C; Gómez, M; Palau, ML; Picazo, JJ; Sánchez, A | 1 |
| Degnan, BA; Farmer, TH; Payne, DJ | 1 |
| Atchison, KP; Atwal, H; Higashitani, F; Hyodo, A; Kunugita, C; Maiti, SN; Micetich, RG; Nishida, K; Phillips, OA; Salama, SM; Spevak, P; Uji, T; Unemi, N | 1 |
| Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I | 1 |
| Cederberg, A; Forssell, H; Ohlin, B; Solhaug, JH; Tveit, E | 1 |
| Czymek, R; Düsel, W; Lenz, S | 1 |
| Brogard, JM; Caro-Sampara, F; Jehl, F; Westphal, JF | 1 |
| Kays, MB | 1 |
| Babini, GS; Livermore, DM | 1 |
| Bonafede, M; Bonomo, RA; Carias, LL; Hoyen, C; Hujer, AM; Hutton, R; Rice, LB | 1 |
| Kotra, LP; Levesque, RC; Mobashery, S; Sanschagrin, F; Therrien, C | 1 |
| Miranda, E; Sader, HS; Sejas, L; Tosin, I | 1 |
| Levesque, RC; Palzkill, T; Sanschagrin, F; Savoie, A; Voyer, N | 1 |
| Huang, N; Janota, K; Lin, YI; Rasmussen, BA; Shlaes, DM; Siegel, MM; Tabei, K; Yang, Y | 1 |
| Amicosante, G; Bianchi, C; Bonfiglio, G; Franceschini, N; Nicoletti, G; Perez, MM; Perilli, M; Segatore, B; Stefani, S; Zollo, A | 1 |
| Cuenca, FF | 1 |
| Carbon, C; Carlet, J; Dupont, H | 1 |
| Aznar, E; Climent, MA; Máiquez, J; Palau, J; Picón, I | 1 |
| Bradley, SJ | 1 |
| Lister, PD | 1 |
| Burgess, DS; Hastings, RW | 1 |
| Cross, JM; May, AK; McGwin, G; Melton, SM; Moser, SA; Rue, LW | 1 |
| Bonnaure-Mallet, M; Buffet, A; Cormier, M; David, S; Dupuy, C; Jolivet-Gougeon, A; Sixou, JL | 1 |
| Li, JT; Zhang, YL | 1 |
| Cohen, J | 1 |
| Baddour, LM; Googe, PB; Prince, TL | 1 |
| Mohammedi, I; Tigaud, S; Tournadre, JP | 1 |
| Christou, N; Eiseman, I; Siami, G; Tack, KJ | 1 |
| Amicosante, G; Belloni, R; Bianchi, C; Lombardi, G; Luzzaro, F; Perilli, M; Toniolo, A; Zollo, A | 1 |
| Coia, JE; Gillespie, TA; Hanson, MF; Johnson, PR; Notman, AW | 1 |
| Anstead, G; Blaser, M; Craig, F; Jorgensen, J; Patterson, T | 1 |
| Chen, Y; Gao, L; Hou, F; Li, J | 1 |
| Gooding, WE; Grandis, JR; Johnson, JT; Myers, EN; Pou, AM; Simons, JP; Vickers, RM; Wagner, RL; Yu, VL | 1 |
| O'Connell, M; Petros, AJ; Roberts, C; van Saene, HK; Wade, P | 1 |
| Allen, MC; Bradley, SJ; Goldstone, AH; Scott, GM; Sher, HA; Wilson, AL | 1 |
| Abi-Said, D; Bivins, C; Hachem, R; Hanna, H; Huaringa, A; Raad, I; Sukumaran, A; Thornby, J; Walsh, G; Whimbey, E | 1 |
| Niki, Y | 1 |
| Hidai, H | 1 |
| Feigelson, GB; Petersen, PJ; Prashad, AS; Sandanayaka, VP; Yang, Y | 1 |
| Bonomo, RA; Hujer, A; Knox, JR; Kuzin, AP; Nukaga, M; Nukaga, Y | 1 |
| Anderson, VE; Bonomo, RA; Chen, Y; Hujer, AM; Liu, J; Ng, L | 1 |
| Mealey, KL | 1 |
| Brown, A; Freeman, J; Wilcox, MH | 1 |
| Bode, U; Fleischhack, G; Hasan, C; Havers, W; Marklein, G; Schmidt-Niemann, M; Wulff, B | 1 |
| Akhan, S; Coskunkan, F; Tansel, O; Vahaboglu, H | 1 |
| Amorusi, P; Dowell, JA; Korth-Bradley, J; Milisci, M; Tantillo, K; Tse, S | 1 |
| Amato, R; Andò, F; Azzaro, R; Bellissima, P; Cicciarella, S; Covelli, I; Delia, S; Fogliani, V; Fraschini, F; Girbino, G; Jacoviello, C; Laganà, P; Magrì, M; Maierna, G; Maria, GD; Marone, P; Messina, G; Muscianisi, G; Napoletano, G; Pela, R; Pezza, A; Rizza, S; Rossi, A; Sabato, V; Sanguinetti, C; Tedeschi, D; Varotto, F; Viola, B; Vitale, S | 1 |
| Dul, MJ; Hoyen, C; Salvator, A; Toltzis, H; Toltzis, P; Walsh, M; Zetts, L | 1 |
| Bauduer, F; Boiron, JM; Boulat, O; Cousin, T; Fegueux, N; Jourdan, E; Molina, L; Reiffers, J; Rigal-Huguet, F | 1 |
| Moland, ES; Thomson, KS | 1 |
| Androulakakis, E; Dimitriou, L; Kafetzis, DA; Lebesii, E; Maltezou, HC; Nikolaidis, P | 1 |
| Backman, JT; Neuvonen, PJ; Takkunen, O; Tiula, E; Valtonen, M | 1 |
| Adinolfi, LE; Andreana, A; Casillo, R; Durante Mangoni, E; Farina, C; Gambardella, M; Sarnataro, G; Tripodi, MF; Utili, R | 1 |
| Bukowski, K; Jakubczak, A; Wolska, MK | 1 |
| Liu, Y; Wang, R; Yu, B | 1 |
| Naber, KG; Salmen, HC; Savov, O | 1 |
| Harris, AD; Johnson, JA; Kaye, KS; Morris, G; Perencevich, E; Roghmann, MC | 1 |
| Cassone, M; Falcone, M; Paris, A; Pavoni, G; Pistella, E; Venditti, M | 1 |
| Minami, S; Takahata, M; Yamada, H | 1 |
| Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D | 1 |
| Ceesay, TP; Gesser, R; Graham, DR; Holtom, P; Lucasti, C; Malafaia, O; McAdams, A; Nichols, RL; Perez, NQ; Woods, GL | 1 |
| Archontaki, HA; Marselos, SC | 1 |
| Batlle, M; Benlloch, L; Capote, FJ; Gutiérrez, M; Jarque, I; Julià, A; Lahuerta, JJ; Larrea, L; López, J; Palau, J; Pérez, C; Ramos, F; Rovira, M; Sanz, MA; Vázquez, L | 1 |
| Ehrlich, M; Galla, TJ; Horch, RE; Kümmerer, K; Trittler, R | 1 |
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Kaygusuz, A | 1 |
| Citron, DM; Gesser, RM; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, Y | 1 |
| Burgess, DS; Waldrep, T | 1 |
| Ahmed, S; Gouda, HE; Najjar, M; Rodriguez, P | 1 |
| Burgess, DS; Nathisuwan, S | 1 |
| Kuti, JL; Nicolau, D; Nightingale, CH; Quintiliani, R | 1 |
| Chang, LK; Tsai, WC | 1 |
| Bassilios, N; Restoux, A; Rondeau, E; Sraer, JD; Vincent, F | 1 |
| Berardi, B; Callea, A; Cormio, L; Fiorentino, N; Sblendorio, D; Traficante, A; Zizzi, V | 1 |
| Bornhauser, M; Ehninger, G; Hanel, M; Kroschinsky, F; Ordemann, R; Schuler, U; Wichmann, G | 1 |
| Choti, MA; Fishman, EK; Geschwind, JF; Kaushik, S; Kobeiter, H; Ramsey, DE | 1 |
| Goldberg, RA; Li, TG | 1 |
| Deng, S; Han, C; Li, X; Liao, Z; Wang, W; Xu, W | 1 |
| Hu, CQ; Jin, SH; Yuan, YZ | 1 |
| Brañas-Fernández, F; Garcia-Porrua, C; Gonzalez-Gay, MA; Pego-Reigosa, R | 1 |
| Faltýn, J; Lochmann, O; Vyhnánek, F | 1 |
| Fixson, A; Glasmacher, A; Gorschlüter, M; Hahn, C; Horré, R; Marklein, G; Mey, U; Molitor, E; Sauerbruch, T; Schmidt-Wolf, IG; Ziske, C | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
| Nakano, R; Okamoto, R | 1 |
| Zaĭtsev, AA | 1 |
| Chapuis, F; Duperret, S; Mohammedi, I; Petit, P; Ploin, D | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Dittrich, P; Maier, A; Matzi, V; Nuhsbaumer, S; Pinter, H; Pinter, J; Smolle, J; Smolle-Jüttner, FM; Tomaselli, F; Woltsche, M | 1 |
| Arndt, PA; Garratty, G; Leger, RM | 2 |
| Adeyi, B; Angel-Muller, E; Hague, C; Higareda, I; Ismail, M; Roy, S; Teppler, H; Woods, GL | 1 |
| Finsterer, J; Kotzailias, N | 1 |
| Maier, A; Smolle-Jüttner, FM; Tomaselli, F | 1 |
| Chin, NX; Della-Latta, P; Libre, PE | 1 |
| Anderson, VE; Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM; Hujer, KM | 1 |
| Fosse, T; Giraud-Morin, C; Madinier, I | 1 |
| Bantar, C; Bertolini, P; Blázquez, N; Borda, N; Casellas, JM; Couto, E; Cudmani, N; Guerrera, J; Juárez, MJ; Littvik, A; López, T; Méndez, E; Notario, R; Ponce, G; Quinteros, M; Salamone, F; Sparo, M; Sutich, E; Tomé, G; Vaylet, S; Wolff, L | 1 |
| Castillo Caparrós, A; Montijano Cabrera, AM | 1 |
| Alos, JI; Gomez-Garces, JL; Hernaiz, C; Picardo, A | 1 |
| Bonomo, RA; Carey, MP; Carey, PR; Helfand, MS; Hujer, AM; Totir, MA | 1 |
| Gesser, RM; McCarroll, KA; Woods, GL | 1 |
| Ribaud, P; Sulahian, A; Touratier, S | 1 |
| Beharry, Z; Buynak, JD; Chen, H; Gadhachanda, VR; Palzkill, T | 1 |
| Bark, B; Perlick, E; Stöver, B | 1 |
| Bonomo, RA; Carey, MP; Carey, PR; Helfand, MS; Hujer, AM; Padayatti, PS; Totir, MA; van den Akker, F | 1 |
| Anderson, VE; Bethel, CR; Bonomo, RA; Guo, B; Helfand, MS; Hujer, AM; Jin, Z; Ng, LM; Pagan-Rodriguez, D; Simmons, R; Zhou, X | 1 |
| Glasmacher, A; Wade, JC | 1 |
| Ahern, JW; Alston, WK | 1 |
| Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T | 1 |
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Bevin, SV; Broadberry, RE; Farren, TW; Garratty, G; Kohler, JA; Poole, J; Skidmore, I; Yates, S | 1 |
| Blosser-Middleton, RS; Ge, Y; Karlowsky, JA; Sahm, DF; Wikler, MA | 1 |
| Häfner, H; Klik, S; Kümmerer, K; Lemmen, SW; Lütticken, R; Zolldann, D | 1 |
| Kwan, TH; Siu, YP; Tong, MK; Yung, CY | 1 |
| Higgins, PG; Seifert, H; Stefanik, D; Wisplinghoff, H | 1 |
| Goessens, WH; Gyssens, IC; Lemmens, N; Mouton, JW; Stearne, LE; van Boxtel, D | 1 |
| Høiby, N; Walther-Rasmussen, J | 1 |
| Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM | 1 |
| Derendorf, H; Liu, Q; Rand, K | 1 |
| Burgess, DS; Hall, RG | 1 |
| Auvrignon, A; Le Guyader, N; Leverger, G; Portier, E; Tabone, MD; Vu-Thien, H | 1 |
| Cassini, M; Corrocher, R; Gabrielli, GB; Stanzial, AM | 1 |
| Aspinall, S; Husain, S; Mietzner, S; Obman, A; Singh, N; Stout, JE | 1 |
| Aksoylar, S; Cetingül, N; Kansoy, S; Kantar, M; Karapinar, D; Kavakli, K | 1 |
| Aron, DC; Donskey, CJ; Gordon, SM; Paterson, DL; Pultz, NJ; Stiefel, U | 1 |
| Apfalter, P; Berger, A; Kretzer, V; Pollak, A; Rohrmeister, K; Zaknun, D | 1 |
| Bonnefoy, A; Delachaume, C; Dupuis-Hamelin, C; Fairley, M; Guitton, M; Lampilas, M; Seys, C; Stachyra, T; Steier, V | 1 |
| Bassotti, G; Chistolini, F; De-Roberto, G; Morelli, A; Sietchiping-Nzepa, F | 1 |
| Extremina, C; Fonseca, AF; Fonseca, AP; Sousa, JC | 1 |
| Georgopapadakou, NH | 1 |
| Li, C; Nicolau, DP; Nightingale, CH; Xuan, D; Ye, M | 1 |
| Bethel, CR; Bonomo, RA; Knox, JR; Sun, T | 1 |
| Danziger, LH; Drusano, GL; Lodise, TP; Lomaestro, B; Rodvold, KA | 1 |
| Crisostomo, AC; Erasmo, AA; Hong, YS; Lee, KU; Lo, CM; Yan, LN | 1 |
| Arzuaga, A; Canut, A; Corral, E; Fonseca, F; Gascón, AR; Isla, A; Maynar, J; Pedraz, JL; Rello, J; Sánchez-Izquierdo, JA | 1 |
| Akgün, H; Caner, F; Erkiliç, K; Eşel, D; Evereklioglu, C; Ozkiriş, A | 1 |
| Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M | 1 |
| Arzuaga, A; Gascón, AR; Isla, A; Martín, A; Maynar, J; Pedraz, JL; Solinís, MA; Toral, D | 1 |
| Baines, SD; Freeman, J; Wilcox, MH | 1 |
| Akgün, H; Erkiliç, K; Esel, D; Evereklioglu, C; Göktas, S; Ozkiris, A | 1 |
| Hameed, S; Johnson, M; Lipman, M; Tariq, S; Tyrer, M | 1 |
| Ashkenazi, S; Bishara, J; Lev, B; Levy, I; Livne, G; Ofir, O; Pitlik, S; Samra, Z | 1 |
| Guymon, CH; McManus, AT; Peng, DZ; Xiao, GX | 1 |
| Aigner, F; Bonatti, H; Hoeller, E; Kafka, R; Stelzmueller, I; Weiss, H; Wiesmayr, S | 1 |
| Bermúdez, A; Besalduch, J; Nocea, G; Pascual, MJ; Rovira, M; Sanz, MA; Sanz-Rodríguez, C | 1 |
| Dana, A; Kuti, JL; Li, C; Mansfield, DL; Nicolau, DP; Nightingale, CH | 1 |
| Bellaire, T; Cornely, OA; Dörken, B; Einsele, H; Krause, S; Kubin, T; Maschmeyer, G; Reich, G; Sandherr, M; Thiel, E | 1 |
| Bonomo, RA; Carey, MP; Carey, PR; Helfand, MS; Padayatti, PS; Totir, MA; van den Akker, F | 1 |
| Jones, MF; Rigge, DC | 1 |
| Pang, XY; Tian, BW; Yang, YJ | 1 |
| Berman, D; Bode, RS; Brachlow, AE; Capouya, JD; Enrione, MA; Forrster, EE; Fuh, BR; Pourrat, M | 1 |
| Dittrich, P; Hoffmann, C; Kerl, H; Krause, R; Legat, FJ; Salmhofer, W; Scholz, S; Tscherpel, J; Tscherpel, T; Zenahlik, P | 1 |
| Arora, V; Prakash, SK; Prashad, R; Sharma, VK | 1 |
| Marinella, MA | 1 |
| Cheng, FW; Fok, TF; Hui, J; Lee, N; Leung, TF; Ng, PC; Yap, F | 1 |
| Bonomo, RA; Donskey, CJ; Harmoinen, J; Helfand, MS; Kääriäinen, S; Koski, P; Lindevall, K; Pultz, NJ; Stiefel, U; Wickstrand, N | 1 |
| Yamabe, S | 1 |
| Hanehara, C; Higashitani, F; Inoue, M; Ishida, N; Mitsuhashi, S; Uji, T | 1 |
| Chin, NX; Neu, HC | 1 |
| Jacobus, NV; Kuck, NA; Petersen, PJ; Tally, FP; Testa, RT; Weiss, WJ | 1 |
| Cheung, WK; Faulkner, RD; Fernandez, P; Greene, DS; Holder, A; Houston, A; Kuye, O; Silber, BM; Smith, MP | 1 |
| Cheung, WK; Faulkner, RD; Greene, DS; Hibberd, M; Houston, A; Kuye, O; Shin, K; Silber, BM; Tonelli, AP | 1 |
| Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Capparelli, FJ; Del Castillo, ME; Diaz, MF; Hlavnika, A; Leiguarda, R; Wainsztein, NA | 1 |
| Bette, M; Menendez, S; Mutters, R; Nüsing, RM; Schulz, S; Zamora, ZB | 1 |
| Benner, A; Egerer, G; Geiss, HK; Goldschmidt, H; Harter, C; Ho, AD; Hoppe-Tichy, T; Schulze, B | 1 |
| Bock, R; Calandra, T; Cometta, A; Crokaert, F; Glauser, MP; Kern, WV; Paesmans, M; Viscoli, C | 1 |
| Aydogdu, I; Ersoy, Y; Kaya, E; Kuku, I; Serefhanoglu, K; Serefhanoglu, S | 1 |
| Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S | 1 |
| Banic, S | 1 |
| Alireza, S; Gholamali, G; Javad, A; Kazem, G; Qulamreza, K; Vahid, P | 1 |
| Alouf, B; Pitone, M | 1 |
| Dana, A; DeRyke, CA; Kuti, JL; Mansfield, D; Nicolau, DP | 1 |
| Bhattacharya, SK; Kumari, N; Mohapatra, TM; Rai, A | 1 |
| Arzuaga, A; Corral, E; Gascón, AR; Isla, A; Maynar, J; Pedraz, JL | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Rice, LB | 1 |
| Bier, U; Callies, R; Regidor, PA; Schindler, AE; Wagner, KJ | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, E; Kamysz, W; Licci, A; Lukasiak, J; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C | 1 |
| Leitner, E; Lode, H; Schmitt, DV; Welte, T | 1 |
| Chang, HT; Chen, IS; Chou, MY; Hsueh, PR; Huang, WK; Hung, MN; Ko, WC; Lee, WS; Lin, CF; Liu, CY; Liu, YC; Luh, KT; Shyr, JM; Teng, LJ; Wang, JH; Wu, JJ | 1 |
| Appavu, SK | 1 |
| Dana, A; Itani, KM; Kuti, JL; Lau, WK; Mansfield, D; Mercer, D; Nicolau, DP | 1 |
| Burgess, DS; Frei, CR; Hampton, SL | 1 |
| Carreras, E; Fernández-Avilés, F; Gallego, C; García, L; Gaya, A; González, M; Granell, M; Hernando, A; Martínez, C; Montserrat, E; Ramiro, L; Rovira, M; Segura, S; Urbano-Ispizua, A; Valverde, M | 1 |
| Anderson, VE; Bethel, CR; Bonomo, RA; Buynak, JD; Carey, MP; Carey, PR; Helfand, MS; Padayatti, PS; Sheri, A; Totir, MA; van den Akker, F | 1 |
| Bernabeu-Wittel, M; de la Cruz-Vicente, F; García-Morillo, JS; López-Ruiz, T | 1 |
| Kinzer, S; Maier, W; Ridder, GJ | 1 |
| Avlamis, A; Daikos, GL; Markogiannakis, A; Papaparaskevas, J; Papapareskevas, J; Petrikkos, G; Stefanakos, G; Zissis, NP | 1 |
| Antretter, H; Bonatti, H; Guggenbichler, JP; Ladurner, R; Laesser, R; Margreiter, R; Mark, W; Muehlmann, G; Stelzmueller, I; Tabarelli, D; Tabarelli, W; Wiesmayr, S; Zimmerhackl, LB | 1 |
| Wang, GJ; Xia, CH; Xiong, YQ | 1 |
| Harada, AS; Lau, W | 1 |
| Khan, HM; Malik, A; Shahid, M; Shujatullah, F; Shukla, I; Singhai, M; Tahira, F | 1 |
| Erba, P; Hintermann, B; Kalbermatten, DF; Laifer, G; Pierer, G; Rieger, UM; Uike, K | 1 |
| Cross, SE; Dalley, AJ; Lipman, J; Roberts, MS; Rudd, M; Venkatesh, B | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
| Tucker, H; Wu, D | 1 |
| Bonomo, RA; Buynak, JD; Carey, PR; Helfand, MS; Taracila, MA; Totir, MA; van den Akker, F | 1 |
| Bonomo, RA; Buynak, JD; Carey, MP; Carey, PR; Helfand, MS; Sheri, A; Totir, MA | 1 |
| Bennett, KM; Dodds-Ashley, E; Hayward, TZ; Kaye, KS; Scarborough, JE; Sharpe, M; Vaslef, SN | 1 |
| Ichikawa, S; Kato, Y; Lane, GJ; Marusasa, T; Miyano, G; Okazaki, T; Yamataka, A; Yanai, T | 1 |
| Adeyemi, OA; Montevecchi, M; Newman, D; Nicolau, DP; Noskin, GA; Postelnick, MJ; Scheetz, MH | 1 |
| Braga, AL; Burattini, MN; Jukemura, EM; Medeiros, EA; Pereira, CA | 1 |
| Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J | 1 |
| Blau, IW; Graf, B; Penack, O; Rempf, P; Thiel, E | 1 |
| Anuradha, K; Lakshmi, V; Sailaja, VV; Satheesh, T; Umabala, P | 1 |
| Clapson, P; Debien, B; Leclerc, T; Lenoir, B; Perez, JP | 1 |
| Black, J; Brasso, W; Moland, ES; Reuben, J; Thomson, KS; Wiles, T | 1 |
| Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Kamysz, E; Kamysz, W; Mocchegiani, F; Orlando, F; Riva, A; Rocchi, M; Saba, V; Scalise, G; Silvestri, C | 1 |
| Abbruzzetti, A; Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C | 1 |
| Ikonomidis, A; Kantzanou, M; Maniatis, AN; Neou, E; Pournaras, S; Tsakris, A | 1 |
| Chow, P; Godambe, S; Maulidi, H | 1 |
| Arora, J; Dogra, A; Rao, P; Taneja, N | 1 |
| Anderson, VE; Buynak, J; Carey, PR; Cha, J; Ishiwata, A; Mobashery, S; Sheri, A; Totir, MA; Wang, B | 1 |
| Cholongitas, E; Dasenaki, M; Kaklamanis, L; Pipili, C | 1 |
| Allaouchiche, B; Boselli, E; Bouvet, L; Breilh, D; Chassard, D; Guillaume, C; Rimmelé, T; Saux, MC; Xuereb, F | 1 |
| Lipman, J; Paratz, JD; Roberts, JA | 1 |
| Barnaud, G; Chevrel, G; Dreyfuss, D; Eveillard, M; Meybeck, A; Mounier, R; Ricard, JD | 1 |
| Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E | 1 |
| Abe, T; Anderson, VE; Bethel, CR; Bonomo, RA; Carey, MP; Carey, PR; Distler, AM; Helfand, MS; Hujer, AM; Hujer, KM; Kalp, M; Leonard, DA; Mansour, TS; Ruszczycky, MW; Taracila, M; Thomson, JM; Venkatesan, AM | 1 |
| Glasmacher, A; Gorschlüter, M; Hahn-Ast, C; Marklein, G; Molitor, E; Orlopp, K; Purr, I; Reiffert, SM; von Lilienfeld-Toal, M; Welter, A | 1 |
| Church, DL; Gregson, DB; Laupland, KB; Le, P; Pitout, JD | 1 |
| Aldeyab, MA; Bailie, R; Elshibly, SM; Hanley, J; Hughes, CM; Kearney, MP; McDowell, DA; McElnay, JC; McMahon, MA; Scott, MG | 1 |
| Cho, YB; Choi, CH; Jang, CH; Park, H | 1 |
| Al Hassan, M; Byrd, RP; Halawa, A; Roy, TM; Yacoub, G | 1 |
| Di Giovamberardino, G; Federici, G; Ferrannini, M; Pastore, A; Testore, GP | 1 |
| Buynak, JD; Carey, PR; Kalp, M; Totir, MA | 1 |
| Burgess, DS; Frei, CR | 1 |
| Batista, N; Fernández, MP; Gambra, ML; Rodríguez, L | 1 |
| Bleeker-Rovers, CP; Koopman, M; Mannaerts, L; Punt, CJ; van Herpen, CM | 1 |
| Cotter, M; Crowley, B; O Connell, N; Roche, C | 1 |
| Kuo, HY; Lin, ML; Liu, CY; Wang, FD; Yen, YF | 1 |
| Bonatti, H; Cejna, M; Hartmann, G; Stelzmueller, I; Tabarelli, W; Wenzl, E | 1 |
| Barie, PS; Cayci, C; Eachempati, SR; Fusco, D; Goldstein, MJ; Huston, JM; Kapur, S; Mathew, M; Rodney, JR; Shou, J | 1 |
| Hu, LD; Huang, XJ; Jia, JS; Li, J; Lu, KY; Wang, C; Wu, DP | 1 |
| Enbawe, S; Lat, A; Lodise, TP; Manor, K; Patel, GW; Patel, N; Smith, R; Trombley, K | 1 |
| Gospodarek, E; Jachna-Sawicka, K | 1 |
| Kulkarni, KP; Pal, P; Pal, RB; Venkatesh, V | 1 |
| Fujimura, S; Nakano, Y; Takane, H; Watanabe, A | 1 |
| Butt, MU; Zakaria, M | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Rotschafer, JC; Ullman, M | 1 |
| Cheatham, SC; Kays, MB; Shea, KM; Smith, DW; Sowinski, KM; Wack, MF | 1 |
| Jones, RN; Moet, GJ; Sader, HS; Watters, AA | 1 |
| Drusano, GL; Lodise, TP; Patel, N; Scheetz, MH | 1 |
| Bulik, CC; Christensen, H; Nicolau, DP | 1 |
| An, MM; Chen, ML; Jiang, YY; Liu, P; Shen, H; Wang, R; Zhang, JD; Zou, Z | 1 |
| Bethel, CR; Bonomo, RA; Distler, AM; Kasuboski, C; Papp-Wallace, KM; Taracila, M | 1 |
| Dundar, D; Otkun, M | 1 |
| Chen, SW; Liu, XK; Wu, HY; Zhang, LL; Zhang, SC | 1 |
| Arias, MJ; de la Torre, A; Díaz, JA; Hernández, AP; Silva, E | 1 |
| Blondiaux, N; Courcol, RJ; Durocher, A; Favory, R; Nseir, S; Onimus, T; Roussel-Delvallez, M; Wallet, F | 1 |
| Apolônio, AC; de Andrade, HM; de Carvalho, MA; Diniz, CG; dos Santos, KV; Farias, Lde M; Giusta, Mda S; Pires, Sda F; Santos, AV; Veloso, Lde C | 1 |
| Foley, RJ; Kannan, S; Kourelis, T | 1 |
| Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
| Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A | 1 |
| Chang, WC; Chen, CP; Chen, TL; Cho, WL; Fung, CP; Kuo, SC; Lee, YT; Siu, LK | 1 |
| Chin, K; Haruna, A; Ichiyama, S; Ito, I; Kadowaki, S; Kase, M; Matsumoto, H; Mishima, M; Nakai, A; Niimi, A; Tanabe, N; Tsukino, M; Yasutomo, Y | 1 |
| De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
| Ge, Y; Livermore, DM; Mushtaq, S | 1 |
| Calcinari, A; Casteletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, E; Kamysz, W; Orlando, F; Rimini, M; Silvestri, C; Tocchini, M | 1 |
| Subaalaxmi, MV | 1 |
| Jahagirdar, R; Khadilkar, AV; Khadilkar, VV; Lalwani, S; Rustagi, VT | 1 |
| Amancio Martins, W; Bahia, JL; Cara, DC; Coutinho, SC; DE Macedo Farias, L; Galuppo Diniz, C; Lopes DE Andrade, JP; Morais Apolonio, AC; Nicoli, JR; Roque DE Carvalho, MA; Valéria Dos Santos, K | 1 |
| Buyle, F; Claus, B; Robays, H; Vogelaers, D | 1 |
| Bonnin, RA; Lecuyer, H; Nordmann, P; Poirel, L; Potron, A; Zahar, JR | 1 |
| Jeong, MS; Seon, JK; Song, EK | 1 |
| Bethel, CR; Bonomo, RA; Drawz, SM; Ke, W; Ori, C; Prati, F; Sampson, JM; van den Akker, F | 1 |
| Bauer, SR; Butler, R; Connor, MJ; Fissell, WH; Groszek, J; Hofmann, CL; Rehm, SJ; Salem, C | 1 |
| Clarke, MJ; Edwards, SJ; Wordsworth, S | 1 |
| Luetzke, A; Ruebben, H; Schenck, M; Schneider, T | 1 |
| Choi, JS; Kee, WJ; Koh, YI; Park, HB; Park, SH | 1 |
| Farrell, DJ; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Champion, MM; Frase, H; Mobashery, S; Smith, CA; Toth, M; Vakulenko, SB | 1 |
| Bethel, CR; Bonomo, RA; Buynak, JD; Ke, W; Nottingham, MD; Pagadala, SR; Sampson, JM; van den Akker, F | 1 |
| Braun, L; Fairchok, M; Flanagan, R; Mahlen, S; Sainato, R | 1 |
| Ge, Y; Giske, CG; Karlsson, IM; Titelman, E | 1 |
| Kılıç, SC; Sarper, N; Zengin, E | 1 |
| Bethel, CR; Bonnet, R; Bonomo, RA; Distler, AM; Endimiani, A; Hujer, AM; Hujer, KM; Papp-Wallace, K; Shyr, T; Taracila, M; Thomson, JM | 1 |
| Chao, CM; Chiu, YH; Hou, CC; Lai, CC; Liu, WL | 1 |
| Baquero, F; Cantón, R; Galán, JC; Novais, A; Ripoll, A; Rodríguez-Domínguez, MJ; Turrientes, MC | 1 |
| Blahut, L; Hricová, K; Kolár, M; Neiser, J; Urbánek, K; Uvízl, R; Vojtová, V | 1 |
| Aldahham, A; Asfar, S; Ayyash, EH; Soliman, MO | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Bernusset, S; Cattoen, C; Cuzon, G; Naas, T; Nordmann, P | 1 |
| Chen, YM; Huang, CC; Kuo, CC; Tsai, CH; Yang, FJ | 1 |
| Funke, M; Janssen, E; Rodloff, AC; Schaumann, R | 1 |
| Benziger, D; Friedland, I; Hershberger, E; Miller, B; Trinh, M | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS | 1 |
| Hansson, J; Johnsson, E; Jönsson, C; Körner, U; Ludwigs, K; Lundholm, K | 1 |
| Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N | 1 |
| Andersson, RE; Schein, M | 1 |
| Kasap, M; Torol, S | 1 |
| Jiang, R; Sun, G | 1 |
| Holzgrabe, U | 1 |
| Chandorkar, G; Gotfried, MH; Huntington, JA; Rodvold, KA; Umeh, O | 1 |
| Inan, D; Ogunc, D; Ongut, G; Ozen, NS; Seyman, D | 1 |
| Bilker, WB; Edelstein, PH; Han, JH; Kasahara, K; Lautenbach, E | 1 |
| Adams, CA; Cioffi, WG; Connolly, MD; Gregg, S; Heffernan, DS; Monaghan, SF; Stephen, A; Thakkar, RK | 1 |
| Bulitta, JB; Drusano, GL; Holzgrabe, U; Kinzig, M; Kirkpatrick, CM; Landersdorfer, CB; Sörgel, F; Stephan, U | 1 |
| Metan, G | 1 |
| Clamp, PJ; Egala, A; Hajioff, D | 1 |
| Chander, J; Garg, R; Gulati, N; Gupta, V; Krishnan, P; Kumarasamy, K | 1 |
| Costa, P; Gattuso, G; Scalzini, A; Tomasoni, D | 1 |
| Chen, HC; Chuang, SH; Huang, JC; Lee, MH; Lin, SY; Shen, MC | 1 |
| Dortet, L; Nordmann, P; Poirel, L | 1 |
| Falagas, ME; Ikawa, K; Tansarli, GS; Vardakas, KZ | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Chai, LY; Chee, YL; Chng, WJ; Ding, Y; Hsu, LY; Jin, J; Lee, YM; Poon, LM; Tan, LK | 1 |
| Jiang, Y; Kuang, C | 1 |
| Andes, DR; Craig, WA | 1 |
| Argento, AC; Heavner, MS; Ruggero, MA; Topal, JE | 1 |
| Firnberg, E; Ostermeier, M | 1 |
| Celebi, S; Demirkaya, M; Hacımustafaoglu, M; Sevinir, B | 1 |
| Conklin, BC; Hutton, RA; Li, M; Skalweit, MJ; Taracila, MA | 1 |
| Hoppe, UC; Kochanek, M; Larbig, R; Lehman, C; Michels, G; Reda, S; Rottländer, D | 1 |
| Chen, CL; Li, R; Wang, YT | 1 |
| Esch, GW; Hu, J; Yang, Y; Zuo, W; Zuo, Y | 1 |
| Choi, EH; Lee, HJ; Lee, J; Oh, CE | 1 |
| Charoenpong, L; Thamlikitkul, V; Tongsai, S | 1 |
| Gümüşderelioğlu, M; Kahraman, AS; Pulat, M; Tan, N | 1 |
| López-Cerero, L; Muniain, MA; Pascual, Á; Retamar, P; Rodríguez-Baño, J | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, B | 1 |
| Chhibba, A; Nayak, U; Patankar, M; Sequeira, L; Sukumaran, S | 1 |
| Ambrose, PG; Bhavnani, SM; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, J; Vanscoy, B | 1 |
| Adam, H; Baxter, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B | 1 |
| Amato, S; Aurello, P; D'Angelo, F; Magistri, P; Ramacciato, G; Sirimarco, D; Virgilio, E | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 3 |
| Althaus, K; Busemann, C; Friesecke, S; Greinacher, A; Hron, G; Knutson, F; Lubenow, N; Thiele, T | 1 |
| Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Dharuman, JG; Vasudevan, M | 1 |
| Creely, D; Dunne, WM; Gayral, JP; Shortridge, D; Shubert, C; Slaughter, J; van Belkum, A; Zambardi, G | 1 |
| Adam, H; Chung, P; Denisuik, A; Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Lynch, JP; Rubinstein, E; Schweizer, F; Walkty, A; Zelenitsky, S; Zhanel, GG | 1 |
| Fortier, LC; Garneau, JR; Valiquette, L | 1 |
| Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Bethel, CR; Bonomo, RA; Buynak, JD; Pagadala, SR; Rodkey, EA; van den Akker, F; Winkler, ML | 1 |
| Chandorkar, G; Hershberger, E; Krishna, G; Miller, B; Wooley, M | 1 |
| Boots, RJ; Jarrett, P; Kirkpatrick, CM; Lipman, J; Roberts, JA; Varghese, JM | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M | 1 |
| Gautam, V; Kaur, R; Ray, P; Singhal, L | 1 |
| Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL | 1 |
| Michels, G; Pfister, R | 1 |
| Bethel, CR; Bonomo, RA; Carey, PR; de Boer, PA; Heidari Torkabadi, H; Papp-Wallace, KM | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
| Bentley, AM; Felton, TW; Goodwin, J; Hope, WW; Isalska, B; Malagon, I; McCalman, K; Whalley, S | 1 |
| Castaño, J; Jaramillo, MC; Mora, CL | 1 |
| Friedland, I; Hershberger, E; Lucasti, C; Miller, B; Solomkin, J; Steenbergen, J; Yankelev, S | 1 |
| Hong, SK; Kim, EC; Kim, JA | 1 |
| Dietrich, KA; Herzinger, T; Ruzicka, T | 1 |
| Ambrose, PG; Bhavnani, SM; Castanheira, M; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Steenbergen, JN; VanScoy, BD | 1 |
| Beceiro, A; Bou, G; Galleni, M; García, P; Gómez-Bertomeu, F; González-López, JJ; Kerff, F; Larrosa, N; Méndez, JA; Miró, E; Navarro, F; Oliver, A; Pérez-Llarena, FJ; Zamorano, L | 1 |
| Aguilar, L; Gilsanz, F; Gimenez, MJ; Maseda, E | 1 |
| Bush, K; Bussell, B; Clugston, SL; Estabrook, M | 1 |
| Bandettini, R; Barco, S; Cangemi, G; Castagnola, E; Maffia, A; Tripodi, G | 1 |
| Chandorkar, G; Hershberger, E; Krishna, G; Mouksassi, MS; Xiao, A | 1 |
| Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
| Conte, V; D'Inzeo, T; De Angelis, G; Di Florio, V; Fiori, B; Giani, T; Giaquinto, A; Palucci, I; Rossolini, GM; Sanguinetti, M; Santangelo, R; Scoppettuolo, G; Spanu, T | 1 |
| Agudelo, M; Rodriguez, CA; Vesga, O; Zuluaga, AF | 1 |
| Bandettini, R; Barco, S; Bruschettini, M; Cangemi, G; Castagnola, E; Ramenghi, LA; Risso, FM; Tripodi, G | 1 |
| Carroll, F; Pai, MP; Truong, J; Zheng, H | 1 |
| Eckmann, C; Solomkin, J | 1 |
| Chong, Y; Jeong, SH; Kim, M; Kim, WH; Lee, K; Lee, Y; Seo, YH; Yim, J; Yong, D | 1 |
| Avidor, I; Gefen, A; Hakim, F; Kassis, I; Shachor-Meyouhas, Y; Weyl Ben-Arush, M; Zaidman, I | 1 |
| Chen, L; Wang, Y; Yang, H; Zhang, C; Zhou, Q | 1 |
| Ender, PT; Kazi, HA; Shaik, S | 1 |
| Kok, J; Lam, VW; McMullan, B; Pollett, S; Qureshi, C | 1 |
| Barie, PS; Collins, S; Eckmann, C; Friedland, I; Hershberger, E; Miller, B; Popejoy, M; Solomkin, J; Steenbergen, J; Yoon, M; Yuan, G | 1 |
| Loureiro, M; Nogueira, C; Portugal, R; Santos, B | 1 |
| Bassetti, M; Righi, E | 1 |
| Baek, JY; Sohn, KM | 1 |
| Cheatham, SC; Chung, EK; Fleming, MR; Healy, DP; Kays, MB; Shea, KM | 1 |
| Lagarde, C; Mavridou, E; Melchers, MJ; Mouton, JW; Seyedmousavi, S; van Mil, AC | 1 |
| Du, Y; Guo, W; He, J; He, Q; Wang, Z; Wei, M; Wu, C; Yang, Z | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL | 1 |
| Cho, SY; Chung, DR; Ha, YE; Jung, CW; Kang, CI; Kang, ES; Ko, JH; Lee, JY; Lee, WJ; Peck, KR; Song, JH | 1 |
| Darouiche, RO; Steenbergen, J; Umeh, O; Wagenlehner, FM; Yuan, G | 1 |
| Melchers, MJ; Mouton, JW; van Mil, AC | 1 |
| Cleveland, KO; Gelfand, MS | 1 |
| Al-Attas, A; Belal, F; El-Enany, N; Nasr, JJ | 1 |
| Skalweit, MJ | 1 |
| Nicolau, DP; Sutherland, CA | 2 |
| Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ | 1 |
| Bolton, D; Gibbons, J; McGill, K; Meade, J; Smith, S; Whyte, P | 1 |
| Cha, MK; Cho, SY; Chung, DR; Ha, YE; Kang, CI; Kim, SH; Peck, KR; Song, JH; Wi, YM | 1 |
| Hwang, GY; Kim, J; Lee, HG; Uh, Y; Yoo, G; Yoon, KJ | 1 |
| Cho, JC; Estrada, SJ; Fiorenza, MA | 1 |
| Hirsch, EB; Liscio, JL; Mahoney, MV | 1 |
| Chahine, EB; Cogan, P; Fete, M; Sucher, AJ | 1 |
| Davin-Regli, A; Franceschi, C; Pagès, JM; Pinet, E; Zambardi, G | 1 |
| Berrazeg, M; Broutin, I; Fournier, D; Jeannot, K; Loeffert, S; Ntsogo Enguéné, VY; Plésiat, P | 1 |
| Akiyama, M; Hasegawa, H; Hashimoto, T; Ishii, N; Kato, Y; Ozawa, H; Tomida, E | 1 |
| Daniels, H; Delforge, M; Martens, PJ | 1 |
| Burnham, CA; Dubberke, ER; Gonzalez, MD; Hink, T; Wallace, MA | 1 |
| Bofarull, AM; Cantón, R; García-Castillo, M; Tato, M | 1 |
| Brock, B; Gjedsted, J; Hardlei, TF; Juul, RV; Kreilgaard, M; Öbrink-Hansen, K; Storgaard, M; Thomsen, MK | 1 |
| Hussar, DA | 1 |
| Ballard, A; Biddy, BA; Bouley, R; Burnham, CA; Chang, M; Dantas, G; Gonzales, PR; Mobashery, S; Pesesky, MW; Schroeder, VA; Suckow, MA; Wolter, WR | 1 |
| Abbas, S; Dortet, L; Nordmann, P; Oueslati, S; Poirel, L | 1 |
| Green, MD; Janowski, AB; Martin, JM; Michaels, MG | 1 |
| Botes, J; Boutlis, CS; Glasgow, AL; Jones, SL; Riordan, JW | 1 |
| Listernick, R | 1 |
| Anderson, AM; Easley, K; Kandiah, S; Kim, T; Patel, M; Rab, S; Wong, J; Xue, W | 1 |
| Arakawa, Y; Fujita, A; Jin, W; Kimura, K; Mikamo, H; Suematsu, H; Wachino, J; Yamada, K; Yamagishi, Y; Yokoyama, S | 1 |
| Armstrong, ES; Farrell, DJ; Palchak, M; Steenbergen, JN | 1 |
| Bowker, KE; MacGowan, AP; Nicholls, D; Noel, AR; Tomaselli, SG | 1 |
| Fowler, RC; Geyer, CN; Hanson, ND; Hawkey, P; Johnson, JR; Johnston, B; Weissman, SJ | 1 |
| Alyousef, AA; Alzahrani, AJ; Krishnappa, LG; Marie, MA; Mubaraki, MA | 1 |
| Cluck, D; Lewis, P; Moorman, J; Spivey, J; Stayer, B | 1 |
| Hsu, AJ; Tamma, PD; Tamma, SM | 1 |
| Geerlings, SE; Holleman, F; Schneeberger, C | 1 |
| Linneman, TW; Lorenz, MA; Moenster, RP | 1 |
| Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P | 1 |
| Bulman, ZP; Forrest, A; Friedrich, LV; Holden, PN; Kelchlin, P; Lenhard, JR; Soon, RL; Steenbergen, JN; Tsuji, BT | 1 |
| Scott, LJ | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, BD | 1 |
| Boyd, D; Carpenter, M; Desruisseau, A; Janecko, N; Mangat, CS; Martz, SL; Mulvey, MR; Reid-Smith, RJ | 1 |
| Bartlett, CS; Groth, ME; McMillian, WD; Redfern, J; Wasilko, SM | 1 |
| Akiyama, K; Hamaoka, S; Katoh, H; Kinoshita, M; Naito, Y; Sawa, T; Shimizu, M | 1 |
| Chen, Y; Gao, W; Li, X; Ouyang, W; Wei, J; Wen, Z; Xue, H | 1 |
| Alkrouk, A; Buehrle, DJ; Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
| Bliss, C; Cloutier, DJ; Goldstein, EJ; Huntington, JA; Sakoulas, G; Steenbergen, JN; Umeh, O | 1 |
| Merluzzi, S; Pagotto, A; Pillinini, P; Valeri, M | 1 |
| Chon, JW; Jeong, DK; Kim, DH; Kim, HS; Kim, YJ; Seo, KH | 1 |
| Arya, A; Barber, KE; Hallesy, J; Rybak, MJ; Singh, NB; Smith, JR; Yim, J | 1 |
| Cadnum, JL; Donskey, CJ; Jury, LA; Kundrapu, S; Musuuza, JS; Nerandzic, MM; Sethi, AK; Sunkesula, VC | 1 |
| Freemantle, N; Nisar, S; Ray, D; Shallcross, LJ | 1 |
| Greenwood-Quaintance, KE; Karau, MJ; Kohner, PC; Patel, R; Schmidt-Malan, SM; Velez Perez, AL | 1 |
| Alverdy, J; Hershberger, E; Miller, B; Popejoy, MW; Steenbergen, JN | 1 |
| Agudelo, M; Aguilar, YA; Rodriguez, CA; Vesga, O; Zuluaga, AF | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Cho, H; Huang, X; Jang, CH; Lee, K; Park, SH; Piao, YL; Yoon, EJ; Zhan, CG | 1 |
| Aitken, SL; Bhatti, MM; DePombo, AM; Gettys, SC; Kontoyiannis, DP; Nicolau, DP; Nunez, CA; Tverdek, FP | 1 |
| Alidjanov, JF; Wagenlehner, FM | 1 |
| Al-Ajmi, J; Ali, HS; George, S; Khan, FY; Shaikh, N | 1 |
| Antony, S; Dominguez, DC; Soto-Ruiz, E; Teleb, M | 1 |
| Ghazi, IM; Kuti, JL; Nicolau, DP; Quintiliani, R; Shore, E | 1 |
| Choudhary, S; Makwana, M; Soni, JP; Tripathi, N | 1 |
| McClain, D; Vickery, SB; Wargo, KA | 1 |
| Forland, SC; Maskiewicz, VK; Veillette, JJ; Winans, SA | 1 |
| Cies, JJ; Kuti, JL; Monogue, ML; Muhlebach, M; Nicolau, DP; Pettit, RS | 1 |
| Borgia, G; Gentile, I; Maraolo, AE | 1 |
| Akbar, M; Ayhan, DH; Bailey, SM; Daly, SM; Greenberg, DE; Tamer, YT; Toprak, E; Wong, M | 1 |
| Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
| Algora-Weber, A; de la Calle-Pedrosa, N; Delgado-Iribarren, A; Gabán-Díez, Á; González-Jiménez, AI; Hernández-Tejedor, A; Martín-Vivas, A; Merino-Vega, CD; Ruiz de Luna-González, R; Temprano-Gómez, I | 1 |
| Mikamo, H; Sugimoto, N; Yamagishi, Y | 1 |
| Bliss, CA; Cloutier, D; Hershberger, E; Huntington, JA; Kaye, KS; Miller, B; Paterson, DL; Popejoy, MW; Steenbergen, JN; Umeh, O | 1 |
| Henson, KE; Rybak, MJ; Sakoulas, G; Smith, JR; Yim, J | 1 |
| Berti, A; Munguia, J; Nizet, V; Nonejuie, P; Olson, J; Pogliano, J; Rose, W; Rybak, MJ; Sakoulas, E; Sakoulas, G | 1 |
| Armstrong, ES; Bliss, CA; Cloutier, DJ; Mikulca, JA; Steenbergen, JN | 1 |
| Baumert, P; Feihl, S; Gastmeier, P; Gebhardt, F; Gölz, H; Hamprecht, A; Kern, WV; Knobloch, J; Kola, A; Mischnik, A; Obermann, B; Peter, S; Querbach, C; Rohde, A; Seifert, H; Tacconelli, E; Willmann, M | 1 |
| Castón, JJ; De la Torre, Á; Ruiz-Camps, I; Sorlí, ML; Torre-Cisneros, J; Torres, V | 1 |
| Connor, KA | 1 |
| Goldstein, EJ; Kullar, R; Long, J; Popejoy, MW; Wagenlehner, FM; Yu, B | 1 |
| Crespo Casal, M; Martinez-Lamas, L; Nodar, A; Perez-Landeiro, A; Perez-Rodríguez, MT; Sousa Dominguez, A | 1 |
| Hamada, Y; Nicolau, DP; Thabit, AK | 1 |
| Burnham, CA; Crotty, MP; Gonzalez, MD; McMullen, AR; Ritchie, DJ; Wallace, MA | 1 |
| Greene, S; Kailainathan, R; Koutsogiannis, Z; Wong, A | 1 |
| Dong, M; Gong, C; Huang, F; Jiao, Y; Li, AH; Li, MZ; Luo, M; Zhang, TG | 1 |
| Duplessis, CA; McGann, P; Perkins, MJ; Snesrud, E | 1 |
| Brockhurst, MA; Davies, EV; James, CE; Winstanley, C | 1 |
| Dizbay, M; Karaşahin, EF; Karaşahin, Ö; Özger, HS | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Chen, Y; Guo, P; Yu, G; Yue, C | 1 |
| Bassetti, M; Castanheira, M; Duncan, LR; Pfaller, MA | 1 |
| Gillani, SJH; Jielani, A; Naqvi, SAR; Rasheed, R; Saeed, N; Zahoor, AF | 1 |
| Cho, SH; Kim, HS; Kim, KY; Kim, YJ; Seo, KH; Whan, CJ; Yim, JH | 1 |
| Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR | 1 |
| Benier, L; Bodrenko, I; Ceccarelli, M; Ghai, I; Pira, A; Scorciapino, MA; Wagner, R; Winterhalter, M | 1 |
| Rademacher, J; Welte, T | 1 |
| Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A | 1 |
| Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N | 1 |
| Álvarez Lerma, F; Gracia Arnillas, MP; Grau, S; Mico García, M; Muñoz Bermudez, R; Recasens, L; Sorli, L | 1 |
| Berenson, CS; Kurtzhalts, KE; Manohar, A; Mergenhagen, KA | 1 |
| Carlier, M; De Cock, PAJG; de Jaeger, A; De Paepe, P; Delanghe, JR; Della Pasqua, OE; Robays, H; van Dijkman, SC; Vande Walle, J; Verstraete, AG; Willems, J | 1 |
| Arai, K; Kato, M; Matsuoka, T; Mori, T; Ohashi, K; Shinoda, Y; Yoshida, S; Yoshimura, T | 1 |
| Huntington, JA; Long, J; Popejoy, MW | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 2 |
| Cai, J; Chan, EW; Chen, S; Cheng, Q; Fang, Y; Gu, D; Shen, Y | 1 |
| Adkin, R; Chaudhry, A; Hill, R; Hopkins, KL; Livermore, DM; Meunier, D; Mushtaq, S; Pike, R; Staves, P; Woodford, N | 1 |
| Ahir, H; Foo, J; Merchant, S; Prabhu, V; Sarpong, E | 1 |
| Ourique, C; Rego-Costa, F; Torres-Ramalho, P | 1 |
| Borgia, G; Buonomo, AR; De Zottis, F; Di Renzo, G; Gentile, I; Maraolo, AE; Scotto, R | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Chiang, TT; Chiu, CC; Lin, TC; Wu, RX; Yang, YS | 1 |
| Cabot, G; Del Barrio-Tofiño, E; Fraile-Ribot, PA; Juan, C; Mulet, X; Oliver, A; Pérez, JL | 1 |
| Davido, B; de Truchis, P; Dinh, A; Salomon, J; Senard, O | 1 |
| Alatoom, A | 1 |
| Bennis, Y; Bodeau, S; Kontar, L; Lemaire-Hurtel, AS; Maizel, J; Masmoudi, K; Quinton, MC; Slama, M; Zerbib, Y | 1 |
| Grupper, M; Nicolau, DP; Sutherland, C | 1 |
| Mueller, BA; Shaw, AR | 1 |
| Flamm, RK; Huband, MD; Jones, RN; Riedel, S; Sader, HS | 1 |
| Borgia, G; Cascella, M; Corcione, S; Cuomo, A; De Rosa, FG; Gentile, I; Maraolo, AE; Nappa, S | 1 |
| Bailoor, K; Chen, T | 1 |
| Aitken, SL; Foolad, F; McDaneld, PM | 1 |
| Cheng, L; Gomez-Simmonds, A; Mehta, M; Nelson, BC; Shi, Q; Uhlemann, AC | 1 |
| Anderson, CW; Cazares, KS; Denunzio, TM; Lustik, MB; Patel, SM | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Sinkó, J | 1 |
| Chen, L; Kreiswirth, BN; MacVane, SH; Pandey, R; Steed, LL | 1 |
| Becker, K; Bletz, S; Idelevich, EA; Mellmann, A; Schaumburg, F | 1 |
| Bodro, M; Marco, F; Martínez, JA; Soriano, A; Xipell, M | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Cheng, S; Clancy, CJ; Cooper, VS; Doi, Y; Haidar, G; Hao, B; Nguyen, MH; Philips, NJ; Potoski, BA; Press, EG; Shields, RK; Snyder, D | 1 |
| Livermore, DM; Mushtaq, S; Turner, SJ; Warner, M; Woodford, N | 1 |
| Guerra Valero, YC; Lipman, J; Naicker, S; Ordenez Meija, JL; Parker, SL; Roberts, JA; Wallis, SC | 1 |
| Bassetti, M; Castaldo, N; Givone, F; Lechiancole, A; Livi, U; Maiani, M; Pea, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Lodise, TP; Natesan, S; Pai, MP | 1 |
| Cipelli, R; Dangoor, A; Hodgson, M; Lester, JF; Naik, J; Newsom-Davis, T; Patel, A; Shah, R; Summerhayes, M; Talbot, D; Talbot, T | 1 |
| Chon, JW; Khan, S; Kim, H; Kim, YJ; Rashid, F; Seo, KH; Sung, K | 1 |
| Aranda-Aguirre, E; Guerrero-Wooley, R; Li, W; Palavecino, E; Wilkin, A | 1 |
| Arcenillas, P; Boix-Palop, L; Calbo, E; Cuchi, E; Dietl, B; Gómez, L; González de Molina, FJ; Nicolás, J; Sánchez, I | 1 |
| Bansal, N; Gopalakrishnan, R; Kumar D, S; Nambi, PS; Ramasubramanian, V; Sukhwani, KS | 1 |
| Bischoff, S; Ebert, M; Gerigk, M; Vogelmann, R; Walter, T | 1 |
| Fridrichová, M; Jakubů, V; Žemličková, H | 1 |
| Hakki, M; Lewis, JS | 1 |
| Fitzgerald, D; Joyce, DA; Lee, YCG; O'Halloran, SJ; Popowicz, ND | 1 |
| Girotto, JE; Nicolau, DP; Rodriguez, BA | 1 |
| Monogue, ML; Nicolau, DP; Nizet, V; Sakoulas, G | 1 |
| Blasi, F; Downey, DG; Elborn, JS; Gramegna, A; Millar, BC; Moore, JE | 1 |
| Bertrand, X; Bouiller, K; Bouxom, H; Fournier, D; Hocquet, D | 1 |
| Ledger, TS | 1 |
| Almirante, B; Arévalo, Á; Campany, D; Escolà-Vergé, L; Ferrer, R; Larrosa, N; Len, O; Los-Arcos, I; Nuvials, X; Pigrau, C; Viñado, B | 1 |
| Colby, J; Fissell, WH; Groszek, JJ; Patel, P; Seegmiller, A; Shotwell, M; Verhoven, SM; Verstraete, A | 1 |
| Chaves, F; Lora-Tamayo, J; Orellana, MÁ; Recio, R; Viedma, E; Villa, J | 1 |
| Aguilar-Aguilar, G; Alós-Almiñana, M; Belda-Nacher, JF; Carbonell, JA; Ezquer-Garin, C; Ferriols-Lisart, R | 1 |
| Asano, T; Hirano, S; Imai, S; Kushiya, H; Miyasaka, D; Nakamura, T; Nakanishi, Y; Noji, T; Okamura, K; Shichinohe, T; Tanaka, K; Tsuchikawa, T | 1 |
| Cho, SB; Hong, JY; Jeong, YH; Joo, YE; Kang, YJ; Kim, JW; Kim, KH; Lee, WS; Myung, DS; Son, DJ | 1 |
| Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K | 1 |
| Caccese, E; Marinai, C; Messori, A; Trippoli, S; Tulli, G | 1 |
| Gad, A; Hindi, Z; Zahoor, T; Zock, RZÀ | 1 |
| Leong, D; Wu, PE | 1 |
| Bergstrom, C; Gupta, A; Nagalla, S | 1 |
| Anagnostopoulos, A; Depmeier, C; Jeger, V; Rifaat, M; Schneemann, M | 1 |
| Cabri, W; Cerisoli, L; Ferrazzano, L; Martelli, G; Ricci, A; Tolomelli, A; Viola, A | 1 |
| Bonomo, RA; Davis, SL; Dhar, S; File, TM; Gerlach, AT; Kaye, KS; Olson, S; Patel, TS; Perez, F; Pogue, JM; Puzniak, LA; Veve, MP | 1 |
| Dorn, C; Eberl, S; Nussbaumer-Pröll, AK; Reiter, B; Stimpfl, T; Zeitlinger, M | 1 |
| Carvalhaes, CG; Duncan, LR; Flamm, RK; Sader, HS; Shortridge, D | 1 |
| Forland, SC; Guerrero-Wooley, RL; Hino, G; Park, SH; Winans, SA | 1 |
| Murri, R; Sacco, E | 1 |
| Caissy, JA; El-Haffaf, I; Marsot, A | 1 |
| Al Jalali, V; Dorn, C; Kratzer, A; Lackner, E; Matzneller, P; Österreicher, Z; Taubert, M; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Chen, Y; Liu, L; Xiang, Q | 1 |
| Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK | 1 |
| Imai, S; Itoh, T; Kadomura, S; Kashiwagi, H; Momo, K; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
| Dhamija, P; Goyal, T; Gupta, P; Trikha, V; Vardhan, G | 1 |
| Kim, HI; Kim, HS; Kim, YK; Lee, DH; Lee, SH; Park, S | 1 |
| Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ | 1 |
| Carolan, C; Chojnowski, G; Egorov, AM; Grigorenko, VG; Lamzin, VS; Pereira, J; Petrova, TE; Rubtsova, MY; Samygina, VR; Uporov, IV | 1 |
| Gillani, SW; Hussain, MW; Mahmood, RK; Rathore, HA; Saeed, MW; Vippadapu, P | 1 |
| Castanheira, M; Chen, WT; Pfaller, M; Shortridge, D; Streit, J; Tulloch, M | 1 |
| Al Jalali, V; Ballarini, N; Bauer, M; Bergmann, F; Jorda, A; König, F; Lackner, E; Nussbaumer-Pröll, A; Oesterreicher, Z; Reiter, B; Stimpfl, T; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Caldwell, JT; Dong, S; Fei, L; Goldstein, SL; Hasson, D; Kaplan, J; Slagle, C; Tang Girdwood, S; Tang, P; Vinks, AA | 1 |
| Gill, CM; Nicolau, DP | 1 |
| An, G; Balevic, SJ; Chan, AW; Cohen-Wolkowiez, M; Conrad, T; Gu, K; Hemmersbach-Miller, M; Kirkpatrick, CMJ; Landersdorfer, CB; Schmader, KE; Swamy, GK; Walter, EB; Winokur, PL | 1 |
| Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH | 1 |
| Akrich, B; DeRyke, CA; Hawser, SP; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH | 1 |
| Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y | 1 |
| Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J | 1 |
| Colman, R; De Cock, PA; De Paepe, P; Devreese, M; Dhont, E; Hermans, E; Vande Walle, J; Verougstraete, N; Zeitlinger, M | 1 |
66 review(s) available for tazobactam and penicillanic acid
| Article | Year |
|---|---|
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Topics: Animals; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Humans; Microbial Sensitivity Tests; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Randomized Controlled Trials as Topic; Tazobactam | 1994 |
Enterococcis: pathogens of the 90s.
Topics: Abdominal Abscess; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Gram-Positive Bacterial Infections; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 1994 |
Anaerobes in polymicrobial surgical infections: incidence, pathogenicity, and antimicrobial resistance.
Topics: Abdominal Abscess; Bacteremia; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; beta-Lactamase Inhibitors; beta-Lactamases; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Incidence; Penicillanic Acid; Peritonitis; Piperacillin; Surgical Wound Infection; Tazobactam; Virulence | 1994 |
Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Topics: Abdomen; Bacterial Infections; beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Injections, Intramuscular; Injections, Intravenous; Metabolic Clearance Rate; Penicillanic Acid; Piperacillin; Soft Tissue Infections; Tazobactam; Tissue Distribution | 1994 |
Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Necrosis; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Ticarcillin | 1994 |
Emerging trends in antimicrobial resistance in surgical infections. A review.
Topics: Bacteroides; beta-Lactamase Inhibitors; Clostridium; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Humans; Methicillin Resistance; Penicillanic Acid; Piperacillin; Staphylococcus; Surgical Wound Infection; Tazobactam | 1994 |
Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
Topics: Abdomen; Bacterial Infections; beta-Lactamase Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Soft Tissue Infections; Tazobactam | 1995 |
Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 1995 |
Treatment of skin and soft-tissue infections.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Fasciitis; Humans; Necrosis; Penicillanic Acid; Piperacillin; Skin Diseases; Soft Tissue Infections; Surgical Wound Infection; Tazobactam | 1995 |
Pharmacokinetic characteristics of piperacillin/tazobactam.
Topics: beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors; Tissue Distribution; Tobramycin; Vancomycin | 1994 |
Piperacillin/tazobactam in the treatment of polymicrobial infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Drug Resistance, Microbial; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1994 |
The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
Topics: Abdomen; Bacterial Infections; beta-Lactamase Inhibitors; Clinical Trials as Topic; Drug Combinations; Humans; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.
Topics: Bacteremia; beta-Lactamase Inhibitors; Clinical Trials as Topic; Drug Combinations; Humans; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
Topics: Animals; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
Topics: Animals; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Tissue Distribution | 1993 |
Piperacillin/tazobactam: a critical review of the evolving clinical literature.
Topics: Drug Therapy, Combination; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Treatment Failure | 1996 |
Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbapenems; Cephalosporins; Child; Child, Preschool; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Molecular Structure; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Ticarcillin | 1996 |
[Development of beta-lactamase inhibitors].
Topics: Animals; Bacteria; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Drug Therapy, Combination; Mice; Penicillanic Acid; Piperacillin; Tazobactam | 1997 |
Beta-lactam/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Models, Biological; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Tazobactam | 1998 |
Pharmacokinetic properties of beta-lactamase inhibitors.
Topics: Absorption; Aging; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Biological Availability; Clavulanic Acid; Drug Synergism; Enzyme Inhibitors; Half-Life; Humans; Kidney Diseases; Penicillanic Acid; Sulbactam; Tazobactam | 1999 |
Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
Topics: Bacterial Infections; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1999 |
[Prevention of infection in war wounds].
Topics: Antibiotic Prophylaxis; Blast Injuries; Drug Therapy, Combination; Half-Life; Humans; Penicillanic Acid; Piperacillin; Practice Guidelines as Topic; Tazobactam; Warfare; Wound Infection; Wounds, Gunshot | 1999 |
[Activity of betalactamase inhibitors against Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Humans; Penicillanic Acid; Sulbactam; Tazobactam | 2000 |
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Topics: beta-Lactamases; Clavulanic Acid; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Penicillanic Acid; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2000 |
[Beta-lactamase inhibitor: tazobactam].
Topics: beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Penicillanic Acid; Peritonitis; Tazobactam | 1997 |
[Fundamental and clinical studies on beta-lactamase inhibitors].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Clavulanic Acid; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2001 |
[Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin].
Topics: Acetamides; Adult; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Linezolid; Oxazolidinones; Penicillanic Acid; Penicillins; Piperacillin; Protein Synthesis Inhibitors; Tazobactam; Virginiamycin | 2001 |
Penicillins and beta-lactamase inhibitor combinations.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Clavulanic Acid; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Penicillanic Acid; Penicillins; Sulbactam; Tazobactam | 2001 |
[Piperacillin-tazobactam in the treatment of severe nosocomial infections].
Topics: Bacteria; beta-Lactamase Inhibitors; Clinical Trials as Topic; Costs and Cost Analysis; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Tazobactam | 2002 |
[beta-Lactamase-inhibitor combinations].
Topics: Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Drug Design; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Penicillanic Acid; Penicillins; Sulbactam; Tazobactam | 2003 |
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2003 |
Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases.
Topics: beta-Lactamases; Cefotaxime; Cephalosporins; Clavulanic Acid; Drug Resistance, Bacterial; Enterobacteriaceae; Enzyme Inhibitors; Gene Transfer, Horizontal; Monobactams; Penicillanic Acid; Penicillins; Phylogeny; Sulbactam; Tazobactam | 2004 |
Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.
Topics: Animals; beta-Lactam Resistance; beta-Lactamase Inhibitors; Enzyme Inhibitors; Humans; Penicillanic Acid; Sulbactam; Tazobactam | 2004 |
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enzyme Inhibitors; Fever; Humans; Neutropenia; Penicillanic Acid; Penicillins; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2006 |
Antimicrobial resistance in gram-positive bacteria.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterococcus faecalis; Gastrointestinal Tract; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin Resistance; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin Resistance | 2006 |
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Hospitalization; Humans; Infusions, Intravenous; Monte Carlo Method; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors | 2009 |
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2009 |
Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; Carbapenems; Drug Administration Schedule; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2013 |
Recent advances in the synthesis of 1-monosubstituted 1,2,3-triazoles.
Topics: Acetylene; Cycloaddition Reaction; Penicillanic Acid; Tazobactam; Triazoles; Vinyl Compounds | 2013 |
Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Overdose; Female; Humans; Inactivation, Metabolic; Liver Failure, Acute; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2013 |
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Enzyme Inhibitors; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2015 |
Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Databases, Factual; Humans; Odds Ratio; Penicillanic Acid; Piperacillin; Renal Insufficiency; Tachycardia; Tazobactam | 2015 |
Delftia lacustris septicemia in a pheochromocytoma patient: case report and literature review.
Topics: Adrenal Gland Neoplasms; Aged; Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Delftia; DNA, Bacterial; DNA, Ribosomal; Gram-Negative Bacterial Infections; Humans; Male; Penicillanic Acid; Pheochromocytoma; Piperacillin; RNA, Ribosomal, 16S; Sepsis; Sequence Analysis, DNA; Tazobactam | 2015 |
Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2015 |
Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam; United States; United States Food and Drug Administration | 2015 |
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Randomized Controlled Trials as Topic; Tazobactam | 2015 |
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Mice; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2015 |
New drugs 2015, part 3.
Topics: Acids, Carbocyclic; Benzoxazines; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cephalosporins; Cyclopentanes; Drug Approval; Drug Combinations; Drug Therapy; Glucagon-Like Peptides; Guanidines; Humans; Imidazoles; Immunoglobulin Fc Fragments; Interferon-beta; Isoquinolines; Penicillanic Acid; Polyethylene Glycols; Pyridines; Quinuclidines; Recombinant Fusion Proteins; Tazobactam; Triazoles; United States; United States Food and Drug Administration | 2015 |
Ceftolozane-tazobactam: A new-generation cephalosporin.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Penicillanic Acid; Tazobactam | 2015 |
Febrile urinary tract infections: pyelonephritis and urosepsis.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Diabetes Complications; Fever; Humans; Immunocompromised Host; Levofloxacin; Penicillanic Acid; Pyelonephritis; Randomized Controlled Trials as Topic; Risk Factors; Sepsis; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2016 |
Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Humans; Intraabdominal Infections; Multicenter Studies as Topic; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2016 |
Bloodstream infection with Oligella ureolytica: a case report and review of the literature.
Topics: Aged; Alcaligenaceae; Anti-Bacterial Agents; Aortic Valve Stenosis; Bacteremia; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Male; Penicillanic Acid; Piperacillin; Risk Factors; Tazobactam; Treatment Outcome | 2016 |
Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Humans; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2016 |
[New antibiotics - standstill or progress].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftaroline; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ephedrine; Humans; Macrolides; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Penicillanic Acid; Phenobarbital; Staphylococcal Infections; Tazobactam; Theophylline; Triazoles | 2017 |
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Critical Illness; Disease Management; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam; Treatment Outcome | 2017 |
[Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?]
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2017 |
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam; Treatment Outcome | 2018 |
Liver abscess caused by Clostridium haemolyticum infection after transarterial chemoembolization for hepatocellular carcinoma: A case report.
Topics: Aged; Anti-Bacterial Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clostridium Infections; Female; Humans; Liver Abscess; Liver Neoplasms; Metronidazole; Penicillanic Acid; Piperacillin; Tazobactam | 2018 |
Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2021 |
Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Tazobactam | 2022 |
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2022 |
122 trial(s) available for tazobactam and penicillanic acid
| Article | Year |
|---|---|
Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacterial Infections; beta-Lactamase Inhibitors; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Fever; Gentamicins; Humans; Leukemia; Lymphoma; Male; Microbial Sensitivity Tests; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam | 1992 |
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 1992 |
Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.
Topics: Adult; Biological Assay; Blister; Drug Evaluation; Drug Interactions; Exudates and Transudates; Humans; Inflammation; Injections, Intravenous; Male; Penicillanic Acid; Piperacillin; Tazobactam; Tissue Distribution | 1991 |
Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
Topics: Abdomen; Abdominal Abscess; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Therapy, Combination; Europe; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam | 1994 |
Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; beta-Lactamase Inhibitors; Clindamycin; Drug Therapy, Combination; Female; Gentamicins; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; North America; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam.
Topics: Aged; Bacterial Infections; beta-Lactamases; Biopsy, Needle; Cefuroxime; Drug Therapy, Combination; Humans; Injections, Intravenous; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Prostate; Prostatic Neoplasms; Tazobactam | 1995 |
Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.
Topics: beta-Lactamase Inhibitors; Child; Child, Preschool; Humans; Infant; Metabolic Clearance Rate; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
[Comprehensive evaluation of pharmacokinetic and clinical studies on tazobactam/piperacillin in pediatric field].
Topics: Adolescent; Bacteria; Bacterial Infections; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Male; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
[Bacteriological and clinical evaluation tazobactam/piperacillin in infectious diseases in surgical field].
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Cholangitis; Cholecystitis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Surgical Wound Infection; Tazobactam | 1995 |
[A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia].
Topics: Adult; Aged; Aged, 80 and over; beta-Lactamase Inhibitors; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Lung Abscess; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam | 1995 |
[A comparative study of tazobactam/piperacillin and piperacillin in chronic respiratory tract infections].
Topics: Adult; Aged; Aged, 80 and over; beta-Lactamase Inhibitors; Chronic Disease; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 1995 |
Inhibition of the renal excretion of tazobactam by piperacillin.
Topics: Animals; beta-Lactamase Inhibitors; Blood Proteins; Depression, Chemical; Dogs; Humans; Inulin; Kidney; Male; Penicillanic Acid; Piperacillin; Probenecid; Protein Binding; Tazobactam | 1994 |
Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; beta-Lactamase Inhibitors; Clavulanic Acids; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam; Ticarcillin | 1994 |
[Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'étude des Aplasies Fébriles].
Topics: Adult; Aged; Amikacin; beta-Lactamase Inhibitors; Ceftazidime; Drug Therapy, Combination; Fever; Humans; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review.
Topics: Adult; Aged; Amikacin; beta-Lactamase Inhibitors; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 1994 |
Piperacillin/tazobactam in complicated urinary tract infections.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Recurrence; Remission Induction; Tazobactam; Urinary Tract Infections | 1994 |
Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
Topics: Adult; Aged; Aged, 80 and over; beta-Lactamase Inhibitors; Bone and Bones; Drug Therapy, Combination; Female; Hip; Hip Prosthesis; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
Topics: Bacteroides Infections; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Tazobactam; Ticarcillin | 1993 |
Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Clindamycin; Drug Administration Schedule; Drug Therapy, Combination; Endometritis; Female; Gentamicins; Humans; Pelvic Inflammatory Disease; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Peritoneal Diseases; Piperacillin; Tazobactam; Treatment Outcome | 1993 |
Safety profile of piperacillin/tazobactam in phase I and III clinical studies.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Injections, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia.
Topics: Abdomen; Adult; Bacteremia; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Skin Diseases, Infectious; Tazobactam | 1993 |
Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.
Topics: Adolescent; Adult; Aged; Amikacin; Bacteremia; Bacteria; Bacterial Infections; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Teicoplanin | 1993 |
Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.
Topics: Bacteria, Anaerobic; Bacterial Infections; beta-Lactamase Inhibitors; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Appendicitis; Bacterial Infections; beta-Lactamase Inhibitors; Cholangitis; Cholecystitis; Clindamycin; Combined Modality Therapy; Diverticulitis; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam | 1993 |
Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
Topics: Adult; Bacterial Infections; beta-Lactamase Inhibitors; Burns; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 1996 |
[Comparison of the therapeutic efficacy of the piperacillin/tazobactame combination vs. ampicillin and gentamycin in in the management of post-cesarean endometritis].
Topics: Adolescent; Adult; Age Factors; Ampicillin; Anti-Bacterial Agents; Cesarean Section; Drug Therapy, Combination; Endometritis; Enzyme Inhibitors; Female; Gentamicins; Humans; Parity; Penicillanic Acid; Penicillins; Piperacillin; Pregnancy; Tazobactam | 1996 |
Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Topics: Adult; Ampicillin; Bacteroides fragilis; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Cross-Over Studies; Drug Therapy, Combination; Enterococcus faecalis; Escherichia coli; Female; Humans; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Serum Bactericidal Test; Sulbactam; Tazobactam; Ticarcillin | 1997 |
[Clinical study of tazobactam/piperacillin in obstetrics and gynecological infections].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Drug Therapy, Combination; Female; Genital Diseases, Female; Humans; Infusions, Intravenous; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1996 |
[Use of piperacillin-tazobactam in abdominal surgery].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Peritonitis; Piperacillin; Sepsis; Surgical Wound Infection; Tazobactam; Treatment Outcome | 1997 |
Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
Topics: Adult; Aged; beta-Lactamases; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hemofiltration; Humans; Least-Squares Analysis; Male; Middle Aged; Multiple Organ Failure; Penicillanic Acid; Penicillins; Piperacillin; Renal Insufficiency; Tazobactam | 1997 |
Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1997 |
Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Cross-Over Studies; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Gentamicins; Half-Life; Humans; Male; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1997 |
Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital.
Topics: Adolescent; Adult; beta-Lactamase Inhibitors; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Hospitals, Teaching; Humans; Imipenem; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Thienamycins; Treatment Outcome | 1998 |
Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Topics: Anti-Infective Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Fever; Humans; Neutropenia; Penicillanic Acid; Pilot Projects; Piperacillin; Prognosis; Prospective Studies; Tazobactam | 1998 |
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Fever; Hematologic Neoplasms; Humans; Multivariate Analysis; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 1998 |
Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Amikacin; Analysis of Variance; Anti-Bacterial Agents; Ceftazidime; Chi-Square Distribution; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prognosis; Prospective Studies; Tazobactam; Treatment Failure; Treatment Outcome | 1998 |
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Topics: Acute Disease; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam | 1998 |
Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1998 |
Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.
Topics: Aged; beta-Lactamase Inhibitors; Cefotaxime; Clostridioides difficile; Cross Infection; Cross-Over Studies; Diarrhea; Drug Combinations; Enterocolitis, Pseudomembranous; Enzyme Inhibitors; Female; Humans; Male; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 1998 |
Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; British Columbia; Cilastatin; Costs and Cost Analysis; Decision Trees; Double-Blind Method; Drug Therapy, Combination; Economics, Pharmaceutical; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Models, Economic; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Protease Inhibitors; Statistics, Nonparametric; Tazobactam; Thienamycins; Treatment Outcome | 1999 |
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Bacteremia; Bacterial Infections; Case-Control Studies; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Fever of Unknown Origin; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Tobramycin; Vancomycin | 1999 |
Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Blood Chemical Analysis; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Safety; Tazobactam; Teicoplanin; Treatment Failure; Vancomycin | 1999 |
Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): a prospective randomized clinical trial.
Topics: Antibiotic Prophylaxis; Cefotaxime; Cephalosporins; Endoscopy; Enteral Nutrition; Enzyme Inhibitors; Female; Gastrostomy; Humans; Incidence; Intubation, Gastrointestinal; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Surgical Wound Infection; Tazobactam | 1999 |
Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections.
Topics: Abdominal Abscess; Appendicitis; Bacterial Infections; beta-Lactamase Inhibitors; Cefuroxime; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Intestinal Perforation; Male; Metronidazole; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Rupture, Spontaneous; Surgical Wound Infection; Tazobactam | 1999 |
[Biliary diffusion of tazocillin in man].
Topics: Bile; Diffusion; Drug Combinations; Humans; Intraoperative Care; Penicillanic Acid; Piperacillin; Tazobactam | 1999 |
Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Peritonitis; Piperacillin; Tazobactam; Treatment Outcome | 2000 |
Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Infectious; Tazobactam | 2001 |
A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Clavulanic Acid; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli Infections; Female; Humans; Male; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Respiratory Tract Infections; Tazobactam; Ticarcillin; Urinary Tract Infections | 1998 |
The role of topical antibiotic prophylaxis in patients undergoing contaminated head and neck surgery with flap reconstruction.
Topics: Administration, Topical; Adult; Aged; Antibiotic Prophylaxis; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mouthwashes; Otorhinolaryngologic Neoplasms; Penicillanic Acid; Piperacillin; Prospective Studies; Surgical Flaps; Surgical Wound Infection; Tazobactam; Therapeutic Irrigation | 2001 |
The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Enterococcus; Female; Glycopeptides; Gram-Positive Bacterial Infections; Hematology; Hospital Units; Humans; Infection Control; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 1999 |
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
Topics: Aged; Amikacin; Aztreonam; Chi-Square Distribution; Clindamycin; Cross Infection; Drug Therapy, Combination; Humans; Middle Aged; Neoplasms; Opportunistic Infections; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Postoperative Complications; Prognosis; Prospective Studies; Tazobactam | 2001 |
Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Gentamicins; Germany; Humans; Neoplasms; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Sulbactam; Tazobactam; Treatment Outcome | 2001 |
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
Topics: Adult; Aged; Aging; Anti-Bacterial Agents; Area Under Curve; beta-Lactamase Inhibitors; Creatinine; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Tobramycin | 2001 |
A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Cefpirome; Cephalosporins; Enzyme Inhibitors; Female; Fever; France; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2001 |
Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.
Topics: Abdominal Abscess; Adolescent; Appendicitis; Bacterial Infections; Cefotaxime; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intestinal Perforation; Male; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2001 |
[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Drug Therapy, Combination; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Skin Diseases; Tazobactam; Treatment Outcome | 2001 |
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Cilastatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Pyelonephritis; Sample Size; Tazobactam; Thienamycins; Urinary Tract Infections | 2002 |
Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Topics: Adolescent; Adult; Area Under Curve; beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Half-Life; Humans; Injections, Intravenous; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2002 |
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Skin Diseases; Staphylococcus aureus; Tazobactam; Treatment Outcome | 2002 |
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2002 |
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Double-Blind Method; Enzyme Inhibitors; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Bacterial; Tazobactam | 2002 |
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Topics: Adult; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2002 |
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy; Ciprofloxacin; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Injections, Intramuscular; Male; Penicillanic Acid; Penicillins; Piperacillin; Postoperative Complications; Prospective Studies; Prostatic Diseases; Tazobactam; Transurethral Resection of Prostate | 2002 |
[A multicenter clinical trial of piperacillin/tazobactam in burn infection].
Topics: Adult; Burns; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Sepsis; Tazobactam; Treatment Outcome | 2002 |
Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Gentamicins; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Treatment Outcome | 2003 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
[Carbapenem antibiotic ertapenem in the treatment of extrahospital intraabdominal infections].
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2003 |
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lactams; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome | 2003 |
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Infusions, Intravenous; Lactams; Logistic Models; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Skin Diseases; Statistics, Nonparametric; Tazobactam; Treatment Outcome | 2004 |
Vancomycin does not benefit persistently febrile neutropenic people with cancer.
Topics: Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Female; Fever; Follow-Up Studies; Humans; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome; Vancomycin | 2004 |
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibility; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Fever of Unknown Origin; Humans; Immunocompromised Host; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Penicillanic Acid; Piperacillin; Prospective Studies; Safety; Tazobactam; Treatment Outcome | 2004 |
Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Agents; Child; Child, Preschool; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Follow-Up Studies; Humans; Infant; Male; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Recurrence; Tazobactam; Treatment Outcome | 2004 |
Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Fever; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Infections; Meropenem; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2004 |
Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Biliary Tract Diseases; Biliary Tract Neoplasms; Drug Combinations; Empirical Research; Female; Humans; Infections; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 2004 |
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.
Topics: Algorithms; Computer Simulation; Cross Infection; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Models, Biological; Monte Carlo Method; Penicillanic Acid; Penicillins; Piperacillin; Population; Tazobactam | 2004 |
Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Cilastatin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2004 |
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cilastatin; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Protease Inhibitors; Spain; Tazobactam; Treatment Outcome | 2005 |
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2005 |
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Male; Meropenem; Middle Aged; Neoplasms; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Thienamycins | 2005 |
Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fever; Humans; Leukemia; Male; Middle Aged; Neutropenia; Penicillanic Acid; Peripheral Blood Stem Cell Transplantation; Piperacillin; Predictive Value of Tests; Prospective Studies; Survival Rate; Tazobactam; Transplantation, Autologous; Treatment Outcome | 2006 |
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Enzyme Inhibitors; Europe; Fever; Hematologic Neoplasms; Humans; Infant; Injections, Intravenous; Middle Aged; Middle East; Neutropenia; North America; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2006 |
Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever; Humans; Immunocompromised Host; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Risk Assessment; Risk Factors; Tazobactam; Thienamycins | 2006 |
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Protease Inhibitors; Tazobactam; Tobramycin; Treatment Outcome | 2006 |
Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
Topics: Abdomen; Adult; Bacterial Infections; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 2006 |
[Antibiotic prophylaxis in cesarean section -- piperacillin versus piperacillin/tazobactam in 300 cesarean sections].
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cesarean Section; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pregnancy; Tazobactam | 2006 |
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.
Topics: Adult; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2006 |
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.
Topics: Abdomen; Adolescent; Adult; Aged; APACHE; Bacterial Infections; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Penicillins; Tazobactam | 2006 |
Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Busulfan; Ceftriaxone; Female; Fever; Health Care Costs; Hematologic Neoplasms; Home Care Services; Hospital Charges; Humans; Inpatients; Male; Middle Aged; Neutropenia; Patient Readmission; Penicillanic Acid; Piperacillin; Stem Cell Transplantation; Tazobactam; Transplantation, Autologous | 2006 |
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
Topics: Aged; Anti-Bacterial Agents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Pulmonary Alveoli; Tazobactam | 2008 |
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Tazobactam; Treatment Outcome | 2008 |
[Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy].
Topics: Adult; Anti-Bacterial Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2009 |
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cilastatin; Community-Acquired Infections; Drug Combinations; Female; Humans; Imipenem; Injections, Intravenous; Male; Nursing Homes; Penicillanic Acid; Piperacillin; Pneumonia, Aspiration; Prospective Studies; Protease Inhibitors; Tazobactam; Treatment Outcome | 2010 |
[Perioperative antibiotic prophylaxis in radical retropubic prostatectomy: a randomised pilot study of perioperative and postoperative administration].
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Body Temperature; C-Reactive Protein; Ciprofloxacin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Neoplasm Staging; Penicillanic Acid; Perioperative Care; Pilot Projects; Piperacillin; Postoperative Complications; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Surgical Wound Infection; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2011 |
Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
Topics: Acute Disease; Adolescent; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult | 2011 |
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Penicillanic Acid; Tazobactam; Young Adult | 2012 |
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Female; Human Experimentation; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Plasma; Tazobactam; Time Factors; Young Adult | 2012 |
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
Topics: Anti-Bacterial Agents; Cross-Over Studies; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Monte Carlo Method; Nonlinear Dynamics; Penicillanic Acid; Piperacillin; Tazobactam | 2012 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Sulbactam; Tazobactam | 2013 |
Pulmonary penetration of piperacillin and tazobactam in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Lung; Male; Middle Aged; Monte Carlo Method; Penicillanic Acid; Permeability; Piperacillin; Tazobactam | 2014 |
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Topics: Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intraabdominal Infections; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome | 2014 |
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Penicillanic Acid; Renal Insufficiency; Tazobactam; Young Adult | 2015 |
Serum galactomannan screening for diagnosis of invasive pulmonary aspergillosis in children after stem cell transplantation or with high-risk leukemia.
Topics: Adolescent; Adult; Allografts; Autografts; Child; Child, Preschool; Female; Galactose; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Invasive Pulmonary Aspergillosis; Leukemia; Male; Mannans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2015 |
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Intraabdominal Infections; Male; Metronidazole; Middle Aged; Penicillanic Acid; Prospective Studies; Tazobactam; Treatment Outcome; Young Adult | 2015 |
Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Mass Index; Body Weight; Computer Simulation; Creatinine; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Monte Carlo Method; Obesity; Penicillanic Acid; Piperacillin; Tazobactam | 2015 |
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2015 |
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Pneumonia; Tazobactam; Young Adult | 2016 |
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; Cephalosporins; Drug Therapy, Combination; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intraabdominal Infections; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2016 |
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Double-Blind Method; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Female; Humans; Intraabdominal Infections; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2016 |
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Patient Safety; Penicillanic Acid; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tazobactam | 2016 |
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cephalosporins; Dose-Response Relationship, Drug; Drug Administration Schedule; Enterobacteriaceae Infections; Female; Follow-Up Studies; Humans; Injections, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Recurrence; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Penicillanic Acid; Renal Insufficiency; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Diabetes Mellitus; Female; Humans; Intraabdominal Infections; Levofloxacin; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2017 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers.
Topics: Anti-Bacterial Agents; Cefepime; Drugs, Generic; Healthy Volunteers; Humans; Linezolid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Therapeutic Equivalency | 2022 |
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Infant, Newborn; Meropenem; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
654 other study(ies) available for tazobactam and penicillanic acid
| Article | Year |
|---|---|
Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease.
Topics: Adult; beta-Lactamase Inhibitors; Creatine; Female; Humans; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Penicillanic Acid; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Renal Dialysis; Tazobactam; Time Factors | 1992 |
OHIO-1 beta-lactamase resistant to mechanism-based inactivators.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Escherichia coli; Molecular Sequence Data; Mutation; Penicillanic Acid; Plasmids; Sequence Homology, Nucleic Acid; Sulbactam; Tazobactam | 1992 |
Effect of pH on antibiotics used to treat anaerobic infection.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Cefoxitin; Clindamycin; Drug Therapy, Combination; Hydrogen-Ion Concentration; Imipenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1992 |
Effect of piperacillin/tazobactam therapy on intestinal microflora.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Feces; Female; Humans; Intestines; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Yeasts | 1992 |
Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
Topics: Animals; beta-Lactamase Inhibitors; beta-Lactamases; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Gentamicins; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rabbits; Tazobactam | 1992 |
Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.
Topics: Adipose Tissue; Adult; Aged; beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Colon; Female; Half-Life; Humans; Infusions, Intravenous; Intestinal Mucosa; Male; Middle Aged; Muscles; Penicillanic Acid; Piperacillin; Premedication; Rectum; Skin; Specimen Handling; Tazobactam | 1992 |
In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Microbial Sensitivity Tests; Oxacillin; Penicillanic Acid; Staphylococcus aureus; Tazobactam | 1992 |
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Topics: beta-Lactamase Inhibitors; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1992 |
Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
Topics: Bacteroides; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Clostridium; Fusobacterium nucleatum; Penicillanic Acid; Sulbactam; Tazobactam | 1992 |
Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
Topics: Bacteria, Anaerobic; Bacteroides; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Clostridium; Fusobacterium nucleatum; Penicillanic Acid; Sulbactam; Tazobactam | 1992 |
Structural studies on tazobactam.
Topics: beta-Lactamase Inhibitors; Computer Simulation; Models, Chemical; Molecular Conformation; Penicillanic Acid; Tazobactam | 1991 |
[In vitro activity of tazobactam and piperacillin combination against 224 strains of Pseudomonas aeruginosa according to the production of beta-lactamase].
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporinase; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; In Vitro Techniques; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 1991 |
[In vitro antibacterial activity of piperacillin-tazobactam combination on hospital isolates and regression curve].
Topics: Acinetobacter; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Enterobacteriaceae; Haemophilus; Humans; In Vitro Techniques; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus; Tazobactam | 1991 |
[In vitro synergistic activity of piperacillin-tazobactam combination against beta-lactam antibiotics resistant strains of Enterobacteriaceae].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Enterobacteriaceae; In Vitro Techniques; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
[Strict anaerobic bacteria: comparative study of various beta-lactam antibiotics in combination with tazobactam or sulbactam].
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Cefotaxime; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; In Vitro Techniques; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 1991 |
Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamases; Cell Membrane Permeability; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
Piperacillin/tazobactam in the treatment of serious acute soft tissue infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; beta-Lactamase Inhibitors; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Chromosomes, Bacterial; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Molecular Weight; Penicillanic Acid; Penicillin Resistance; Penicillins; Pseudomonas; Sulbactam; Tazobactam | 1991 |
Effect of a beta-lactamase inhibitor, tazobactam, on growth and penicillin-binding proteins of Borrelia burgdorferi.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; Borrelia burgdorferi Group; Carrier Proteins; Cell Division; Hexosyltransferases; Molecular Weight; Muramoylpentapeptide Carboxypeptidase; Penicillanic Acid; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Tazobactam | 1991 |
[Chemical structure, anti-bacterial activity and pharmacokinetics of penicillins].
Topics: beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Humans; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 1991 |
Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
Topics: beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Drug Synergism; Enterobacter cloacae; Escherichia coli; Klebsiella; Penicillanic Acid; Piperacillin; Proteus vulgaris; Pseudomonas aeruginosa; Staphylococcus aureus; Sulbactam; Tazobactam | 1991 |
In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefotaxime; Cefozopran; Cefpirome; Cephalosporins; Drug Stability; Enterobacteriaceae; Hydrolysis; Microbial Sensitivity Tests; Moxalactam; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Clavulanic Acids; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
Topics: Ampicillin Resistance; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus.
Topics: Acinetobacter; Acinetobacter Infections; Animals; beta-Lactamase Inhibitors; Humans; Male; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1990 |
Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1990 |
The effect of tazobactam on bilirubin-albumin binding.
Topics: Albumins; Bilirubin; Binding, Competitive; Chemical Phenomena; Chemistry; Humans; Infant, Newborn; Penicillanic Acid; Piperacillin; Tazobactam | 1990 |
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Topics: Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Enzyme Induction; Half-Life; Kinetics; Penicillanic Acid; Piperacillin; Tazobactam; Ticarcillin | 1990 |
Interaction of beta-lactamase inhibitors with various beta-lactamases.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Enterobacter; Escherichia coli; Humans; Klebsiella; Penicillanic Acid; Plasmids; Proteus vulgaris; Staphylococcus aureus; Sulbactam; Tazobactam | 1990 |
In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Chromosomes; Citrobacter; Drug Synergism; Enterobacter; Enzyme Induction; Humans; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas; Serratia marcescens; Tazobactam | 1990 |
Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.
Topics: Bacteroides fragilis; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Humans; Nephelometry and Turbidimetry; Penicillanic Acid; Piperacillin; Tazobactam | 1990 |
Poor induction of beta-lactamases by tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1990 |
Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Topics: Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acids; Drug Synergism; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 1990 |
Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Escherichia coli; Escherichia coli Infections; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rabbits; Tazobactam | 1990 |
The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Serratia; Tazobactam | 1990 |
Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
Topics: beta-Lactamases; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Penicillanic Acid; Piperacillin; Tazobactam | 1990 |
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Child; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Male; Penicillanic Acid; Pseudomonas aeruginosa; Sputum; Tazobactam | 1990 |
Beta-lactamase inhibitors and Acinetobacter spp.
Topics: Acinetobacter; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Species Specificity; Sulbactam; Tazobactam | 1990 |
In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Microbial; Drug Synergism; Enterobacteriaceae; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Staphylococcus; Tazobactam | 1990 |
Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
Topics: beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Hydrogen-Ion Concentration; Penicillanic Acid; Piperacillin; Tazobactam; Ticarcillin | 1990 |
Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Topics: 4-Quinolones; Anti-Infective Agents; Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactamase Inhibitors; Drug Therapy, Combination; Fluoroquinolones; Fusobacterium; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Quinolones; Tazobactam | 1990 |
[Efficiency of tazobactam as inhibitor of beta-lactamases, combined with piperacillin, against resistant strains to this penicillin].
Topics: Amoxicillin; beta-Lactamases; Chemical Phenomena; Chemistry; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Enterobacteriaceae; Female; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Tazobactam | 1989 |
Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
Topics: Amoxicillin; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Synergism; Haemophilus influenzae; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Sulbactam; Tazobactam | 1989 |
Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acids; Escherichia coli; Hydrolysis; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcus aureus; Tazobactam; Ticarcillin | 1989 |
In vitro activity of YTR 830.
Topics: Ampicillin; Bacteroides fragilis; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Therapy, Combination; Enterobacteriaceae; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Proteus vulgaris; Sulbactam; Tazobactam; Ticarcillin | 1989 |
In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria.
Topics: Animals; Bacteria; beta-Lactamases; Cefoxitin; Clavulanic Acids; Drug Therapy, Combination; Female; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Tazobactam | 1989 |
Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Combinations; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Ticarcillin | 1989 |
In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefotaxime; Cephalosporinase; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Drug Interactions; Drug Resistance, Microbial; Enterobacteriaceae; Enzyme Induction; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Ticarcillin | 1989 |
Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography.
Topics: Anti-Bacterial Agents; Bile; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Piperacillin; Spectrophotometry, Ultraviolet; Tazobactam | 1989 |
Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Topics: Animals; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Female; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 1989 |
The effects of three beta-lactamase inhibitors: YTR830H, sulbactam and clavulanic acid on the growth of human cells in culture.
Topics: beta-Lactamase Inhibitors; Cell Division; Cells, Cultured; Clavulanic Acid; Clavulanic Acids; Humans; Penicillanic Acid; Sulbactam; Tazobactam | 1987 |
Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acids; DNA, Bacterial; Drug Resistance, Microbial; Drug Synergism; Enterobacteriaceae; Genes, Bacterial; Humans; Nucleic Acid Hybridization; Penicillanic Acid; Penicillin Resistance; Penicillins; R Factors; Sulbactam; Tazobactam | 1988 |
Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
Topics: Bacteria; Bacterial Proteins; beta-Lactamase Inhibitors; Carrier Proteins; Clavulanic Acids; Hexosyltransferases; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillanic Acid; Penicillin-Binding Proteins; Peptidyl Transferases; Sulbactam; Tazobactam | 1988 |
High-performance liquid chromatographic determination of a new beta-lactamase inhibitor and its metabolite in combination therapy with piperacillin in biological materials.
Topics: Animals; beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Dogs; Feces; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Penicillanic Acid; Piperacillin; Rats; Species Specificity; Spectrophotometry, Ultraviolet; Tazobactam; Tissue Distribution | 1988 |
Degradation of beta-lactamase inhibitor, (2S,3R,5S)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thi a-1- azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (YTR-830H), in aqueous solutions and alkaline methanol solution: pathway and structural e
Topics: beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry; Magnetic Resonance Spectroscopy; Penicillanic Acid; Spectrophotometry, Ultraviolet; Tazobactam | 1988 |
The activity of a sulphone beta-lactamase inhibitor, YTR 830.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Enterobacteriaceae; Microbial Sensitivity Tests; Penicillanic Acid; R Factors; Sulbactam; Tazobactam | 1987 |
Non-mutagenicity of YTR 830 H, a novel beta-lactamase inhibitor.
Topics: beta-Lactamase Inhibitors; Mutagenicity Tests; Mutation; Penicillanic Acid; Salmonella typhimurium; Tazobactam | 1985 |
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Drug Interactions; Microbial Sensitivity Tests; Penicillanic Acid; Plasmids; Tazobactam | 1986 |
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Topics: Ampicillin; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Synergism; Gram-Negative Aerobic Bacteria; Penicillanic Acid; Penicillins; Plasmids; Sulbactam; Tazobactam | 1986 |
Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice.
Topics: Amoxicillin; Animals; Bacterial Infections; Citrobacter; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Mice; Penicillanic Acid; Proteus Infections; Staphylococcal Infections; Tazobactam | 1986 |
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1986 |
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
Topics: Ampicillin; Bacteria; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry; Clavulanic Acid; Clavulanic Acids; Escherichia coli; Penicillanic Acid; Sulbactam; Tazobactam; Triazoles | 1987 |
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Topics: Amoxicillin; Ampicillin; Bacteria; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Penicillanic Acid; Sulbactam; Tazobactam | 1984 |
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Therapy, Combination; Enterobacter cloacae; Enzyme Inhibitors; Klebsiella pneumoniae; Least-Squares Analysis; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam; Time Factors | 1995 |
Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Enzyme Inhibitors; Hydrogen-Ion Concentration; Kinetics; Penicillanic Acid; Sulbactam; Tazobactam | 1995 |
A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
Topics: beta-Lactamase Inhibitors; Drug Therapy, Combination; Enterobacteriaceae; Germany; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections.
Topics: Abdomen; Animals; Bacterial Infections; beta-Lactamase Inhibitors; Clindamycin; Drug Therapy, Combination; Gentamicins; Imipenem; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam | 1994 |
Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration.
Topics: Chromatography, High Pressure Liquid; Drug Incompatibility; Humans; Ondansetron; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
[The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Bacteria; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1995 |
[Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Enzyme Inhibitors; Gentamicins; Humans; In Vitro Techniques; Penicillanic Acid; Penicillin Resistance; Piperacillin; Tazobactam; Ticarcillin | 1995 |
[In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients].
Topics: Cefepime; Cefotaxime; Cefpirome; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 1995 |
Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
Topics: Animals; beta-Lactamase Inhibitors; beta-Lactamases; Citrobacter freundii; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Male; Mice; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Proteus vulgaris; Tazobactam | 1995 |
In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cefotaxime; Ceftazidime; Ceftriaxone; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Sulbactam; Tazobactam | 1995 |
Influence of beta-lactamase inhibitors on the activity of oxacillin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Penicillanic Acid; Staphylococcus aureus; Sulbactam; Tazobactam | 1995 |
A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Enzyme Inhibitors; Escherichia coli; Feces; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Plasmids; Population Surveillance; Tazobactam | 1995 |
Stability of piperacillin sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride minibags.
Topics: beta-Lactamase Inhibitors; Drug Packaging; Drug Stability; Humans; Penicillanic Acid; Piperacillin; Polypropylenes; Polyvinyl Chloride; Syringes; Tazobactam | 1995 |
[In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
Topics: Amikacin; Amoxicillin; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; In Vitro Techniques; Netilmicin; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.
Topics: Adult; Aged; beta-Lactamase Inhibitors; Bronchi; Drug Combinations; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Topics: Ampicillin; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Clavulanic Acids; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Streptococcus pneumoniae; Sulbactam; Tazobactam; Ticarcillin | 1994 |
[Drugs: piperacillin/tazobactam].
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Humans; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Penicillanic Acid; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Renal Insufficiency; Tazobactam | 1994 |
beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cell Division; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Isoniazid; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium avium; Penicillanic Acid; Streptomycin; Sulbactam; Tazobactam | 1995 |
Biliary elimination and hepatic disposition of an association of piperacillin and tazobactam: experimental evaluation.
Topics: Animals; beta-Lactamase Inhibitors; Bile; Biotransformation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; In Vitro Techniques; Liver; Penicillanic Acid; Perfusion; Piperacillin; Rabbits; Tazobactam | 1994 |
Distribution and characterization of beta-lactamases of mycobacteria and related organisms.
Topics: Anti-Bacterial Agents; beta-Lactamases; Corynebacterium; Drug Resistance, Microbial; Drug Synergism; Isoelectric Focusing; Isoenzymes; Mycobacterium; Mycobacterium chelonae; Nocardia; Nontuberculous Mycobacteria; Penicillanic Acid; Rhodococcus; Tazobactam | 1995 |
Rapid determination of sulbactam and tazobactam in human serum by high-performance liquid chromatography.
Topics: beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Hydrogen-Ion Concentration; Microchemistry; Penicillanic Acid; Sulbactam; Tazobactam | 1995 |
Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration.
Topics: beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Humans; Penicillanic Acid; Pharmaceutical Vehicles; Piperacillin; Ranitidine; Sodium Chloride; Solutions; Tazobactam | 1994 |
Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveilla
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Ciprofloxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
[In vitro synergistic effects of tazobactam/piperacillin with various antibiotics].
Topics: beta-Lactamase Inhibitors; Drug Synergism; Drug Therapy, Combination; Methicillin Resistance; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Tazobactam | 1994 |
Inoculum effects on Etests and agar dilution minimum inhibitory concentrations. Piperacillin and piperacillin-tazobactam against Staphylococcus aureus.
Topics: Bacteriological Techniques; beta-Lactamase Inhibitors; beta-Lactamases; Colony Count, Microbial; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Staphylococcus aureus; Tazobactam | 1994 |
The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
[Single-dose toxicity studies of tazobactam/piperacillin and tazobactam].
Topics: Animals; beta-Lactamase Inhibitors; Dogs; Drug Therapy, Combination; Female; Lethal Dose 50; Male; Mice; Mice, Inbred ICR; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Respiration; Tazobactam | 1994 |
[A six-month intraperitoneal repeated dose toxicity study of tazobactam/piperacillin and tazobactam in rats].
Topics: Animals; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Glycogen; Injections, Intraperitoneal; Male; Organ Size; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam | 1994 |
[A six-month intravenous repeated dose toxicity study of tazobactam/piperacillin and tazobactam in dogs].
Topics: Animals; beta-Lactamase Inhibitors; Dogs; Drug Therapy, Combination; Female; Injections, Intravenous; Male; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
[Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam(1)--Fertility and general reproduction study in rats with intraperitoneal administration].
Topics: Animals; beta-Lactamase Inhibitors; Drug Therapy, Combination; Embryonic and Fetal Development; Female; Fertility; Injections, Intraperitoneal; Male; Penicillanic Acid; Piperacillin; Pregnancy; Rats; Rats, Sprague-Dawley; Reproduction; Tazobactam | 1994 |
[Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (2)--Teratological study in rats with intravenously administration].
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; beta-Lactamase Inhibitors; Drug Therapy, Combination; Embryonic and Fetal Development; Female; Injections, Intravenous; Male; Penicillanic Acid; Piperacillin; Pregnancy; Rats; Rats, Sprague-Dawley; Reproduction; Tazobactam | 1994 |
[Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (3)--Perinatal and postnatal study in rats with intraperitoneal administration].
Topics: Animals; Animals, Newborn; beta-Lactamase Inhibitors; Drug Therapy, Combination; Embryonic and Fetal Development; Female; Injections, Intraperitoneal; Male; Penicillanic Acid; Piperacillin; Pregnancy; Rats; Rats, Sprague-Dawley; Reproduction; Tazobactam | 1994 |
[Antigenicity tests of tazobactam/piperacillin, tazobactam and piperacillin].
Topics: Animals; Antigens; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Guinea Pigs; Humans; Immunization; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Passive Cutaneous Anaphylaxis; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam | 1994 |
[Mutagenicity tests of tazobactam/piperacillin, tazobactam and piperacillin].
Topics: Animals; Cricetinae; Cricetulus; Drug Therapy, Combination; Escherichia coli; Male; Mice; Mice, Inbred ICR; Mutagenesis; Mutagenicity Tests; Penicillanic Acid; Piperacillin; Salmonella typhimurium; Tazobactam | 1994 |
Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
Topics: Bacteria; beta-Lactamase Inhibitors; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 1994 |
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Cefoxitin; Ciprofloxacin; Fluoroquinolones; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperazines; Quinolones; Tazobactam | 1994 |
Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Ceftriaxone; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1994 |
In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Drug Therapy, Combination; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 1994 |
Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
Topics: Anti-Bacterial Agents; Ceftazidime; Clavulanic Acids; Enterobacteriaceae; Enterococcus faecalis; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillanic Acid; Piperacillin; Predictive Value of Tests; Pseudomonas aeruginosa; Staphylococcus; Tazobactam; Ticarcillin | 1994 |
Stability of piperacillin sodium in the presence of tazobactam sodium in 5% dextrose and normal saline injections.
Topics: beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stability; Glucose; Hydrogen-Ion Concentration; Penicillanic Acid; Piperacillin; Sodium Chloride; Tazobactam | 1994 |
Synthesis and beta-lactamase inhibitory activity of 6-[(1-heteroarylthioethyl-1,2,3-triazol-4-yl)-methylene]penam sulfones.
Topics: beta-Lactamase Inhibitors; Drug Synergism; Molecular Structure; Penicillanic Acid; Structure-Activity Relationship; Sulbactam; Tazobactam; Thiadiazoles | 1994 |
In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
Topics: Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactamase Inhibitors; Ceftriaxone; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1994 |
Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
Topics: Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Penicillanic Acid; Plasmids; Sulbactam; Tazobactam | 1994 |
Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study.
Topics: Amino Acid Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Cephalosporins; Computer Simulation; Models, Molecular; Molecular Sequence Data; Penicillanic Acid; Peptide Fragments; Staphylococcus aureus; Tazobactam | 1994 |
Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.
Topics: beta-Lactamase Inhibitors; Drug Therapy, Combination; Evaluation Studies as Topic; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Predictive Value of Tests; Quality Control; Tazobactam | 1993 |
Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
Topics: beta-Lactamase Inhibitors; Culture Media; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; Streptomycin; Tazobactam | 1993 |
Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Clindamycin; Drug Resistance, Microbial; Drug Synergism; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1993 |
[Bacteremia by Escherichia coli resistant to amoxycillin/clavulanic acid, ampicillin/sulbactam and piperacillin/tazobactam].
Topics: Aged; Ampicillin; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Penicillanic Acid; Sulbactam; Tazobactam | 1994 |
Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.
Topics: beta-Lactamase Inhibitors; Drug Synergism; Drug Therapy, Combination; Humans; Legionella; Legionellosis; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Antibacterial activity of clavulanate and tazobactam on Peptostreptococcus spp.
Topics: Amoxicillin; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Peptostreptococcus; Piperacillin; Tazobactam | 1994 |
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
Topics: Animals; beta-Lactamase Inhibitors; beta-Lactamases; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Klebsiella Infections; Klebsiella pneumoniae; Meningitis, Bacterial; Penicillanic Acid; Piperacillin; Rabbits; Tazobactam | 1994 |
In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.
Topics: Animals; Ceftriaxone; Cells, Cultured; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Therapy, Combination; Extracellular Space; Guinea Pigs; Intracellular Fluid; Legionella; Legionella pneumophila; Legionnaires' Disease; Macrophages, Alveolar; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
Topics: Bacteria, Aerobic; Bacterial Infections; beta-Lactamase Inhibitors; Culture Media; Diffusion; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam; United Kingdom | 1993 |
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Drug Combinations; Drug Therapy, Combination; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Spectinomycin; Tazobactam; Thienamycins; Virginiamycin | 1993 |
Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Topics: Bacteria, Anaerobic; Drug Combinations; Drug Therapy, Combination; Enterococcus; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Reproducibility of Results; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae; Tazobactam | 1993 |
Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis.
Topics: Abdomen; Abscess; Animals; Bacteroides fragilis; Bacteroides Infections; Ceftriaxone; Disease Models, Animal; Drug Therapy, Combination; Male; Penicillanic Acid; Peritoneal Diseases; Rats; Rats, Sprague-Dawley; Tazobactam | 1993 |
Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
Topics: Adult; beta-Lactamase Inhibitors; Biological Assay; Chromatography, High Pressure Liquid; Clavulanic Acid; Clavulanic Acids; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Serum Bactericidal Test; Tazobactam; Ticarcillin | 1993 |
Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Cloning, Molecular; Drug Resistance, Microbial; Escherichia coli; Genes, Bacterial; Humans; Mutation; Penicillanic Acid; Phenotype; Sulbactam; Tazobactam | 1993 |
In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Escherichia coli; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1993 |
Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Drug Synergism; Drug Therapy, Combination; Enzyme Induction; Indicators and Reagents; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Staphylococcus aureus; Tazobactam | 1993 |
Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Lactams; Penicillanic Acid; Sulbactam; Tazobactam | 1993 |
Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Topics: beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
Therapy of soft tissue infections with piperacillin/tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Risk Factors; Skin Diseases, Infectious; Tazobactam | 1993 |
Susceptibility survey of piperacillin alone and in the presence of tazobactam.
Topics: Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
Effect of piperacillin/tazobactam treatment on human bowel microflora.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; beta-Lactamase Inhibitors; Drug Therapy, Combination; Feces; Female; Humans; Intestines; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 1993 |
Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests.
Topics: Ampicillin Resistance; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Haemophilus influenzae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Quality Control; Tazobactam | 1993 |
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Hydrolysis; Isoelectric Focusing; Kinetics; Molecular Weight; Penicillanic Acid; Spectrophotometry, Ultraviolet; Tazobactam | 1993 |
Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
Topics: Ampicillin; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Drug Synergism; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1993 |
Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Campylobacter coli; Clavulanic Acid; Clavulanic Acids; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1993 |
Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
Topics: Amoxicillin; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Clavulanic Acids; Conjugation, Genetic; Drug Resistance, Microbial; Escherichia coli; Isoelectric Focusing; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Plasmids; Restriction Mapping; Sulbactam; Tazobactam | 1993 |
In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Cefotaxime; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Drug Interactions; Drug Stability; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1993 |
Breakpoint determination: piperacillin/tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Drug Combinations; Enterobacteriaceae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1993 |
Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions.
Topics: beta-Lactamase Inhibitors; Dialysis Solutions; Drug Stability; Enzyme Inhibitors; Humans; Penicillanic Acid; Penicillins; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Tazobactam | 1995 |
In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals.
Topics: Bacteria; beta-Lactamase Inhibitors; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1995 |
Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis.
Topics: beta-Lactamase Inhibitors; Drug Hypersensitivity; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Middle Aged; Osteomyelitis; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1995 |
Chemical modification of tazobactam. Synthesis of 2 beta-[(4-substituted)-1,2,3-triazol-1-yl]methyl penicillanic acid sulfone derivatives.
Topics: Ampicillin; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Drug Synergism; Electrochemistry; Enzyme Inhibitors; Escherichia coli; Gram-Negative Bacteria; Klebsiella pneumoniae; Molecular Structure; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Structure-Activity Relationship; Tazobactam; Triazoles | 1995 |
High-performance liquid chromatographic determination of tazobactam by precolumn derivatization.
Topics: beta-Lactamase Inhibitors; Calibration; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Hemofiltration; Humans; Indicators and Reagents; Kidney Diseases; Penicillanic Acid; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tazobactam | 1995 |
In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ceftazidime; Ciprofloxacin; Enzyme Inhibitors; Escherichia coli; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination; Xanthomonas | 1996 |
Life-threatening neutropenia secondary to piperacillin/tazobactam therapy.
Topics: Adult; Drug Therapy, Combination; Humans; Male; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1995 |
Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
Topics: Bacteria; Belgium; beta-Lactamase Inhibitors; Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitals; Humans; Luxembourg; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Quality Control; Tazobactam | 1996 |
An evaluation of the in vitro activity of piperacillin/tazobactam.
Topics: Bacteroides fragilis; beta-Lactamase Inhibitors; Escherichia coli; Haemophilus influenzae; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Proteus mirabilis; Pseudomonas aeruginosa; Staphylococcus; Streptococcus pneumoniae; Tazobactam | 1996 |
A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Cephamycins; Clavulanic Acid; Clavulanic Acids; Enterobacter cloacae; Enzyme Inhibitors; Escherichia coli; Hydrolysis; Kinetics; Molecular Structure; Penicillanic Acid; Recombinant Proteins; Substrate Specificity; Sulbactam; Tazobactam | 1996 |
Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Drug Synergism; Enterobacteriaceae; Enzyme Inhibitors; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Oxygen; Penicillanic Acid; Tazobactam | 1995 |
High-performance liquid chromatographic determination of tazobactam and piperacillin in human plasma and urine.
Topics: Chromatography, High Pressure Liquid; Circadian Rhythm; Drug Stability; Enzyme Inhibitors; Humans; Linear Models; Penicillanic Acid; Penicillins; Piperacillin; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tazobactam; Temperature | 1996 |
Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefotaxime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Drug Combinations; Drug Therapy, Combination; Female; Klebsiella Infections; Klebsiella pneumoniae; Lung; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia, Bacterial; Tazobactam; Ticarcillin | 1996 |
Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Campylobacter coli; Campylobacter jejuni; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Sulbactam; Tazobactam | 1996 |
Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests?
Topics: beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1996 |
A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone.
Topics: Acinetobacter; Ciprofloxacin; Citrobacter freundii; Drug Therapy, Combination; Enterobacteriaceae; Gentamicins; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Serratia marcescens; Tazobactam | 1996 |
Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Intensive Care Units; Klebsiella; Klebsiella Infections; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Tazobactam | 1996 |
Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci.
Topics: Ampicillin; Disease Outbreaks; Drug Resistance, Microbial; Enterococcus; Enterococcus faecium; Gastrointestinal Diseases; Gram-Positive Bacterial Infections; Humans; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam; Vancomycin | 1996 |
Studies on penam sulfones. I. Synthesis and beta-lactamase inhibitory activity of 2 beta-alkoxycarbonyl penicillanic acid sulfones.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Synergism; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Structure-Activity Relationship; Sulfones; Tazobactam | 1996 |
Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.
Topics: Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Kidney Diseases; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1996 |
Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Ceftazidime; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Therapy, Combination; Enterobacter cloacae; Enzyme Inhibitors; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serratia marcescens; Tazobactam; Ticarcillin; Time Factors | 1996 |
Reversible bone marrow depression by high-dose piperacillin/tazobactam.
Topics: Adolescent; Body Weight; Bone Marrow Diseases; Drug Therapy, Combination; Female; Fever; Humans; Neutropenia; Pancytopenia; Penicillanic Acid; Piperacillin; Tazobactam; Weight Loss | 1996 |
In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; beta-Lactamase Inhibitors; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Gentamicins; Kinetics; Macrolides; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1997 |
Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Topics: Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli; Kinetics; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1997 |
Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Topics: Bacteria; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Klebsiella; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Penicillins; Piperacillin; Sulbactam; Tazobactam | 1997 |
[Enzyme determination in vitro of inhibitor activity of beta-lactamase from tazobactam. Comparison with high performance liquid chromatography].
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Chromatography, High Pressure Liquid; Clinical Enzyme Tests; Enzyme Inhibitors; In Vitro Techniques; Penicillanic Acid; Reproducibility of Results; Tazobactam | 1997 |
An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin
Topics: Ampicillin; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Fibrin; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests; Nafcillin; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcus aureus; Sulbactam; Tazobactam; Vancomycin | 1997 |
Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.
Topics: Aged; Area Under Curve; Chromatography, High Pressure Liquid; Drug Combinations; Enzyme Inhibitors; Female; Half-Life; Humans; Hydrocephalus; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1997 |
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.
Topics: Abdominal Abscess; Animals; beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Enzyme Inhibitors; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam | 1997 |
Parvovirus B19 associated neutropenia. Treatment with Rh G-CSF.
Topics: Adenocarcinoma; Adult; Amikacin; Colonic Neoplasms; DNA, Viral; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Liver Neoplasms; Neutropenia; Parvoviridae Infections; Parvovirus B19, Human; Pefloxacin; Penicillanic Acid; Piperacillin; Recombinant Proteins; Tazobactam | 1997 |
Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Topics: Ampicillin; beta-Lactamase Inhibitors; Cefoperazone; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Retrospective Studies; Sulbactam; Tazobactam; Ticarcillin; Urinary Tract; Urinary Tract Infections | 1997 |
SYN-1012: a new beta-lactamase inhibitor of penem skeleton.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Drug Synergism; Enzyme Inhibitors; Humans; Lactams; Male; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Rabbits; Tazobactam | 1997 |
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Cefoxitin; Ciprofloxacin; Clostridium perfringens; Fluoroquinolones; Fusobacterium; Gram-Negative Anaerobic Bacteria; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Peptostreptococcus; Piperacillin; Prevotella melaninogenica; Quinolones; Tazobactam | 1997 |
Assessment of biliary excretion of piperacillin-tazobactam in humans.
Topics: Adult; beta-Lactamase Inhibitors; Bile; Cholecystectomy; Drainage; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1997 |
Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Chromatography, High Pressure Liquid; Citrobacter freundii; Enterobacter cloacae; Enzyme Inhibitors; Kinetics; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Plasmids; Tazobactam | 1997 |
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 1997 |
High rates of resistance to piperacillin/tazobactam among Escherichia coli and Klebsiella pneumoniae strains isolated in a Greek hospital.
Topics: Enzyme Inhibitors; Escherichia coli; Greece; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 1997 |
Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.
Topics: beta-Lactamase Inhibitors; Colony-Forming Units Assay; Computer Simulation; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Humans; Models, Biological; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1997 |
Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
Topics: Amoxicillin; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 1997 |
Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cilastatin; Ciprofloxacin; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Imipenem; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Protease Inhibitors; Retrospective Studies; Tazobactam; Thienamycins | 1998 |
Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Drug Resistance, Microbial; Escherichia coli; Kinetics; Models, Molecular; Molecular Conformation; Penicillanic Acid; Protein Conformation; Sulbactam; Tazobactam | 1998 |
Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.
Topics: Bacterial Proteins; beta-Lactamases; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1998 |
Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Enzyme Inhibitors; Penicillanic Acid; Sulbactam; Tazobactam | 1998 |
Piperacillin/tazobactam therapy for diabetic foot infection.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Foot; Drug Combinations; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcal Infections; Tazobactam | 1998 |
Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Molecular Sequence Data; Penicillanic Acid; Protein Conformation; Sequence Alignment; Sequence Homology, Amino Acid; Tazobactam | 1998 |
Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
Topics: Amoxicillin; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Enzyme Inhibitors; Escherichia coli; Models, Molecular; Mutagenesis, Site-Directed; Penicillanic Acid; Penicillins; Phenotype; Tazobactam | 1998 |
Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Clavulanic Acid; Drug Interactions; Drug Resistance, Multiple; Enzyme Inhibitors; Isoelectric Focusing; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Penicillanic Acid; Providencia; Sulbactam; Tazobactam | 1998 |
In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
Topics: beta-Lactamase Inhibitors; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Zimbabwe | 1998 |
Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cross Infection; Enzyme Inhibitors; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Italy; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Circular Dichroism; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli; Isoleucine; Kinetics; Methionine; Microbial Sensitivity Tests; Penicillanic Acid; Point Mutation; Protein Conformation; Sulbactam; Tazobactam | 1998 |
Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Structure-Activity Relationship; Sulbactam; Tazobactam | 1998 |
[Transferability of tazobactam/piperacillin (TAZ/PIPC) to cerebrospinal fluid of rabbit with meningitis caused by Staphylococcus aureus].
Topics: Animals; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Meningitis, Bacterial; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rabbits; Staphylococcal Infections; Tazobactam; Time Factors | 1998 |
[A three-dimensional model for in vitro study of the association of three antibiotics. Application to the activity of piperacillin, tazobactam and amikacin against five strains of enterobacteria as a function of their phenotype of beta-lactam resistance].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Penicillins; Phenotype; Piperacillin; Tazobactam | 1998 |
Immune thrombocytopenia caused by piperacillin/tazobactam.
Topics: Aged; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Thrombocytopenia | 1998 |
[A national multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish Piperacillin-Tazobactam Group].
Topics: Bacteria; beta-Lactamase Inhibitors; Chi-Square Distribution; Drug Combinations; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Spain; Tazobactam | 1998 |
[Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
Topics: Anti-Bacterial Agents; Bacteria; Bacteroides fragilis; beta-Lactamase Inhibitors; Clavulanic Acid; Haemophilus influenzae; Humans; Klebsiella; Klebsiella pneumoniae; Moraxella catarrhalis; Penicillanic Acid; Proteus vulgaris; Staphylococcus aureus; Streptococcus pneumoniae; Sulbactam; Tazobactam | 1998 |
[Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Topics: beta-Lactamase Inhibitors; Body Fluids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Tazobactam | 1998 |
A hospital outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Penicillin Resistance; Piperacillin; Tazobactam | 1999 |
Interaction between class B beta-lactamases and suicide substrates of active-site serine beta-lactamases.
Topics: beta-Lactamases; Binding Sites; Catalysis; Clavulanic Acid; Isomerism; Penicillanic Acid; Substrate Specificity; Sulbactam; Tazobactam | 1999 |
Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.
Topics: Animals; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Extracellular Space; Male; Microdialysis; Penicillanic Acid; Penicillins; Piperacillin; Rats; Rats, Wistar; Tazobactam; Tissue Distribution | 1998 |
Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.
Topics: Anti-Bacterial Agents; Cephalosporinase; Clavulanic Acid; Enzyme Induction; Enzyme Inhibitors; Genes, Bacterial; Humans; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 1999 |
Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.
Topics: Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Penicillanic Acid; Piperacillin; Tazobactam | 1999 |
Efficacy of beta-lactam and inhibitor combinations in a diffusion chamber model in rabbits.
Topics: Animals; Ceftriaxone; Cephalosporin Resistance; Cephalosporins; Colony Count, Microbial; Diffusion Chambers, Culture; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Rabbits; Tazobactam | 1999 |
Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Asparagine; Aspartic Acid; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1999 |
In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacteroides fragilis; beta-Lactamase Inhibitors; Cefoxitin; Ceftizoxime; Chloramphenicol; Clavulanic Acid; Clindamycin; Drug Therapy, Combination; Enzyme Inhibitors; Imipenem; Metronidazole; Mezlocillin; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Species Specificity; Sulbactam; Tazobactam; Thienamycins; Ticarcillin | 1999 |
Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Cell Membrane Permeability; Clavulanic Acid; Enterobacter cloacae; Enzyme Inhibitors; Escherichia coli; Gram-Negative Bacteria; Klebsiella pneumoniae; Lactams; Penicillanic Acid; Periplasm; Sulbactam; Tazobactam | 1999 |
In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.
Topics: Animals; beta-Lactamase Inhibitors; beta-Lactamases; Cefpirome; Ceftazidime; Cephalosporins; Citrobacter freundii; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae; Enzyme Induction; Enzyme Inhibitors; Female; Male; Mice; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 1999 |
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins | 1999 |
Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors | 1999 |
Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Conalbumin; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Escherichia coli; Iron Chelating Agents; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2000 |
High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.
Topics: Bacterial Outer Membrane Proteins; Base Sequence; beta-Lactamases; Biological Transport; Ceftazidime; Cephalosporins; Chromosomes; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Microbial; Enzyme Inhibitors; Gene Expression Regulation, Bacterial; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Hybridization; Penicillanic Acid; Penicillins; Piperacillin; Promoter Regions, Genetic; Sequence Homology, Nucleic Acid; Tazobactam | 2000 |
Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
Topics: Acylation; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Carbenicillin; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Escherichia coli; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Penicillanic Acid; Penicillin Resistance; Penicillinase; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thermodynamics | 2000 |
Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Clavulanic Acid; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam; Ticarcillin | 2000 |
Structure-function analysis of alpha-helix H4 using PSE-4 as a model enzyme representative of class A beta-lactamases.
Topics: beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Circular Dichroism; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Recombinant Proteins; Structure-Activity Relationship; Sulbactam; Tazobactam | 2000 |
Mechanism of inhibition of the class A beta -lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Mass Spectrometry; Penicillanic Acid; Recombinant Proteins; Serine Endopeptidases; Tazobactam; Trypsin | 2000 |
A kinetic study on the interaction between tazobactam (a penicillanic acid sulphone derivative) and active-site serine beta-lactamases.
Topics: Acinetobacter; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Citrobacter; Enzyme Inhibitors; Escherichia coli; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Morganella; Mycobacterium fortuitum; Penicillanic Acid; Providencia; Pseudomonas aeruginosa; Serine; Serratia marcescens; Tazobactam | 2000 |
[Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer].
Topics: Amikacin; Antineoplastic Agents; Breast Neoplasms; Drug Costs; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Neutropenia; Penicillanic Acid; Piperacillin; Spain; Tazobactam; Teicoplanin; Transplantation Conditioning; Treatment Failure; Treatment Outcome; Vancomycin | 2000 |
Control of glycopeptide-resistant enterococci in an oncology unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cohort Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Glycopeptides; Humans; Infection Control; Neoplasms; Neutropenia; Oncology Service, Hospital; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2000 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.
Topics: Burn Units; Cephalosporins; Clinical Protocols; Cross Infection; Drug Utilization; Enterococcus; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Methicillin Resistance; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Vancomycin; Vancomycin Resistance; Wounds and Injuries | 2000 |
In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Capnocytophaga; Clavulanic Acid; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2000 |
Combination antibiotic therapy for severe peritonitis.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Penicillins; Peritonitis; Polypharmacy; Tazobactam | 2000 |
Possible role of cellular immunity: a case of cellulitis.
Topics: Cellulitis; Clindamycin; Drug Eruptions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hypersensitivity, Delayed; Middle Aged; Nafcillin; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Vancomycin | 2001 |
Emergence of piperacillin/tazobactam-resistant Escherichia coli.
Topics: beta-Lactamase Inhibitors; Communicable Diseases, Emerging; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; France; Humans; Infection Control; Intensive Care Units; Patient Selection; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2000 |
Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Proteus Infections; Proteus mirabilis; Tazobactam | 2001 |
Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit.
Topics: Bacteremia; Cross Infection; Drug Resistance, Multiple; Enzyme Inhibitors; Hospitals, General; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Oncology Service, Hospital; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sanitary Engineering; Scotland; Species Specificity; Sputum; Tazobactam | 2000 |
Thermophilic multidrug-resistant Campylobacter fetus infection with hypersplenism and histiocytic phagocytosis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Campylobacter fetus; Campylobacter Infections; Ceftazidime; Cephalosporins; Diarrhea; Drug Resistance, Microbial; Enzyme Inhibitors; Erythromycin; Histiocytes; Histiocytosis; Humans; Hypersplenism; Male; Penicillanic Acid; Penicillins; Phagocytosis; Piperacillin; Quinolones; Splenic Infarction; Splenomegaly; Tazobactam | 2001 |
Systemic antibiotics fail to clear multidrug-resistant Klebsiella from a pediatric ICU.
Topics: Amikacin; beta-Lactamase Inhibitors; Cohort Studies; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Infant; Intensive Care Units, Pediatric; Klebsiella; Klebsiella Infections; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2001 |
Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
Topics: Alkenes; Alkynes; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Enzyme Inhibitors; Escherichia coli; Inhibitory Concentration 50; Molecular Conformation; Penicillanic Acid; Sulfones; Tazobactam; Triazoles | 2001 |
Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Enzyme Inhibitors; Hydrogen-Ion Concentration; Klebsiella pneumoniae; Models, Molecular; Penicillanic Acid; Solvents; Sulfones; Tazobactam; Temperature | 2001 |
Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.
Topics: Amino Acid Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Enzyme Inhibitors; Mass Spectrometry; Models, Chemical; Molecular Sequence Data; Penicillanic Acid; Tazobactam; Trypsin | 2001 |
Faecal concentrations of piperacillin and tazobactam in elderly patients.
Topics: Aged; Aged, 80 and over; Clostridioides difficile; Enterocolitis, Pseudomembranous; Enzyme Inhibitors; Feces; Female; Humans; Male; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2001 |
Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae.
Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cross Infection; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Klebsiella Infections; Klebsiella pneumoniae; Molecular Sequence Data; Penicillanic Acid; Penicillins; Piperacillin; Polymerase Chain Reaction; Tazobactam; Turkey | 2001 |
An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Disease Susceptibility; Female; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 2001 |
Molecular epidemiology of antibiotic-resistant gram-negative bacilli in a neonatal intensive care unit during a nonoutbreak period.
Topics: Anti-Bacterial Agents; Ceftazidime; DNA, Bacterial; Drug Resistance, Microbial; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Gentamicins; Gram-Negative Bacteria; Humans; Intensive Care Units, Neonatal; Molecular Epidemiology; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2001 |
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Chromosomes, Bacterial; Drug Resistance, Microbial; Enterobacteriaceae; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2001 |
Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
Topics: Acute Kidney Injury; Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hemodiafiltration; Hemofiltration; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2001 |
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage; Ciprofloxacin; Female; Heart Transplantation; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Nocardia; Nocardia Infections; Penicillanic Acid; Piperacillin; Postoperative Complications; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2001 |
[Occurrence of beta-lactamase type ESBL and IBL in Pseudomonas aeruginosa rods].
Topics: Animals; beta-Lactamases; Cattle; Cefoxitin; Clavulanic Acid; Dogs; Fishes; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Species Specificity; Swine; Tazobactam | 2001 |
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
Topics: Adult; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas Infections; Regression Analysis; Risk Factors; Tazobactam | 2002 |
[In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
Topics: Amikacin; Anti-Bacterial Agents; Drug Antagonism; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Gentamicins; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2002 |
Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder.
Topics: Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Particle Size; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Powders; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tazobactam | 2002 |
New and rapid fully automated method for determination of tazobactam and piperacillin in fatty tissue and serum by column-switching liquid chromatography.
Topics: Adipose Tissue; Automation; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam | 2002 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
Infecting one animal with two different strains of the same bacteria may cause misleading results.
Topics: Abscess; Animals; Disease Models, Animal; Enzyme Inhibitors; Hindlimb; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Reproducibility of Results; Tazobactam | 2002 |
Successful medical management of emphysematous pyelonephritis.
Topics: Adult; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Emphysema; Female; Follow-Up Studies; Humans; Insulin; Magnetic Resonance Imaging; Penicillanic Acid; Piperacillin; Pyelonephritis; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sensitivity and Specificity; Tazobactam | 2002 |
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index; Tazobactam; Treatment Outcome | 2002 |
Morganella morganii causing solitary liver abscess complicated by pyopericardium and left pleural effusion in a nondiabetic patient.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Humans; Leukocyte Count; Liver Abscess; Middle Aged; Morganella morganii; Penicillanic Acid; Pericardium; Piperacillin; Pleural Effusion; Radiography; Suppuration; Tazobactam | 2002 |
Piperacillin/Tazobactam inducing seizures in a hemodialysed patient.
Topics: Enzyme Inhibitors; Female; Humans; Kidney Failure, Chronic; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Renal Dialysis; Seizures; Tazobactam; Treatment Failure | 2002 |
Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Bacterial Infections; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Middle Aged; Mycoses; Penicillanic Acid; Pilot Projects; Piperacillin; Tazobactam; Transplantation, Autologous; Transplantation, Homologous | 2002 |
Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors.
Topics: Adenocarcinoma; Aged; Antibiotic Prophylaxis; Carcinoma, Neuroendocrine; Cephalexin; Chemoembolization, Therapeutic; Humans; Liver Abscess; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2002 |
Postoperative infection with group A beta-hemolytic Streptococcus after blepharoplasty.
Topics: Blepharoplasty; Combined Modality Therapy; Debridement; Drug Therapy, Combination; Eye Infections, Bacterial; Eyelid Diseases; Fasciitis, Necrotizing; Female; Humans; Hyperbaric Oxygenation; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Rhytidoplasty; Streptococcus pyogenes; Tazobactam | 2002 |
[Study on water of crystallization in tazobactam].
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Crystallization; Enzyme Inhibitors; Molecular Conformation; Molecular Structure; Penicillanic Acid; Tazobactam; Water; X-Ray Diffraction | 2002 |
Sciatic nerve palsy as presenting sign of a perianal abscess.
Topics: Abscess; Anus Diseases; Diagnosis, Differential; Drainage; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Sciatic Neuropathy; Tazobactam; Treatment Outcome | 2003 |
[Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum].
Topics: Abdominal Abscess; Adult; Aged; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Humans; Intestinal Perforation; Intestine, Large; Male; Middle Aged; Penicillanic Acid; Penicillins; Peritonitis; Piperacillin; Postoperative Complications; Rectal Diseases; Retrospective Studies; Surgical Wound Dehiscence; Tazobactam | 2002 |
Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Escherichia coli; France; Humans; Intensive Care Units; Penicillanic Acid; Piperacillin; Prospective Studies; Risk Factors; Tazobactam | 2003 |
Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.
Topics: Adult; Aged; Area Under Curve; Enzyme Inhibitors; Female; Humans; Lung; Male; Microdialysis; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Sepsis; Tazobactam | 2003 |
Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells.
Topics: Anemia, Hemolytic; beta-Lactamase Inhibitors; Coombs Test; Erythrocytes; Humans; Immunoproteins; Penicillanic Acid; Tazobactam | 2003 |
Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Platelet Count; Pneumonia, Bacterial; Tazobactam; Thrombocytosis | 2003 |
[Pharmacokinetics of antibiotics in inflamed and healthy lung tissue].
Topics: Anti-Bacterial Agents; Cefpirome; Cephalosporins; Empyema, Pleural; Extracellular Space; Humans; Lung; Microbial Sensitivity Tests; Microdialysis; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam; Thoracotomy | 2003 |
Intracameral antibiotic agents for endophthalmitis prophylaxis: a pharmacokinetic model.
Topics: Anti-Bacterial Agents; Endophthalmitis; Enzyme Inhibitors; Eye; Half-Life; Humans; Methicillin Resistance; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Vancomycin | 2003 |
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Topics: Ampicillin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Binding, Competitive; Clavulanic Acid; Drug Resistance, Microbial; Enzyme Inhibitors; Escherichia coli; Kinetics; Models, Chemical; Mutagenesis; Mutagenesis, Site-Directed; Penicillanic Acid; Plasmids; Serine; Tazobactam; Thermodynamics; Time Factors | 2003 |
[Phenotypes of beta-lactam resistance in the genus Aeromonas].
Topics: Aeromonas; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Enzyme Inhibitors; Isoelectric Focusing; Isoelectric Point; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Tazobactam | 2003 |
Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Topics: Adult; Anti-Bacterial Agents; Argentina; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam | 2003 |
[Candida parapsilosis endocarditis after prolonged antibiotic therapy].
Topics: Candida; Candidiasis; Cardiac Tamponade; Cefazolin; Disease Susceptibility; Drug Therapy, Combination; Endocarditis; Fatal Outcome; Humans; Ischemia; Leg; Male; Middle Aged; Opportunistic Infections; Penicillanic Acid; Piperacillin; Postoperative Complications; Superinfection; Tazobactam | 2002 |
Nosocomial bacteremia and catheter infection by Bacillus cereus in an immunocompetent patient.
Topics: Aged; Bacillaceae Infections; Bacillus cereus; Bacteremia; Catheterization, Central Venous; Catheters, Indwelling; Cross Infection; Digestive System Surgical Procedures; Drug Therapy, Combination; Humans; Immunocompetence; Male; Penicillanic Acid; Piperacillin; Tazobactam | 2003 |
Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
Topics: Amines; Amino Acid Substitution; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Crystallization; Deuterium Oxide; Enzyme Inhibitors; Kinetics; Microscopy; Models, Molecular; Penicillanic Acid; Recombinant Proteins; Spectrum Analysis, Raman; Sulbactam; Tazobactam; Water | 2003 |
False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.
Topics: Antigens, Fungal; Aspergillosis; Aspergillus; beta-Lactamase Inhibitors; Cross Reactions; Drug Therapy, Combination; False Positive Reactions; Galactose; Humans; Mannans; Penicillanic Acid; Piperacillin; Tazobactam | 2003 |
Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis.
Topics: Anti-Bacterial Agents; Bacillus anthracis; beta-Lactamases; Chelating Agents; Clavulanic Acid; Enzyme Inhibitors; Hydrolysis; Inhibitory Concentration 50; Iron; Kinetics; Models, Chemical; Penicillanic Acid; Penicillins; Spectrophotometry; Tazobactam | 2004 |
[Thoracic wall crossing (pseudo-?) tumor in a child: abscess-forming thoracic actinomycosis caused by Actinomyces meyeri et israeli].
Topics: Actinomyces; Actinomycosis; Anti-Infective Agents; beta-Lactamase Inhibitors; Child; Clindamycin; Diagnosis, Differential; Enzyme Inhibitors; Female; Humans; Lung Abscess; Penicillanic Acid; Piperacillin; Radiography, Thoracic; Tazobactam; Thoracic Diseases; Thoracic Wall; Tomography, X-Ray Computed; Ultrasonography | 2004 |
Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
Topics: Acylation; Alanine; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Crystallography, X-Ray; Glutamic Acid; Models, Molecular; Molecular Conformation; Penicillanic Acid; Recombinant Proteins; Spectrum Analysis, Raman; Tazobactam | 2004 |
Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
Topics: beta-Lactamases; Binding Sites; Crystallography, X-Ray; Enzyme Inhibitors; Glycine; Kinetics; Mass Spectrometry; Models, Chemical; Penicillanic Acid; Serine; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Trypsin | 2004 |
Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin.
Topics: Clostridioides difficile; Cross Infection; Diarrhea; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; United States | 2004 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells.
Topics: Adolescent; Adsorption; Anemia, Hemolytic; beta-Lactamase Inhibitors; Cell Survival; Coombs Test; Erythrocytes; Humans; Immunoglobulin G; Male; Penicillanic Acid; Pneumonia; Tazobactam | 2004 |
In vitro antimicrobial activity of doripenem, a new carbapenem.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Cephalosporins; Doripenem; Drug Therapy, Combination; Enterobacteriaceae; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 2004 |
Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Escherichia coli; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2004 |
Piperacillin/tazobactam-induced acute delirium in a peritoneal dialysis patient.
Topics: Anti-Bacterial Agents; Bacterial Infections; Confusion; Delirium; Drug Therapy, Combination; Gram-Positive Bacterial Infections; Hallucinations; Humans; Kidney Failure, Chronic; Male; Middle Aged; Penicillanic Acid; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Tazobactam | 2004 |
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Clavulanic Acid; DNA; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 2004 |
Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixe
Topics: Abscess; Animals; Bacteroides fragilis; Ceftizoxime; Cephalosporins; Colony Count, Microbial; Drug Resistance; Enterobacter cloacae; Enzyme Inhibitors; Female; Mice; Mice, Inbred BALB C; Mutation; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2004 |
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2004 |
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Topics: Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Mathematics; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2004 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
[Pyogenic sacroiliitis complicated by iliopsoas muscle abscess].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Arthritis, Infectious; Diagnosis, Differential; Female; Humans; Magnetic Resonance Imaging; Penicillanic Acid; Piperacillin; Psoas Abscess; Sacroiliac Joint; Streptococcal Infections; Streptococcus; Suppuration; Tazobactam; Time Factors | 2004 |
Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum.
Topics: Antigens, Fungal; Aspergillus; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Galactose; Mannans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2004 |
Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Enterococcus; Humans; Ohio; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin Resistance | 2004 |
Safety evaluation of piperacillin/tazobactam in very low birth weight infants.
Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Drug Therapy, Combination; Enterocolitis, Necrotizing; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Infant, Very Low Birth Weight; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2004 |
In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.
Topics: Azepines; Bacteria; beta-Lactamases; Ceftazidime; Cephalosporins; Clavulanic Acid; Dealkylation; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcus aureus; Sulfuric Acid Esters; Tazobactam | 2004 |
Effect of subinhibitory concentration of piperacillin/tazobactam on Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Humans; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Oxidative Stress; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Surface Properties; Tazobactam | 2004 |
Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study.
Topics: Animals; Body Fluids; Diffusion Chambers, Culture; Female; Penicillanic Acid; Piperacillin; Rabbits; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tazobactam | 2005 |
Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
Topics: Alanine; Amino Acid Substitution; Apoenzymes; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Catalysis; Crystallography, X-Ray; Enzyme Inhibitors; Escherichia coli Proteins; Genetic Variation; Glutamic Acid; Glycine; Hydrolysis; Models, Molecular; Mutagenesis, Site-Directed; Penicillanic Acid; Serine; Tazobactam | 2004 |
Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
Topics: Aged; Area Under Curve; Chromatography, High Pressure Liquid; Critical Care; Drug Therapy, Combination; Female; Half-Life; Hemofiltration; Humans; Inpatients; Intensive Care Units; Kidney; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors | 2005 |
A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Colony Count, Microbial; Drug Therapy, Combination; Endophthalmitis; Enzyme Inhibitors; Eye Infections, Bacterial; Female; Injections; Male; Penicillanic Acid; Piperacillin; Pseudomonas Infections; Rabbits; Retina; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin | 2004 |
Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC.
Topics: Anti-Bacterial Agents; Calibration; Chromatography, High Pressure Liquid; Hemofiltration; Humans; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Ultrafiltration | 2005 |
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Cytotoxins; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Intestines; Penicillanic Acid; Piperacillin; Spores, Bacterial; Tazobactam | 2005 |
The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
Pseudomonal sepsis with subcutaneous nodules in an HIV-infected individual with high CD4 counts.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Gentamicins; Glucocorticoids; HIV Infections; Humans; Lymphocyte Count; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Respiration, Artificial; Sepsis; Skin Diseases; Tazobactam; Treatment Outcome | 2005 |
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Adult; Amikacin; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Child; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Bacterial; Enzyme Inhibitors; Escherichia coli; Humans; In Vitro Techniques; Israel; Klebsiella pneumoniae; Microbial Sensitivity Tests; Odds Ratio; Penicillanic Acid; Piperacillin; Prevalence; Tazobactam | 2005 |
[Preliminary study on the release of DNA from Pseudomona aeruginosa induced by piperacillin/tazobactam in vitro].
Topics: Anti-Bacterial Agents; DNA, Bacterial; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2005 |
Severe intra-abdominal infection due to Streptococcus Milleri following adjustable gastric banding.
Topics: Abdominal Abscess; Body Mass Index; Combined Modality Therapy; Device Removal; Drainage; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Balloon; Gastroplasty; Humans; Middle Aged; Obesity, Morbid; Penicillanic Acid; Piperacillin; Postoperative Complications; Severity of Illness Index; Streptococcal Infections; Streptococcus milleri Group; Tazobactam | 2005 |
High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Binding Sites; Clavulanic Acid; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Klebsiella pneumoniae; Models, Chemical; Models, Molecular; Mutation; Penicillanic Acid; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Serine; Spectrum Analysis, Raman; Sulbactam; Tazobactam; Time Factors; X-Rays | 2005 |
Shelf lives of aseptically prepared medicines--stability of piperacillin/tazobactam in PVC and non-PVC bags.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Drug Stability; Penicillanic Acid; Piperacillin; Polyvinyl Chloride; Tazobactam | 2005 |
[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
Topics: Amikacin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2005 |
Index of suspicion.
Topics: Acidosis; Adolescent; Appendectomy; Appendicitis; beta-Lactamase Inhibitors; Child; Comorbidity; Diagnosis, Differential; Ethylene Glycol; Female; Humans; Infant; Leukopenia; Male; Metabolism, Inborn Errors; Neutropenia; Osteomyelitis; Pelvic Inflammatory Disease; Penicillanic Acid; Poisoning; Tazobactam | 2005 |
Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Diabetic Foot; Extracellular Fluid; Female; Humans; Inflammation; Male; Microdialysis; Middle Aged; Penicillanic Acid; Piperacillin; Soft Tissue Infections; Tazobactam | 2005 |
In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ceftriaxone; Cephalosporins; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Hospital Units; In Vitro Techniques; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2005 |
Group C streptococcal sepsis complicating Fournier gangrene.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Debridement; Diabetes Mellitus, Type 2; Drug Combinations; Fournier Gangrene; Humans; Male; Penicillanic Acid; Perineum; Piperacillin; Scrotum; Sepsis; Streptococcal Infections; Tazobactam | 2005 |
Fever, pulmonary haemorrhage, and acute renal failure in a young girl.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Hemorrhage; Humans; Lung Diseases; Multiple Organ Failure; Penicillanic Acid; Piperacillin; Tazobactam; Weil Disease | 2005 |
Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Bacteria; beta-Lactam Resistance; beta-Lactamases; Drug Synergism; Mice; Penicillanic Acid; Piperacillin; Tazobactam | 2005 |
YTR-830H: its origin, the present and the future.
Topics: Bacteroides; Citrobacter; Enterobacteriaceae; Enzyme Inhibitors; Klebsiella; Microbial Sensitivity Tests; Morganella; Penicillanic Acid; Proteus; Staphylococcus; Tazobactam | 1989 |
In vitro evaluation of new beta-lactamase inhibitor: YTR830H and derivatives.
Topics: Anti-Bacterial Agents; Bacteria; Drug Combinations; Enzyme Inhibitors; Morganella; Penicillanic Acid; Piperacillin; Structure-Activity Relationship; Tazobactam | 1989 |
In vitro activity of YTR-830H in combination with beta-lactamase unstable beta-lactams.
Topics: Anti-Bacterial Agents; Bacteria; Drug Combinations; Drug Stability; Drug Synergism; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1989 |
Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Gastric Juice; Hydrogen-Ion Concentration; Mice; Microbial Sensitivity Tests; Mucins; Penicillanic Acid; Piperacillin; Swine; Tazobactam | 1989 |
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteroides fragilis; beta-Lactamase Inhibitors; Clavulanic Acid; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 1989 |
Pharmacokinetics of YTR830H in healthy human subjects.
Topics: Adolescent; Adult; Analysis of Variance; Area Under Curve; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Metabolic Clearance Rate; Middle Aged; Penicillanic Acid; Placebos; Reference Values; Tazobactam | 1989 |
Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration.
Topics: Adolescent; Adult; Area Under Curve; Drug Combinations; Enzyme Inhibitors; Humans; Infusions, Intravenous; Kinetics; Metabolic Clearance Rate; Penicillanic Acid; Piperacillin; Reference Values; Tazobactam | 1989 |
Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Brain; Cefepime; Cefixime; Cephalosporins; Confusion; Consciousness Disorders; Delirium; Epididymitis; Humans; Kidney; Male; Metabolic Clearance Rate; Neurotoxicity Syndromes; Penicillanic Acid; Piperacillin; Recovery of Function; Secondary Prevention; Systemic Inflammatory Response Syndrome; Tazobactam; Urinary Tract Infections; Withholding Treatment | 2005 |
Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum.
Topics: Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; Interleukin-1; Male; Ozone; Penicillanic Acid; Peritonitis; Piperacillin; Pneumoperitoneum; Rats; Rats, Wistar; Tazobactam; Tumor Necrosis Factor-alpha | 2006 |
Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Enterobacteriaceae; Enzyme Inhibitors; Klebsiella pneumoniae; Microbial Sensitivity Tests; Morganella morganii; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2006 |
Piperacillin/tazobactam in treatment of brain abscess.
Topics: Anti-Bacterial Agents; Basal Ganglia; Brain Abscess; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Tazobactam; Treatment Outcome | 2006 |
Picture of the month. Infected urachal cyst.
Topics: Anti-Bacterial Agents; Combined Modality Therapy; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Infant; Male; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Ultrasonography; Umbilicus; Urachal Cyst | 2006 |
In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2006 |
Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient.
Topics: Acrylic Resins; Acrylonitrile; Anti-Bacterial Agents; Biocompatible Materials; Critical Care; Drug Therapy, Combination; Hemofiltration; Humans; In Vitro Techniques; Membranes, Artificial; Penicillanic Acid; Piperacillin; Polymers; Statistics, Nonparametric; Sulfones; Tazobactam | 2006 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Amphibian peptides prevent endotoxemia and bacterial translocation in bile duct-ligated rats.
Topics: Amphibian Proteins; Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteremia; Bacterial Translocation; beta-Lactamase Inhibitors; Bile Ducts; Endotoxins; Enterococcus faecalis; Enzyme Inhibitors; Escherichia coli; Jaundice, Obstructive; Ligation; Liver; Lymph Nodes; Magainins; Male; Penicillanic Acid; Peptides; Peritoneum; Piperacillin; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Tazobactam; Tumor Necrosis Factor-alpha; Xenopus Proteins | 2006 |
In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data.
Topics: Bacteria; Cefoperazone; Drug Combinations; Humans; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2007 |
Can the ravages of uncontrolled systemic inflammatory response be regulated by amphibian antimicrobial peptides?
Topics: Amphibian Proteins; Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacterial Translocation; Bile Ducts; Disease Models, Animal; Endotoxins; Jaundice, Obstructive; Magainins; Penicillanic Acid; Peptides; Piperacillin; Rats; Tazobactam; Xenopus Proteins | 2006 |
Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Data Interpretation, Statistical; Enzyme Inhibitors; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2006 |
Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
Topics: Amines; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Stability; Enzyme Inhibitors; Kinetics; Models, Molecular; Penicillanic Acid; Protein Conformation; Sulfones; Tazobactam | 2006 |
[Hepatic abscess due to Klebsiella pneumoniae in an Asian immigrant].
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Biliary Fistula; China; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis; Combined Modality Therapy; Diagnosis, Differential; Drainage; Duodenal Diseases; Emigration and Immigration; Hepatitis; Humans; Intestinal Fistula; Jaundice, Obstructive; Klebsiella Infections; Klebsiella pneumoniae; Liver Abscess; Male; Penicillanic Acid; Piperacillin; Spain; Sphincterotomy, Endoscopic; Tazobactam | 2006 |
[Peritonsillar abscess: a life threatening disease--diagnostic and therapeutic aspects].
Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Male; Mediastinitis; Multiple Organ Failure; Penicillanic Acid; Peritonsillar Abscess; Piperacillin; Radiography, Thoracic; Shock, Septic; Tazobactam; Tobramycin; Tomography, X-Ray Computed; Tonsillectomy | 2007 |
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospita
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Greece; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Prospective Studies; Tazobactam; Time Factors | 2007 |
Experience with the use of piperacillin-tazobactam in pediatric non-renal solid organ transplantation.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Child; Child, Preschool; Drug Therapy, Combination; Humans; Infant; Mycoses; Organ Transplantation; Penicillanic Acid; Piperacillin; Tazobactam | 2007 |
An improved high-performance liquid chromatographic method with a solid-phase extraction for the determination of piperacillin and tazobactam: application to pharmacokinetic study of different dosage in Chinese healthy volunteers.
Topics: Anti-Bacterial Agents; China; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Penicillanic Acid; Piperacillin; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tazobactam | 2007 |
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole.
Topics: Alcaligenes; Amphotericin B; Amputation, Surgical; Antifungal Agents; Cefazolin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Drug Resistance, Multiple, Fungal; Escherichia coli Infections; Fatal Outcome; Fluconazole; Gangrene; Graft Rejection; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Leg; Leg Ulcer; Male; Middle Aged; Mucor; Mucormycosis; Penicillanic Acid; Phosphatidylcholines; Phosphatidylglycerols; Piperacillin; Postoperative Complications; Pyrimidines; Renal Dialysis; Reoperation; Sepsis; Skin Transplantation; Tazobactam; Triazoles; Voriconazole | 2007 |
In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Ceftriaxone; Drug Combinations; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2007 |
[Infection with Aeromonas hydrophila after use of leeches (Hirudo medicinalis) in a free microvascular osteo-(myo-)cutaneous flap--suggestions for successful management].
Topics: Adult; Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Follow-Up Studies; Foot; Gram-Negative Bacterial Infections; Hirudo medicinalis; Humans; Leeching; Male; Penicillanic Acid; Piperacillin; Radiography; Surgical Flaps; Tazobactam; Time Factors; Treatment Outcome | 2007 |
Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; beta-Lactams; Burns; Cephalothin; Debridement; Drug Administration Schedule; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2007 |
Appropriate comparators for alternate dosing strategies.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Risk Assessment; Tazobactam; Treatment Outcome | 2007 |
Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Crystallography, X-Ray; Enzyme Inhibitors; Glycine; Penicillanic Acid; Serine; Spectrum Analysis, Raman; Stereoisomerism; Tazobactam | 2007 |
Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
Topics: Acrylates; Amino Acid Substitution; beta-Lactamases; Catalytic Domain; Clavulanic Acid; Crystallization; Enzyme Inhibitors; Imines; Kinetics; Molecular Structure; Penicillanic Acid; Recombinant Proteins; Serine; Spectrum Analysis, Raman; Sulbactam; Tazobactam | 2007 |
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Incidence; Intensive Care Units; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Probability; Retrospective Studies; Sensitivity and Specificity; Tazobactam; Treatment Outcome | 2007 |
New primary management for appendiceal masses in children: laparoscopic drainage.
Topics: Adolescent; Appendectomy; Appendix; C-Reactive Protein; Cecal Diseases; Child; Child, Preschool; Drainage; Female; Humans; Length of Stay; Male; Penicillanic Acid; Tazobactam | 2007 |
Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
Topics: Adult; Drug Therapy, Combination; Humans; Male; Obesity, Morbid; Penicillanic Acid; Piperacillin; Tazobactam | 2007 |
Control of multi-resistant bacteria and ventilator-associated pneumonia: is it possible with changes in antibiotics?
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Tazobactam | 2007 |
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam | 2007 |
False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam--is it still an issue?
Topics: Adult; Antigens, Fungal; Aspergillosis; False Positive Reactions; Galactose; Humans; Immunoenzyme Techniques; Mannans; Penicillanic Acid; Piperacillin; Tazobactam | 2008 |
Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
Topics: Acinetobacter; Amoxicillin; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactams; Clavulanic Acid; Enterobacteriaceae; Enzyme Inhibitors; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas; Stenotrophomonas; Tazobactam; Ticarcillin | 2007 |
[Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Minocycline; Penicillanic Acid; Piperacillin; Shock, Septic; Tazobactam; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2007 |
Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
Topics: Anti-Bacterial Agents; Escherichia coli; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2008 |
Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; DNA-Binding Proteins; Drug Synergism; Enterococcus faecalis; Escherichia coli; Granulocyte Colony-Stimulating Factor; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Peptides, Cyclic; Peritonitis; Piperacillin; Survival Rate; Tazobactam; Time Factors | 2008 |
Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Gram-Positive Bacterial Infections; Male; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Rats; Rats, Wistar; Shock, Septic; Tazobactam; Treatment Outcome | 2008 |
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
Topics: Adult; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2008 |
Suspected drug reaction with piperacillin/tazobactam, in a premature infant.
Topics: Anti-Bacterial Agents; Exanthema; Humans; Infant, Newborn; Infant, Premature; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Tazobactam | 2008 |
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Humans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Urinary Tract Infections | 2008 |
Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Crystallography; Enzyme Inhibitors; Penicillanic Acid; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrum Analysis, Raman; Sulbactam; Tazobactam | 2008 |
Piperacillin/tazobactam-induced Sweet syndrome in a patient with chronic lymphocytic leukemia and autoimmune cholangitis.
Topics: Aged; Autoimmune Diseases; Biopsy, Needle; Cholangitis; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Penicillanic Acid; Piperacillin; Severity of Illness Index; Sweet Syndrome; Tazobactam | 2008 |
Continuous infusion of beta-lactams in the intensive care unit--best way to hit the target?
Topics: Anti-Bacterial Agents; beta-Lactams; Body Fluids; Epithelium; Humans; Infusions, Intravenous; Intensive Care Units; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Tazobactam | 2008 |
Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cohort Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; France; Humans; Incidence; Intensive Care Units; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Treatment Outcome | 2008 |
Inhibition of OXA-1 beta-lactamase by penems.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Bridged Bicyclo Compounds; Enzyme Inhibitors; Escherichia coli; Heterocyclic Compounds; Kinetics; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Structure-Activity Relationship; Tazobactam | 2008 |
False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem?
Topics: Aged; Antigens, Fungal; Aspergillosis; Aspergillus; Enzyme-Linked Immunosorbent Assay; False Positive Reactions; Galactose; Humans; Mannans; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2008 |
Serological studies of piperacillin antibodies.
Topics: Adsorption; Anemia, Hemolytic; Antibodies; Antibody Specificity; beta-Lactamase Inhibitors; Blood Donors; Coombs Test; Drug Hypersensitivity; Erythrocyte Membrane; Humans; Penicillanic Acid; Penicillin G; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Tazobactam | 2008 |
Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Automation; beta-Lactamases; Deoxyribonucleases, Type II Site-Specific; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Polymerase Chain Reaction; Sequence Analysis, DNA; Tazobactam | 2008 |
Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ciprofloxacin; Cross Infection; Data Interpretation, Statistical; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Hand Disinfection; Hygiene; Intensive Care Units; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Personnel, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections; Tazobactam | 2008 |
Evaluating the ototoxicity of topical piperacillin-tazobactam.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cell Membrane; Cochlea; Drug Combinations; Evoked Potentials, Auditory, Brain Stem; Guinea Pigs; Hair Cells, Auditory; Male; Microscopy, Electron, Scanning; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2008 |
Dacryocystitis: an unusual form of Mucorales infection.
Topics: Adult; Anti-Bacterial Agents; Dacryocystitis; Enzyme Inhibitors; Female; Humans; Mucorales; Mucormycosis; Penicillanic Acid; Piperacillin; Tazobactam; Tobramycin; Vancomycin | 2008 |
High performance liquid chromatographic determination of plasma free and total tazobactam and piperacillin.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Piperacillin; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tazobactam | 2009 |
Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Crystallography, X-Ray; Enzyme Inhibitors; Imines; Penicillanic Acid; Quantum Theory; Spectrum Analysis, Raman; Sulbactam; Tazobactam | 2009 |
Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
Topics: Acinetobacter baumannii; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacterial Infections; Half-Life; Humans; Intensive Care Units; Lung Diseases; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Patient Admission; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2008 |
[Fournier's gangrene caused by Streptococcus agalactiae in a non-pregnant woman].
Topics: Adult; Anti-Bacterial Agents; Clindamycin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 1; Disease Susceptibility; Drug Therapy, Combination; Female; Fournier Gangrene; Humans; Metronidazole; Obesity; Penicillanic Acid; Perineum; Piperacillin; Reoperation; Streptococcal Infections; Streptococcus agalactiae; Tazobactam | 2009 |
Pylephlebitis after a duodenal ulcer in a patient with metastasised colon carcinoma treated with chemotherapy and bevacizumab: a case report.
Topics: Aged; Amoxicillin; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bacterial Infections; Bevacizumab; Clavulanic Acid; Colorectal Neoplasms; Duodenal Ulcer; Humans; Male; Penicillanic Acid; Piperacillin; Portal Vein; Tazobactam; Thrombophlebitis | 2009 |
First identification of class A carbapenemase-producing Klebsiella pneumoniae in the Republic of Ireland.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Ireland; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam | 2009 |
In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Cefoperazone; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2009 |
Clostridium perfringens liver abscess after pancreatic resection.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bacteremia; Clostridium Infections; Fatal Outcome; Female; Humans; Liver; Liver Abscess; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Penicillanic Acid; Piperacillin; Postoperative Complications; Tazobactam | 2009 |
Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient.
Topics: Aged, 80 and over; Albendazole; Animals; Anti-Infective Agents; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Ivermectin; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Protein C; Recombinant Proteins; Respiratory Distress Syndrome; Shock, Septic; Strongyloides stercoralis; Strongyloidiasis; Superinfection; Tazobactam; Treatment Outcome | 2009 |
Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2009 |
[Evaluation of occurrence of Alcaligenes faecalis in clinical samples of patients of the university hospital in Bydgoszcz].
Topics: Alcaligenes faecalis; Carbapenems; Drug Resistance, Bacterial; Environmental Microbiology; Environmental Monitoring; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Suppuration; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination; Urine | 2009 |
Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Bacteria; Penicillanic Acid; Tazobactam | 2008 |
In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Synergism; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2009 |
Epidural abscess and meningitis, a complication of spinal anesthesia in a bacteraemic patient.
Topics: Anesthesia, Spinal; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Enzyme Inhibitors; Epidural Abscess; Humans; Male; Meningitis, Bacterial; Middle Aged; Penicillanic Acid; Piperacillin; Spinal Puncture; Streptococcal Infections; Streptococcus agalactiae; Tazobactam | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Topics: Adult; Aged; Drug Administration Schedule; Gram-Negative Bacterial Infections; Hospitalization; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Tazobactam | 2009 |
Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
Topics: Anti-Bacterial Agents; Bacteria; Drugs, Generic; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2009 |
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
Topics: Area Under Curve; Bayes Theorem; Cross Infection; Drug Combinations; Female; Hospitalization; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Pneumococcal; Reproducibility of Results; Tazobactam; United States; United States Food and Drug Administration | 2010 |
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Young Adult | 2010 |
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamases; Catalytic Domain; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Kinetics; Microbial Sensitivity Tests; Penicillanic Acid; Spectrometry, Mass, Electrospray Ionization; Sulbactam; Tazobactam | 2010 |
In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tobramycin | 2010 |
[Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Ceftriaxone; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2009 |
Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration.
Topics: Animals; Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Campylobacter Infections; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Infusions, Intravenous; Injections, Intravenous; Meropenem; Mice; Mice, Inbred BALB C; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Tissue Distribution | 2010 |
Daily serum piperacillin monitoring is advisable in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Drug Monitoring; Female; France; Hospitals, Teaching; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Serum; Tazobactam; Time Factors | 2010 |
Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Two-Dimensional; Escherichia coli; Escherichia coli Proteins; Mass Spectrometry; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Proteomics; Tazobactam | 2010 |
An unusual case of septic shock in a geriatric patient.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antidiuretic Agents; Capnocytophaga; Female; Fluid Therapy; Gram-Negative Bacterial Infections; Humans; Multiple Organ Failure; Penicillanic Acid; Piperacillin; Risk Factors; Shock, Septic; Tazobactam; Vancomycin; Vasopressins | 2010 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2010 |
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Promoter Regions, Genetic; Recombination, Genetic; Sequence Analysis, DNA; Species Specificity; Tazobactam | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2010 |
Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis.
Topics: Amphibian Proteins; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Penicillanic Acid; Piperacillin; Tazobactam | 2011 |
Septicemic melioidosis.
Topics: Humans; Male; Melioidosis; Penicillanic Acid; Piperacillin; Sepsis; Tazobactam; Time Factors; Treatment Outcome | 2010 |
Right atrial thrombus in a six- year- old Indian boy with metabolic syndrome.
Topics: Acanthosis Nigricans; Anti-Bacterial Agents; Anticoagulants; Child; Drug Therapy, Combination; Echocardiography, Doppler; Heart Atria; Heart Diseases; Heparin, Low-Molecular-Weight; Humans; Male; Metabolic Syndrome; Obesity; Penicillanic Acid; Piperacillin; Positive-Pressure Respiration; Tazobactam; Thrombosis; Treatment Outcome; Warfarin | 2010 |
In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; beta-Lactam Resistance; beta-Lactams; Ertapenem; Germ-Free Life; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Tazobactam; Virulence | 2010 |
Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Administration Routes; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2010 |
Carbapenem-hydrolyzing GES-type extended-spectrum beta-lactamase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Escherichia coli; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Penicillanic Acid; Polymerase Chain Reaction; Tazobactam | 2011 |
Delayed-type hypersensitivity reaction to piperacillin/tazobactam in a patient with an infected total knee replacement.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Bone Cements; Drug Combinations; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Penicillanic Acid; Piperacillin; Prosthesis-Related Infections; Reoperation; Tazobactam | 2010 |
Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.
Topics: beta-Lactamase Inhibitors; Boronic Acids; Cefoperazone; Ceftazidime; Clavulanic Acid; Enzyme Inhibitors; Klebsiella pneumoniae; Magnetic Resonance Spectroscopy; Penicillanic Acid; Sulbactam; Tazobactam | 2011 |
Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Dialysis Solutions; Drug Monitoring; Female; Hemofiltration; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Tazobactam | 2011 |
Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cost-Benefit Analysis; Critical Care; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Markov Chains; Meropenem; Middle Aged; Models, Economic; Penicillanic Acid; Piperacillin; Pneumonia; Quality-Adjusted Life Years; Tazobactam; Thienamycins; Treatment Failure; United Kingdom | 2012 |
Drug fever due to piperacillin/tazobactam loaded into bone cement.
Topics: Aged; Anti-Bacterial Agents; Arthritis; Bone Cements; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Humans; Penicillanic Acid; Piperacillin; Tazobactam | 2011 |
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.
Topics: Bacteroides fragilis; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2011 |
Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry.
Topics: Aldehydes; Amino Acid Motifs; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Catalysis; Catalytic Domain; Cross-Linking Reagents; Crystallography, X-Ray; Kinetics; Mass Spectrometry; Models, Chemical; Penicillanic Acid; Protein Conformation; Spectrophotometry, Ultraviolet; Tazobactam | 2011 |
Ligand-dependent disorder of the Omega loop observed in extended-spectrum SHV-type beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamases; Escherichia coli; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Tazobactam; X-Ray Diffraction | 2011 |
Severe human parechovirus sepsis beyond the neonatal period.
Topics: Anti-Bacterial Agents; Blood Coagulation Disorders; Ceftriaxone; Enterocolitis, Necrotizing; Enzyme Inhibitors; Fever; Heart Failure; Hepatitis; Humans; Infant; Male; Parechovirus; Penicillanic Acid; Picornaviridae Infections; Piperacillin; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sepsis; Sequence Analysis, RNA; Tazobactam | 2011 |
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Typing; Penicillanic Acid; Tazobactam | 2011 |
Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli Proteins; Kinetics; Meropenem; Molecular Dynamics Simulation; Molecular Structure; Penicillanic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam; Tazobactam; Thienamycins | 2011 |
Biliary tract infection caused by Vibrio fluvialis in an immunocompromised patient.
Topics: Abdominal Pain; Aged, 80 and over; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Choledocholithiasis; Diabetes Mellitus; Diagnosis, Differential; Female; Gallstones; Humans; Immunocompromised Host; Kidney Failure, Chronic; Liver Cirrhosis; Penicillanic Acid; Piperacillin; Risk Factors; Taiwan; Tazobactam; Treatment Outcome; Vibrio; Vibrio Infections; Vomiting | 2011 |
In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistance; Clavulanic Acid; DNA, Bacterial; Escherichia coli; Escherichia coli Proteins; Evolution, Molecular; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Plasmids; Selection, Genetic; Tazobactam | 2011 |
Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.
Topics: Amikacin; Anti-Bacterial Agents; Cefoperazone; Ceftazidime; Ciprofloxacin; Czech Republic; Drug Resistance, Multiple, Bacterial; Gentamicins; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam | 2011 |
Necrotizing fasciitis of the breast: a case managed without mastectomy.
Topics: Abscess; Anti-Bacterial Agents; Breast; Breast Diseases; Combined Modality Therapy; Debridement; Fasciitis, Necrotizing; Female; Humans; Middle Aged; Penicillanic Acid; Tazobactam | 2011 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacter cloacae; Enterobacteriaceae Infections; France; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam | 2012 |
Bubbles in the urinary bladder.
Topics: Anti-Bacterial Agents; Cystitis; Female; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Shock, Septic; Tazobactam; Tomography, X-Ray Computed; Urinary Bladder; Urinary Bladder Diseases | 2012 |
In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Topics: Anti-Infective Agents; Bacteroides fragilis; Clindamycin; Imipenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Vancomycin | 2012 |
Antibiotics as first-line therapy for acute appendicitis: evidence for a change in clinical practice.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Female; Humans; Male; Metronidazole; Penicillanic Acid; Piperacillin; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam | 2012 |
A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autonomic Nervous System Diseases; Biological Transport; Child; Cholestasis; Cyclophosphamide; Cytochrome P-450 CYP3A; Daunorubicin; Drug Combinations; Drug Interactions; Facial Pain; Female; Humans; Intestinal Obstruction; Intestinal Pseudo-Obstruction; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nalbuphine; Neoplasm Proteins; Neuralgia; Penicillanic Acid; Piperacillin; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Seizures; Tazobactam; Vincristine | 2012 |
Antibiotics as first-line therapy for acute appendicitis: evidence for a change in clinical practice.
Topics: Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Female; Humans; Male; Metronidazole; Penicillanic Acid; Piperacillin; Tazobactam | 2012 |
Purification and characterization of OXA-23 from Acinetobacter baumannii.
Topics: Acinetobacter baumannii; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Dose-Response Relationship, Drug; Enzyme Activation; Escherichia coli; Kinetics; Models, Molecular; Penicillanic Acid; Structure-Activity Relationship; Substrate Specificity; Sulbactam; Surface Properties; Tazobactam | 2013 |
[Determination of target compounds in cefoperazone sodium and tazobactam sodium for injection by capillary electrophoresis].
Topics: Anti-Bacterial Agents; Cefoperazone; Drug Compounding; Electrophoresis, Capillary; Injections; Penicillanic Acid; Powders; Tazobactam | 2012 |
[Inhibitors of the New Delhi-Metallolactamase].
Topics: Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; Cell Membrane; Clavulanic Acid; Drug Resistance, Bacterial; Drug Resistance, Microbial; Enzyme Inhibitors; Klebsiella pneumoniae; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Tazobactam | 2012 |
Pseudomonas aeruginosa septic arthritis of knee after intra-articular ozone injection.
Topics: Aged, 80 and over; Arthritis, Infectious; Body Temperature; Humans; Injections, Intra-Articular; Knee Joint; Male; Microbial Sensitivity Tests; Ozone; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2012 |
Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Case-Control Studies; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Regression Analysis; Risk Factors; Tazobactam | 2012 |
Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
Topics: Acetamides; Anti-Bacterial Agents; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Retrospective Studies; Tazobactam; Treatment Outcome; Vancomycin; Wounds and Injuries | 2013 |
The interaction between piperacillin-tazobactam and Aspergillus galactomannan antigenemia assay: is the story over?
Topics: Aspergillus; Cross Reactions; Galactose; Humans; Mannans; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam | 2013 |
Ear pain and facial palsy.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Ear Canal; Facial Paralysis; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Necrosis; Otitis Externa; Penicillanic Acid; Piperacillin; Tazobactam | 2012 |
AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Humans; India; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2012 |
[Disseminated nocardiosis in a patient with haemophilia: a problem of differential diagnosis].
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Drug Therapy, Combination; Hemophilia A; Humans; Immunocompromised Host; Inpatients; Male; Middle Aged; Nocardia asteroides; Nocardia Infections; Opportunistic Infections; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2012 |
Piperacillin-induced thrombocytopenia reversed by high-flux hemodialysis in an uremic patient.
Topics: Aged; Anti-Bacterial Agents; Enzyme Inhibitors; Female; Humans; Penicillanic Acid; Piperacillin; Platelet Count; Renal Dialysis; Tazobactam; Thrombocytopenia; Uremia | 2012 |
Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cost-Benefit Analysis; Drug Resistance, Multiple, Bacterial; Edetic Acid; Enterobacteriaceae; Hydrolysis; Imipenem; Penicillanic Acid; Pseudomonas; Reproducibility of Results; Tazobactam; Zinc Sulfate | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
Topics: Academic Medical Centers; Adult; Bacteremia; Carbapenems; Ceftazidime; Drug Resistance, Multiple; Febrile Neutropenia; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prevalence; Prospective Studies; Risk Factors; Sepsis; Singapore; Tazobactam; Treatment Outcome; Universities | 2012 |
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2013 |
PFunkel: efficient, expansive, user-defined mutagenesis.
Topics: Amino Acid Substitution; beta-Lactam Resistance; beta-Lactamases; Codon; DNA; DNA, Single-Stranded; Mutagenesis, Site-Directed; Penicillanic Acid; Plasmids; Tazobactam; Templates, Genetic | 2012 |
N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactamases; Catalysis; Cefoxitin; Escherichia coli; Escherichia coli Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2013 |
[Systemic hantavirus-infection in a comatose HIV patient].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Agents; Coma; Critical Care; Diagnosis, Differential; Drug Therapy, Combination; Hemorrhagic Fever with Renal Syndrome; Hepatitis B, Chronic; Humans; Male; Penicillanic Acid; Piperacillin; Puumala virus; Respiratory Distress Syndrome; Sepsis; Tazobactam | 2013 |
Why tazobactam and sulbactam have different intermediates population with SHV-1 β-lactamase: a molecular dynamics study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Catalytic Domain; Hydrogen Bonding; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Penicillanic Acid; Protein Binding; Sulbactam; Tazobactam | 2013 |
Hemophagocytic syndrome as uncommon presentation of disseminated toxoplasmosis in an immunocompetent adult from Chinese Kunming.
Topics: Adult; Aminoglycosides; Asian People; Bone Marrow; Cefoperazone; China; DNA, Protozoan; Fatal Outcome; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Penicillanic Acid; Seroepidemiologic Studies; Tazobactam; Toxoplasma; Toxoplasmosis | 2013 |
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2013 |
Effectiveness and safety of generic formulation of piperacillin/tazobactam (Astaz-P) for treatment of infected patients at Siriraj Hospital.
Topics: Adolescent; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Child; Drugs, Generic; Female; Hospitals; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Thailand; Young Adult | 2013 |
Sequential antibiotic and growth factor releasing chitosan-PAAm semi-IPN hydrogel as a novel wound dressing.
Topics: Acrylic Resins; Animals; Anti-Bacterial Agents; Bandages; Biocompatible Materials; Cell Line; Chitosan; Epidermal Growth Factor; Hydrogels; Kinetics; Mice; Penicillanic Acid; Piperacillin; Tazobactam; Water; Wounds and Injuries | 2013 |
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cohort Studies; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2013 |
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
Topics: Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Cephalosporins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Molecular Sequence Data; Penicillanic Acid; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Tazobactam | 2013 |
Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Cefoperazone; Cephalosporin Resistance; Disk Diffusion Antimicrobial Tests; Drug Combinations; Humans; India; Penicillanic Acid; Respiratory Tract Infections; Sulbactam; Tazobactam; Urinary Tract Infections | 2012 |
Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Escherichia coli; Gene Expression; Genetic Engineering; Kinetics; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam | 2013 |
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
Topics: Anti-Bacterial Agents; Canada; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2013 |
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Escherichia coli; Escherichia coli Infections; Gene Expression; Half-Life; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Plasmids; Tazobactam | 2013 |
Is conservative management expedient in the treatment of Zargar's grade 3b gastric injuries after formalin ingestion?
Topics: Anti-Bacterial Agents; Burns, Chemical; Disinfectants; Diuretics; Drug Therapy, Combination; Eating; Enzyme Inhibitors; Follow-Up Studies; Formaldehyde; Gastric Mucosa; Gastroscopy; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Proton Pump Inhibitors; Radiography; Stomach; Tazobactam; Trauma Severity Indices | 2013 |
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
Topics: Anti-Infective Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; United States | 2013 |
Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test.
Topics: Aged; Critical Illness; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Femoral Neck Fractures; Heparin; Humans; Methotrexate; Pancytopenia; Penicillanic Acid; Piperacillin; Platelet Count; Platelet Factor 4; Purpura, Thrombocytopenic; Tazobactam; Thrombocytopenia; Transfusion Reaction | 2013 |
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections | 2014 |
Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteroides fragilis; Cephalosporins; Clostridium; Drug Combinations; Fusobacterium; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prevotella; Propionibacterium; Tazobactam | 2014 |
Reliability-targeted HPLC-UV method validation--a protocol enrichment perspective.
Topics: Bayes Theorem; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Reproducibility of Results; Ritonavir; Spectrophotometry, Ultraviolet; Tazobactam | 2014 |
Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2014 |
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clostridioides difficile; Humans; Metronidazole; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ribotyping; Spores, Bacterial; Tazobactam; Tigecycline; Vancomycin | 2014 |
Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2014 |
Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Catalytic Domain; Crystallography, X-Ray; Heterocyclic Compounds, 2-Ring; Kinetics; Models, Molecular; Penicillanic Acid; Protein Binding; Structure-Activity Relationship; Sulfones; Tazobactam; Thiazolidines | 2014 |
Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.
Topics: Adolescent; Adult; Aged; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Penicillanic Acid; Prospective Studies; Tazobactam; Young Adult | 2014 |
Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Critical Illness; Extracellular Fluid; Female; Half-Life; Hemofiltration; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Tazobactam | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Humans; India; Penicillanic Acid; Tazobactam | 2014 |
Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Creatinine; Critical Illness; Cross-Sectional Studies; Female; Humans; Kidney Diseases; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Wounds and Injuries; Young Adult | 2014 |
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Citrobacter; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Europe; Gram-Negative Aerobic Bacteria; Humans; Intraabdominal Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Proteus mirabilis; Pseudomonas aeruginosa; Serratia; Tazobactam; United States; Urinary Tract Infections | 2014 |
[70-year-old man with treatment-refractory pneumonia].
Topics: Aged; Anti-Bacterial Agents; Combined Modality Therapy; Diagnosis, Differential; Empyema, Pleural; Humans; Male; Penicillanic Acid; Piperacillin; Pleural Effusion; Pneumonia, Bacterial; Tazobactam; Thoracic Surgery, Video-Assisted; Treatment Failure; Ultrasonography | 2014 |
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam; United States | 2014 |
Following drug uptake and reactions inside Escherichia coli cells by Raman microspectroscopy.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Escherichia coli; Escherichia coli Proteins; Freeze Drying; Penicillanic Acid; Spectrum Analysis, Raman; Tazobactam | 2014 |
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Genotype; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
[Inhibitory activity of dihydroxy-phenyl-propenone on betalactamase of Enterobacter cloacae : preliminary study for drug development to overcome bacterial resistance. ].
Topics: Ampicillin; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; Chalcones; Chromatography, Affinity; Colony Count, Microbial; Colorimetry; Drug Evaluation, Preclinical; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Molecular Structure; Penicillanic Acid; Penicillinase; Tazobactam | 2014 |
Capnocytophaga sputigena bacteremia in a patient with chronic lymphocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Capnocytophaga; Gram-Negative Bacterial Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Sequence Homology, Nucleic Acid; Tazobactam; Transplantation, Homologous; Treatment Outcome | 2014 |
[Whirlpool-dermatitis with "hot hands"].
Topics: Adolescent; Drug Therapy, Combination; Hand Dermatoses; Humans; Hydrotherapy; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Water Microbiology | 2014 |
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; Cephalosporins; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2014 |
Genetic and kinetic characterization of the novel AmpC β-lactamases DHA-6 and DHA-7.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Clavulanic Acid; Enterobacter cloacae; Escherichia coli; Humans; Klebsiella oxytoca; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 2014 |
In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.
Topics: Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; United States | 2014 |
Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography/tandem mass spectrometry.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child; Chromatography, Liquid; Drug Monitoring; Humans; Limit of Detection; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam; Thienamycins | 2015 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
Catheter-related bacteremia by Cupriavidus metallidurans.
Topics: Adult; Aged; Bacteremia; Catheter-Related Infections; Cupriavidus; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam | 2015 |
Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Disease Models, Animal; Enterobacter cloacae; Humans; Mesothelin; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2015 |
A validated LC-MS/MS method for the quantification of piperacillin/tazobactam on dried blood spot.
Topics: Adult; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Monitoring; Drug Stability; Freezing; Humans; Infant, Newborn; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam | 2014 |
Do formulation differences between the reference listed drug and generic piperacillin-tazobactam impact reconstitution?
Topics: Administration, Intravenous; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Drugs, Generic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2015 |
Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
Topics: Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Inhibitory Concentration 50; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Republic of Korea; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Tertiary Care Centers; Thienamycins | 2015 |
Rapid-onset piperacillin-tazobactam induced thrombocytopenia.
Topics: Anti-Bacterial Agents; Female; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Thrombocytopenia | 2015 |
A 68-year-old type 2 diabetic man of Korean ethnicity with fever, abdominal pain, and right eye visual disturbance.
Topics: Abdominal Pain; Aged; Anti-Bacterial Agents; Bacteremia; Diabetes Mellitus, Type 2; Endophthalmitis; Eye Infections, Bacterial; Fever; Humans; Klebsiella Infections; Klebsiella pneumoniae; Liver Abscess; Male; Metronidazole; Penicillanic Acid; Piperacillin; Radiography; Tazobactam; Vision Disorders | 2015 |
Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases.
Topics: Adolescent; Anemia, Hemolytic; Anemia, Sickle Cell; Anti-Bacterial Agents; Erythrocyte Transfusion; Hemolysis; Humans; Male; Penicillanic Acid; Piperacillin; Retrospective Studies; Syndrome; Tazobactam | 2015 |
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Enterobacteriaceae; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Investigational New Drug Application; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2015 |
Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Female; Klebsiella pneumoniae; Mice; Penicillanic Acid; Protein Binding; Tazobactam; Thigh | 2015 |
Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; China; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Utilization Review; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers | 2015 |
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Drug Combinations; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United States | 2015 |
Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Topics: Anti-Bacterial Agents; Body Weight; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2016 |
Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Fungal; Aspergillosis; Case-Control Studies; False Positive Reactions; Female; Galactose; Humans; Male; Mannans; Middle Aged; Neoplasms; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Time Factors | 2015 |
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2015 |
A green capillary zone electrophoresis method for the simultaneous determination of piperacillin, tazobactam and cefepime in pharmaceutical formulations and human plasma.
Topics: Cefepime; Cephalosporins; Dosage Forms; Electrophoresis, Capillary; Green Chemistry Technology; Humans; Linear Models; Penicillanic Acid; Piperacillin; Reproducibility of Results; Sensitivity and Specificity; Tazobactam | 2015 |
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2015 |
Restoring the selectivity of modified charcoal cefoperazone deoxycholate agar for the isolation of Campylobacter species using tazobactam, a β-lactamase inhibitor.
Topics: Agar; Animals; Bacteriological Techniques; beta-Lactamase Inhibitors; Campylobacter; Cefoperazone; Charcoal; Chickens; Culture Media; Deoxycholic Acid; Escherichia coli; Meat; Penicillanic Acid; Reproducibility of Results; Tazobactam | 2015 |
In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefixime; Ceftazidime; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2015 |
Multidrug-Resistant Corynebacterium striatum Bacteremia: First Case in Korea.
Topics: Anti-Bacterial Agents; Bacteremia; C-Reactive Protein; Corynebacterium; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Quadriplegia; Republic of Korea; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam | 2015 |
Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Culture Media; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Penicillanic Acid; Piperacillin; Porins; Tazobactam | 2015 |
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Topics: Adaptation, Physiological; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Structure, Secondary; Protein Structure, Tertiary; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2015 |
Causative drug detection by drug-induced lymphocyte stimulation test in drug-induced linear IgA bullous dermatosis.
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Drug Combinations; Drug Eruptions; Female; Humans; Linear IgA Bullous Dermatosis; Lymphocyte Activation; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2016 |
Lymphoproliferative associated type 1 cryoglobulinemia.
Topics: Aged, 80 and over; Biopsy; Cryoglobulinemia; Humans; Immunoglobulin M; Immunohistochemistry; Lymphoproliferative Disorders; Male; Methylprednisolone; Penicillanic Acid; Piperacillin; Rituximab; Tazobactam | 2016 |
Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.
Topics: Anti-Bacterial Agents; Cephalosporins; Clostridioides difficile; Microbial Sensitivity Tests; Penicillanic Acid; Phylogeny; Tazobactam | 2015 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2015 |
Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
Topics: Aged; Anti-Bacterial Agents; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Shock, Septic; Tazobactam | 2015 |
Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.
Topics: Allosteric Regulation; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression; Humans; Linezolid; Meropenem; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Operon; Penicillanic Acid; Penicillin-Binding Proteins; Piperacillin; Staphylococcal Infections; Tazobactam; Thienamycins | 2015 |
Genetic and Biochemical Characterization of FRI-1, a Carbapenem-Hydrolyzing Class A β-Lactamase from Enterobacter cloacae.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Clavulanic Acid; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Plasmids; Sequence Homology, Amino Acid; Tazobactam | 2015 |
Piperacillin-Tazobactam Usage at a Tertiary Pediatric Hospital: An Antimicrobial Stewardship Review.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Child; Hospitals, Pediatric; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2016 |
Two cases of spondylodiscitis caused by Parvimonas micra.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; C-Reactive Protein; Clavulanic Acid; Clindamycin; Discitis; Female; Gram-Positive Bacterial Infections; Humans; Magnetic Resonance Imaging; Male; Penicillanic Acid; Peptostreptococcus; Tazobactam | 2015 |
A 13-Year-Old Boy with Pancytopenia and a Sacrococcygeal Abscess.
Topics: Abscess; Adolescent; Anti-Bacterial Agents; Diagnosis, Differential; Glucocorticoids; Humans; Male; Pancytopenia; Penicillanic Acid; Piperacillin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Sacrococcygeal Region; Tazobactam; Vancomycin | 2015 |
Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Regression Analysis; Risk Factors; Tazobactam; Vancomycin | 2015 |
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Klebsiella Infections; Klebsiella oxytoca; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Tazobactam | 2015 |
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Bioreactors; Cephalosporins; Chromatography, High Pressure Liquid; Colony Count, Microbial; Computer Simulation; Escherichia coli; Gene Expression; Half-Life; Infusion Pumps; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Porins; Pseudomonas aeruginosa; Tazobactam | 2016 |
Evaluation of CTX-M steady-state mRNA, mRNA half-life and protein production in various STs of Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Disk Diffusion Antimicrobial Tests; Escherichia coli; Genotype; Humans; Immunoblotting; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Tazobactam | 2016 |
A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Sulbactam; Tazobactam; Thienamycins | 2015 |
Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
Topics: Anti-Bacterial Agents; Cephalosporins; Child; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2016 |
Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2016 |
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Prospective Studies; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2015 |
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Computer Simulation; Dose-Response Relationship, Drug; Escherichia coli; Gene Expression; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Tazobactam | 2016 |
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Computer Simulation; Drug Therapy, Combination; Escherichia coli; Gene Expression; Microbial Sensitivity Tests; Models, Statistical; Organisms, Genetically Modified; Penicillanic Acid; Piperacillin; Plasmids; Tazobactam; Transcription, Genetic | 2016 |
Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada.
Topics: Amino Acid Sequence; Animals; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Canada; Carbapenems; Cephalosporins; Clavulanic Acid; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Penaeidae; Penicillanic Acid; Penicillins; Seafood; Sequence Alignment; Sequence Analysis, DNA; Tazobactam; Vibrio cholerae | 2016 |
Surgical Site Infections in Patients With Type 3 Open Fractures: Comparing Antibiotic Prophylaxis With Cefazolin Plus Gentamicin Versus Piperacillin/Tazobactam.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefazolin; Cohort Studies; Drug Combinations; Female; Fractures, Open; Gentamicins; Humans; Longitudinal Studies; Male; Middle Aged; Patient Readmission; Penicillanic Acid; Piperacillin; Prevalence; Retrospective Studies; Risk Factors; Surgical Wound Infection; Survival Rate; Tazobactam; Treatment Outcome; Vermont | 2016 |
Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.
Topics: Animals; Anti-Bacterial Agents; Body Temperature; Colistin; Cytokines; Edema; Immunoglobulin G; Immunoglobulins, Intravenous; Leukopenia; Lung; Male; Mice; Mice, Inbred ICR; Penicillanic Acid; Peroxidase; Piperacillin; Pneumonia, Bacterial; Pre-Exposure Prophylaxis; Protective Agents; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China.
Topics: Anti-Bacterial Agents; Carbapenems; China; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterococcus faecalis; Epidemiologic Studies; Escherichia coli; Female; Gentamicins; Humans; Intraabdominal Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome | 2016 |
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 2016 |
Evaluation of Tazobactam-Supplemented, Modified Charcoal-Cefoperazone-Deoxycholate Agar for Qualitative Detection of Campylobacter from Chicken Carcass Rinse.
Topics: Agar; Animals; Anti-Bacterial Agents; Campylobacter; Charcoal; Chickens; Culture Media; Deoxycholic Acid; Food Microbiology; Penicillanic Acid; Tazobactam | 2016 |
Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Plasma; Reproducibility of Results; Sodium Chloride; Swine; Tazobactam | 2016 |
Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Topics: Anti-Bacterial Agents; Cefazolin; Cephalosporins; Daptomycin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Staphylococcus aureus; Tazobactam | 2016 |
Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
Topics: Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; Feces; Hospitals; Humans; Intestines; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Risk Factors; Tazobactam | 2016 |
A cross-sectional study of blood cultures and antibiotic use in patients admitted from the Emergency Department: missed opportunities for antimicrobial stewardship.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Bacteremia; Cross-Sectional Studies; Emergency Service, Hospital; Female; Hospitals, University; Humans; Male; Microbiological Techniques; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2016 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Topics: Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Drugs, Generic; Mice; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Therapeutic Equivalency | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
Modeling and Re-Engineering of Azotobacter vinelandii Alginate Lyase to Enhance Its Catalytic Efficiency for Accelerating Biofilm Degradation.
Topics: Alginates; Amino Acid Sequence; Anti-Bacterial Agents; Azotobacter vinelandii; Biofilms; Catalysis; Glucuronic Acid; Hexuronic Acids; Mutagenesis, Site-Directed; Mutant Proteins; Penicillanic Acid; Piperacillin; Polysaccharide-Lyases; Pseudomonas aeruginosa; Tazobactam | 2016 |
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Leukemia; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Epidemiology and Outcome of Ventilator-Associated Pneumonia in a Heterogeneous ICU Population in Qatar.
Topics: Acinetobacter; Adolescent; Adult; Aged; Anti-Infective Agents; Comorbidity; Critical Care; Data Collection; Drug Resistance, Multiple, Bacterial; Female; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Pseudomonas; Qatar; Retrospective Studies; Risk Factors; Tazobactam; Treatment Outcome; Young Adult | 2016 |
ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Female; Humans; Liver Abscess; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2018 |
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Topics: Aged; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Chromatography, High Pressure Liquid; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Male; Penicillanic Acid; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; United States | 2016 |
Pneumocephalus in Child Following Bilateral Otomastoiditis and Nasal Septum Infection.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Infant; Male; Mastoiditis; Nasal Septum; Otitis Media; Penicillanic Acid; Piperacillin; Pneumocephalus; Pseudomonas Infections; Subdural Effusion; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2016 |
A simple and rapid RP-HPLC method for the simultaneous determination of piperacillin and tazobactam in human plasma.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Liquid-Liquid Extraction; Penicillanic Acid; Piperacillin; Solid Phase Extraction; Tazobactam; Time Factors | 2016 |
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2016 |
Sequence-Specific Targeting of Bacterial Resistance Genes Increases Antibiotic Efficacy.
Topics: Anti-Bacterial Agents; Base Sequence; Carrier Proteins; Cell Line; Drug Resistance, Bacterial; Escherichia coli Proteins; Gene Knockdown Techniques; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Oligodeoxyribonucleotides, Antisense; Penicillanic Acid; Piperacillin; Sulfamethoxazole; Tazobactam; Trimethoprim | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Off-Label Use; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Female; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam | 2017 |
β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Daptomycin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2017 |
Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; beta-Lactamase Inhibitors; Cathelicidins; Cell Membrane; Colistin; Daptomycin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred BALB C; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam | 2017 |
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Cephalosporin Resistance; Cephalosporins; Clavulanic Acid; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Germany; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Young Adult | 2017 |
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Salvage Therapy; Shock, Septic; Survival Analysis; Tazobactam | 2017 |
Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Combinations; Education, Medical, Continuing; Humans; Intensive Care Units; Penicillanic Acid; Tazobactam; United States | 2016 |
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam | 2017 |
Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
Topics: Anti-Bacterial Agents; Cephalosporins; Chemistry, Pharmaceutical; Drug Incompatibility; Excipients; Glucose; Humans; Infusions, Intravenous; Injections, Intravenous; Nephelometry and Turbidimetry; Penicillanic Acid; Sodium Chloride; Solubility; Tazobactam; Urinary Tract Infections | 2017 |
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Cephalosporins; DNA, Bacterial; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Real-Time Polymerase Chain Reaction; Tazobactam | 2017 |
Recognition of gamma-hydroxybutyric acid withdrawal: Rapid progression and prolonged symptomatology.
Topics: Adult; Anti-Bacterial Agents; Australia; Baclofen; Benzodiazepines; Diazepam; Humans; Hydroxybutyrates; Male; Penicillanic Acid; Phenobarbital; Piperacillin; Pneumonia; Psychomotor Agitation; Substance Withdrawal Syndrome; Sweating; Tazobactam; Tremor | 2017 |
A Pneumonia Case Associated with Type 2 Polio Vaccine Strains.
Topics: Ambroxol; Anti-Bacterial Agents; Humans; Infant; Male; Penicillanic Acid; Pneumonia; Poliomyelitis; Tazobactam; Vaccines | 2017 |
Clostridium sphenoides Chronic Osteomyelitis Diagnosed Via Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry, Conflicting With 16S rRNA Sequencing but Confirmed by Whole Genome Sequencing.
Topics: Anti-Bacterial Agents; Chronic Disease; Clostridium; Clostridium Infections; Daptomycin; Fractures, Open; Humans; Male; Osteomyelitis; Penicillanic Acid; Piperacillin; Radius Fractures; RNA, Ribosomal, 16S; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Ulna Fractures; Whole Genome Sequencing; Young Adult | 2017 |
Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model.
Topics: Bacteriophages; beta-Lactamases; Biodiversity; Biofilms; Biological Evolution; Culture Media; Cystic Fibrosis; Drug Resistance, Microbial; Penicillanic Acid; Phenotype; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2017 |
Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Superinfection; Tazobactam; Treatment Outcome | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Simultaneous determination of clavulanic acid and tazobactam in bovine milk by HPLC.
Topics: Animals; Anti-Bacterial Agents; Calibration; Cattle; Chromatography, High Pressure Liquid; Clavulanic Acid; Female; Food Contamination; Humans; Lactation; Limit of Detection; Milk; Penicillanic Acid; Tazobactam | 2017 |
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Europe; Humans; Intraabdominal Infections; Israel; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Turkey; Urinary Tract Infections | 2017 |
Topics: Animals; Chemistry Techniques, Synthetic; Hydrogen-Ion Concentration; Ligands; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Quality Control; Rabbits; Radiochemistry; Radionuclide Imaging; Rats; Reducing Agents; Salmonella enterica; Salmonella Infections; Tazobactam; Technetium; Tissue Distribution | 2017 |
Improvement of Karmali Agar by Supplementation with Tazobactam for Detecting Campylobacter in Raw Poultry.
Topics: Agar; Animals; beta-Lactamases; Campylobacter; Chickens; Culture Media; Escherichia coli; Food Microbiology; Penicillanic Acid; Poultry; Tazobactam | 2016 |
Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Topics: Animals; Anti-Bacterial Agents; Cattle; Cephalosporins; Drug Dosage Calculations; Hemodialysis Solutions; Humans; Membranes, Artificial; Metabolic Clearance Rate; Models, Biological; Penicillanic Acid; Renal Replacement Therapy; Tazobactam | 2017 |
General Method to Determine the Flux of Charged Molecules through Nanopores Applied to β-Lactamase Inhibitors and OmpF.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Membrane Potentials; Molecular Dynamics Simulation; Nanopores; Penicillanic Acid; Sulbactam; Tazobactam | 2017 |
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2017 |
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin | 2017 |
Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
Topics: Acute-Phase Proteins; Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of multidrug-resistant
Topics: Cephalosporins; Cystectomy; Debridement; Drug Resistance, Multiple, Bacterial; Fistula; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas Infections; Pubic Symphysis; Tazobactam; Treatment Outcome | 2017 |
Dose optimization of piperacillin/tazobactam in critically ill children.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tazobactam | 2017 |
Effectiveness of a Computer-facilitated, Pharmacist-driven Antimicrobial Stewardship Program for Infection Management.
Topics: Anti-Bacterial Agents; Carbapenems; Computer Systems; Cost Savings; Databases, Factual; Drug Monitoring; Drug Utilization; Drug Utilization Review; Humans; Infection Control; Methicillin-Resistant Staphylococcus aureus; Monitoring, Physiologic; Penicillanic Acid; Pharmacists; Piperacillin; Tazobactam | 2017 |
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; United States | 2017 |
Genetic and Functional Characterization of
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Conjugation, Genetic; Kinetics; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Penicillanic Acid; Plasmids; Sulbactam; Tazobactam | 2017 |
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cephalosporins; Epidemiological Monitoring; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Polymerase Chain Reaction; Tazobactam; United Kingdom | 2017 |
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Cephalosporins; Clinical Protocols; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Male; Metronidazole; Models, Econometric; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Tazobactam; United Kingdom | 2017 |
Unusual course of a haematoma of the thigh.
Topics: Anti-Bacterial Agents; Delayed Diagnosis; Drainage; Female; Hematoma; Humans; Linezolid; Magnetic Resonance Imaging; Middle Aged; Muscle, Skeletal; Osteomyelitis; Penicillanic Acid; Piperacillin; Soft Tissue Infections; Tazobactam; Thigh | 2017 |
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fractures, Bone; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Recurrence of Cytomegalovirus Viremia Causing Gastrointestinal Tract Bleeding at Different Sites in an Immuno-competent Patient.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Blood Transfusion; Colitis; Colon; Cytomegalovirus; Cytomegalovirus Infections; Diarrhea; Esomeprazole; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Humans; Immunocompetence; Male; Penicillanic Acid; Piperacillin; Pneumonia; Pulmonary Disease, Chronic Obstructive; Steroids; Tazobactam; Treatment Outcome; Viremia | 2017 |
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; DNA Gyrase; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Porins; Pseudomonas aeruginosa; Tazobactam | 2017 |
Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Penicillanic Acid; Tazobactam | 2017 |
Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam against multidrug-resistant organisms.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Penicillanic Acid; Tazobactam | 2017 |
Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients.
Topics: Aged; Anti-Bacterial Agents; Critical Care; Critical Illness; Drug Monitoring; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nervous System Diseases; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2017 |
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guidelines as Topic; Humans; Penicillanic Acid; Quality Control; Tazobactam | 2017 |
Fungating groin mass in a woman with a history of follicular lymphoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ceftriaxone; Cyclophosphamide; Diagnosis, Differential; Escherichia coli Infections; Female; Groin; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Penicillanic Acid; Piperacillin; Positron-Emission Tomography; Rituximab; Tazobactam; Tomography, X-Ray Computed; Vincristine | 2017 |
Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Enterobacteriaceae; Enterobacteriaceae Infections; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2017 |
Reply to Aitken et al., "Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?"
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Enterobacteriaceae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2017 |
Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Hospitals, Military; Humans; Incidence; Logistic Models; Male; Middle Aged; Military Personnel; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Tertiary Care Centers; Vancomycin | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Wound Infection | 2017 |
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Cytoskeletal Proteins; Drug Resistance, Multiple, Bacterial; Germany; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Genome, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pennsylvania; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2018 |
A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent.
Topics: Calibration; Chromatography, High Pressure Liquid; Critical Illness; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Renal Replacement Therapy; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam; Urine | 2018 |
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Heart Transplantation; Heart-Assist Devices; Humans; Male; Middle Aged; Penicillanic Acid; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Retrospective Studies; Sepsis; Taxoids; Tazobactam | 2017 |
Improvement of Bolton broth by supplementation with tazobactam for the isolation of Campylobacter from chicken rinses.
Topics: Animals; Bacteriological Techniques; beta-Lactamase Inhibitors; Campylobacter; Chickens; Culture Media; Escherichia coli; Food Microbiology; Meat; Penicillanic Acid; Tazobactam | 2018 |
Case Report:
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Immunological; Antiparasitic Agents; Bacteremia; Fatal Outcome; Humans; Immunocompromised Host; Ivermectin; Klebsiella pneumoniae; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Penicillanic Acid; Piperacillin; Rituximab; Strongyloides stercoralis; Strongyloidiasis; Tazobactam | 2017 |
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Hospitalization; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult | 2018 |
Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Female; Fluoroquinolones; Gentamicins; Germany; Humans; Male; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Risk Factors; ROC Curve; Tazobactam; Urinary Tract Infections | 2018 |
[Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Czech Republic; Drug Resistance, Bacterial; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections | 2017 |
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Oregon; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Chromatography, Liquid; Empyema, Pleural; Humans; Limit of Detection; Linear Models; Male; Penicillanic Acid; Piperacillin; Pleural Effusion; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2018 |
Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Lung; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Thigh | 2018 |
In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Topics: Achromobacter denitrificans; Adult; beta-Lactamase Inhibitors; Burkholderia cenocepacia; Cephalosporins; Colistin; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Sputum; Stenotrophomonas maltophilia; Tazobactam | 2018 |
Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2018 |
Topics: Amoxicillin; Anti-Bacterial Agents; Clavulanic Acid; Clindamycin; Diagnosis, Differential; Female; Humans; Middle Aged; Penicillanic Acid; Penicillin G; Peritonitis; Piperacillin; Streptococcal Infections; Streptococcus pyogenes; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Female; Follow-Up Studies; Humans; Infection Control; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Monitoring; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Tazobactam | 2018 |
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; beta-Lactamases; Ceftazidime; Cephalosporins; Clone Cells; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Gene Expression; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Survival Analysis; Tazobactam | 2018 |
Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma.
Topics: Anti-Bacterial Agents; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Plasma; Tazobactam | 2018 |
The use of broad-spectrum antibiotics reduces the incidence of surgical site infection after pancreatoduodenectomy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Cefmetazole; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Incidence; Intraoperative Period; Male; Middle Aged; Pancreaticoduodenectomy; Penicillanic Acid; Piperacillin; Retrospective Studies; Surgical Wound Infection; Tazobactam; Time Factors; Vancomycin | 2018 |
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2018 |
Piperacillin-Tazobactam: Extended Infusion Versus Continuous Infusion.
Topics: Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2018 |
Superior mesenteric venous thrombosis complicating acute appendicitis: A case report.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Appendectomy; Appendicitis; Diagnostic Errors; Early Medical Intervention; Heparin, Low-Molecular-Weight; Humans; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Penicillanic Acid; Piperacillin; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2018 |
Acute Kidney Injury Due to Concomitant Vancomycin and Piperacillin-Tazobactam.
Topics: Acute Kidney Injury; Febrile Neutropenia; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 2018 |
Acute Kidney Injury Due to Concomitant Vancomycin and Piperacillin-Tazobactam-Reply.
Topics: Acute Kidney Injury; Febrile Neutropenia; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 2018 |
[CME: Fusobacterium nucleatum/naviforme - a Rare but Serious Cause for Pyogenic Liver Abscesses].
Topics: Adult; Chest Pain; Combined Modality Therapy; Diagnosis, Differential; Drainage; Drug Therapy, Combination; Fusobacterium Infections; Fusobacterium nucleatum; Humans; Infusions, Intravenous; Levofloxacin; Liver Abscess; Liver Function Tests; Magnetic Resonance Imaging; Male; Metronidazole; Penicillanic Acid; Piperacillin; Tazobactam; Tomography, X-Ray Computed | 2018 |
Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability study.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2020 |
Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections | 2020 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Europe; Europe, Eastern; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2021 |
Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthy Volunteers; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Microdialysis; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2021 |
Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Topics: Anti-Bacterial Agents; Cefoperazone; Diarrhea; Humans; Microbial Sensitivity Tests; Neurosurgery; Penicillanic Acid; Piperacillin; Retrospective Studies; Sulbactam; Tazobactam | 2021 |
Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Endocarditis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data.
Topics: Cefepime; Drug Therapy, Combination; Humans; Japan; Leucovorin; Methotrexate; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2022 |
In vitro study of elution kinetics and biological activity of piperacillin/tazobactam and gentamicin in acrylic bone cement.
Topics: Anti-Bacterial Agents; Bone Cements; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymethyl Methacrylate; Tazobactam | 2022 |
Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
Topics: Adult; Anti-Bacterial Agents; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Republic of Korea; Tazobactam | 2022 |
Crystal structures of the molecular class A β-lactamase TEM-171 and its complexes with tazobactam.
Topics: beta-Lactamases; Crystallography, X-Ray; Enzyme Inhibitors; Penicillanic Acid; Tazobactam | 2022 |
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; New Zealand; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2022 |
Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Vancomycin; Young Adult | 2023 |
Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Mitomycin; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2023 |
Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.
Topics: Aged; Anti-Bacterial Agents; Canada; Creatinine; Frailty; Humans; Longevity; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2023 |
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Intraabdominal Infections; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
Microdialysis as a safe and feasible method to study target-site piperacillin-tazobactam disposition in septic piglets and children.
Topics: Animals; Anti-Bacterial Agents; Child; Humans; Microdialysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Swine; Tazobactam | 2023 |